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Chapter 1: Introduction 
Section 1.1: The function of non-coding DNA in the human genome 
Section 1.1.1. Functional roles of non-coding elements in the human genome 
The vast majority of DNA sequence in the human genome does not code for 
protein1. Non-coding DNA can serve many functional roles including transcriptional 
activation, repression, and three-dimensional genome organisation. Based on comparative 
evolutionary analyses, between 3% to 15% of the non-coding genome is predicted to be 
under purifying selection2-4, while protein-coding sequence comprises less than 2% of the 
genome1. Thus, the amount of functional non-coding sequence likely outnumbers functional 
coding sequence, yet the function of most non-coding sequence is poorly understood. 
The regulation of gene expression in time and space is an essential part of 
organismal development. The ‘core promoter’ includes a transcription start site (TSS), a 
binding site for RNA polymerase II, and binding sites for more general transcription factors5. 
The proximal promoter is less rigidly defined and includes regulatory sequence to the 5’ end 
of the transcribed strand which may harbour tissue-specific transcription factors (TFs). For 
many genes, particularly those with complex tissue-specific regulation, enhancers play an 
important role in regulating transcription6,7. Enhancers contain numerous transcription 
factor binding sites (TFBS), which can be identified by distinctive sequence patterns called 
motifs. These sequence patterns are often very flexible, maintaining binding efficiency 
despite changes to the underlying sequence. Furthermore, enhancers and TFBS show a high 
degree of evolutionary turnover8,9. Villar et. al identified putative regulatory regions in the 
liver of twenty different mammals and showed that nearly half of all enhancers show rapid 
lineage specific evolution9. While some principles of the enhancer ‘grammar’ have emerged, 
including cooperation and antagonism between different TFs10, the nucleotide-level logic in 
most enhancers are poorly understood. Enhancers can be proximal (tens of kilobases from 
the TSS) as well as distal (in some cases, more than one million bases from the TSS).  
While distal enhancers may be hundreds of kilobases from the genes they regulate in 
genomic space, they often colocalise in physical space. Topologically associated domains 
(TADs) are large genomic segments (median size 880kb) that interact more frequently than 
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expected under a model of random interactions11. The prevailing model by which looping is 
thought to occur is by loop extrusion by the cohesin complex, until the complex encounters 
a ‘boundary element’ containing the transcription factor CTCF12. TAD boundaries have been 
shown to be highly conserved across different cell types and tissues11. Interactions between 
regulatory elements and genes are far more likely occur within a TAD than between TADs, 
although there are examples of interactions between enhancers and promoters in different 
TADs13. While physical looping has been proposed as the primary mechanism for long-range 
enhancer-promoter interactions (Figure 1A), there is evidence that looping may not occur in 
all cases14. In particular, other mechanisms have been proposed including induced phase-
separation, chromatin decompaction, and subsequent diffusion of transcription factors 
(Figure 1B)14,15. Via looping or diffusion, general transcription factors and tissue specific 
transcription factors complex with RNA polymerase II to promote transcription16. While 
general principles of gene regulation are beginning to emerge, there is still no broad 
consensus around a unified model of gene regulation in all cases.  
 
 
Figure 1 Schematic of transcriptional activation via enhancer looping and diffusion facilitated by 
chromatin decompaction and phase separation (a) Looping brings enhancers into physical proximity 
of the gene promoter. (b) Phase transition and chromatin decompaction allows rapid 1D diffusion of 
transcription factors to the target promoter.  
 
 Many genes encoding transcription factors are only transcribed in a subset of cells, 
tissues, or developmental time-points. As a result, enhancers and promoters harbouring 
binding sites for these TFs can drive tissue-specific transcriptional patterns. For example, the 
GLI3 gene is expressed primarily in the developing brain and limb. Antagonistic interactions 
between GLI3 and Sonic Hedgehog (SHH) in the developing limb results in SHH expression in 
the Zone of Polarising activity, but nowhere else in the developing limb bud. Together, 
interactions between GLI3 and SHH impact the expression of more than 1,000 downstream 
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genes in the developing limb17. Detailed annotations of enhancer activity across mouse 
development suggest that the majority of enhancers are expressed during temporally-
restricted windows, which were associated with different stages of organogenesis18. 
Multiple enhancers can act in a particular tissue or time-point in a coordinated 
manner. For example, the Wap gene is upregulated more than 1,000 fold in the mouse 
mammary gland19 by the coordinated interaction of three different enhancers. A series of 
experiments deleting or perturbing individual enhancers and pairs of enhancers in the locus 
showed that all three were necessary to achieve the 1,000-fold upregulation. Clusters of 
coordinated enhancers, bound by the mediator complex, with non-additive contributions to 
gene expression have been termed super-enhancers20. However, the appropriateness and 
utility of this new category has been disputed, and it is not clear whether super-enhancers 
are simply collections of ‘normal’ enhancers with acting with varying degrees of strength or 
represent a novel functional category where constituent enhancers display synergistic 
properties21. 
Enhancers can also exhibit functional redundancy22. Osterwalder et. al created ten 
mouse lines with homozygous deletions of individual enhancers shown to regulate genes 
critical for normal limb development. Single deletions showed no discernible limb 
malformations. However, combinatorial deletion of multiple enhancers in a single locus did 
result in limb malformations. For example, deletion of mm1179 and hs1586, two enhancers 
shown to regulate GLI3 expression, results in a duplication of the first digit23. 
Section 1.1.2. Characterising non-coding elements in the human genome 
In light of the evidence for an important functional role for non-coding elements in 
the human genome, there have been a number of efforts to annotate non-coding function. 
These efforts have introduced novel methods to annotate non-coding function and 
collaborative efforts have been formed to apply new and established methods to a diverse 
range of organisms, tissues, and time points. 
The earliest large-scale annotations of putative functional non-coding DNA leveraged 
DNA sequence from different mammalian and vertebrate species to identify non-coding 
sequence with low levels of sequence divergence24. Early work on ultra-conserved non-
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coding elements (defined as having >97% sequence identity between human, mouse, and 
rat) showed that a large fraction of these elements were likely acting as enhancers24-27. 
These enhancers were enriched near genes previously known to be involved in 
development, suggesting that their evolutionary conservation was due to a highly conserved 
role in gene expression during development27. Beyond the most highly ultra-conserved 
elements, which comprised a very small fraction of the genome, multi-species alignments 
indicated that 3-15% of the genome was conserved2-4. As only 1-2% of genome encodes 
protein-coding, large-scale efforts are underway to annotate non-coding functional 
elements genome-wide. 
The Encyclopedia of DNA Elements (ENCODE) project launched in 2007 to 
systematically map functional elements across the human genome using a variety of 
different biochemical methods28,29. Nucleosome occupancy and epigenetic modification of 
the histone proteins comprising the core of the nucleosome have a profound impact on the 
accessibility of a segment of DNA. DNase-seq identifies regions of DNA that are sensitive to 
cleavage by DNase I30. These regions are often denoted as ‘open’ as they are fully or 
partially free of nucleosomes. More recently, ATAC-seq has emerged as the method of 
choice for identifying open chromatin due to its low requirement for input material 
compared to DNase-seq, and comparative speed and ease of use31. 
 In addition to nucleosome occupancy, epigenetic modifications to histone proteins 
can shed light on the underlying function of a piece of DNA. Promoter regions and 
transcription start sites are often marked by trimethylation of K4 (H3K4me3)32 and the 
bodies of transcribed genes by trimethylation of histone H3 at lysine 36 (H3K36me3)33. Like 
promoters, active enhancers can be identified by distinctive chromatin signatures, including 
open chromatin, monomethylation of histone H3 at lysine 4 (H3K4me1) and acetylation of 
histone H3 at lysine 27 (H3K27ac)34. H3K27ac by p300/CBP has been shown to destabilise 
nucleosomes, promoting accessibility by transcriptional machinery and TFs. In contrast, 
repressed or inactive chromatin is marked by trimethylation at histone H3 lysine 27 
(H3K27me3) or trimethylation at histone H3 lysine 9 (H3K9me3)35,36. These marks are 
assayed using a technique called chromatin immunoprecipitation followed by high 
throughput sequencing (ChIP-seq)37-39. In the ChIP-seq method, DNA is first cross-linked to 
preserve any DNA-protein interactions. An antibody to the protein of interest in then used 
to extract the short DNA fragments bound to the protein. These short fragments are 
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sequenced and mapped back to the reference genome, providing indication of where the 
protein was bound37-39. 
While there are many other potential histone modifications, six core marks 
(H3K27ac, H3K4me1, H3K4me3, H3K36me3, H3K27me3, H3K9me3) have been shown to 
sufficient to define a number of different ‘chromatin states’. Assaying these modifications 
has been the focus of large-scale efforts such as the ENCODE project29 and the Roadmap 
Epigenome Project40 to annotate non-coding function across different tissues and 
developmental time-points. A number of methods have been developed to integrate data 
from open chromatin assays and histone modifications to define the chromatin state. One 
of the most widely used methods, chromHMM, integrates aligned reads from each input 
feature and uses a hidden markov model to partition the genome into predicted chromatin 
states41. The simplest model has 15-states, which include active states such as strong and 
weak transcription, active/weak/poised promoters, and active/weak/poised enhancers as 
well as inactive or repressed states such as heterochromatin, or polycomb repression. 
 Beyond histone modifications, ChIP-seq can be used to identify DNA-binding events 
for any protein for which an antibody is available. To date, the ENCODE project has assayed 
more than 167 human transcription factors in 127 different tissue/cell types. These data 
sets have been used to identify canonical and non-canonical transcription factor binding 
motifs42. Due to the difficulties associated with testing thousands of transcription factors 
across hundreds of different spatial and temporal contexts, machine learning techniques 
have been developed to detect TF-binding motifs in the absence of direct measurement by 
ChIP-seq43. 
 Regulatory elements can also be identified using variation in gene expression or 
chromatin features resulting from natural genetic variation in a population. Associations 
between genetic variation and gene expression, termed expression quantitative trait loci44-
46 (eQTLs), were first established using Lymphoblastoid Cell Lines (LCLs) and have expanded 
substantially to include a wide range of cell types and tissues47-49. Analysis of the underlying 
genetic architecture of eQTLs suggests that a large fraction of associations fall within open 
chromatin peaks and directly impact transcription factor binding50. The majority of SNPs 
implicated in genome-wide association studies of common and complex disease risk fall 
outside coding regions, and there is a substantial overlap between these risk-associated loci 
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and eQTLs in disease-relevant cell types, suggesting gene mis-regulation as a primary 
contribution to common and complex disease49.  
 As discussed in section 1.1, genomic elements that are far apart in sequence space 
may interact by forming loops in three-dimensional space. The spatial organisation of 
chromatin can be detected by a number of different methods. The most widely used 
techniques are innovations around the chromosome conformation capture (3C) technique51. 
The original 3C technique, which used PCR to check for interaction between known 
fragments, has been modified to produce genome-wide interaction maps (Hi-C52), and 
detailed interaction maps centred on promoters or other elements of interest (Capture-C53-
55). Hi-C has been used to define TADs in a number of different tissues and cell types11. 
However, Hi-C and Capture-C can also reveal more fine-grained regulatory interactions 
within TADs, including promoter-promoter and enhancer-promoter interactions. While Hi-C 
and Capture-C have proved valuable tools for linking enhancers to putative target genes, the 
sheer complexity of potential tissues, cell types, and time points to assay, combined with 
the incomplete sensitivity of the tools means that gene target prediction remains a 
challenge. 
 Other methods for interrogating three-dimensional organisation that are not based 
on ligation have recently emerged. Genome architecture mapping (GAM) assays three-
dimensional organisation by freezing the cells of interest, cryosectioning the frozen cells, 
and isolating nuclei using laser capture microdissection. The DNA in each of these thin slices 
is sequenced and the frequency of interaction is quantified based on the proportion of 
cellular slices in which two genomic segments are sequenced together13. This method has 
the advantage of improved detection of interactions between three different segments – in 
ligation based methods where only two interacting segments can be identified at a time, 
two separate pair-wise interactions cannot be easily disambiguated from a single three-way 
interaction. Furthermore, GAM requires a small amount of cellular material and makes use 
of laser microdissection, which enables this method to be used on rare cell types or directly 
on patient tissue13. 
 The applications of open chromatin assays, ChIP-seq, and 3C techniques in the 
ENCODE and Roadmap Epigenome Projects have produced fundamental insights into 
human biology, but have focused primarily on natural variation present in human tissues, 
cell lines, induced pluripotent stem cells (iPSCs) and iPSC-derived tissues29,40. Improvements 
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in oligo synthesis and genome-editing technologies have given rise to new high-throughput 
methods for generating programmed variation in the underlying DNA sequence. 
Reporter assays have been long been used to test putative promoters and enhancers 
for their ability to drive gene expression56. Reporter assays use a bacterial plasmid with a 
putative regulatory element upstream of a reporter gene, often GFP or luciferase. These 
plasmids can then be transfected into a cell type of interest and the output of the reporter 
gene quantified, either by measuring fluorescence intensity or by quantitative PCR. The 
original reporter assays, designed to test a small number of putative regulatory elements, 
have been adapted to allow testing of tens of thousands of elements at once. For example, 
massively parallel reporter assays (MPRAs) can quantify the regulatory activity of tens of 
thousands of enhancers in a single experiment57,58. MPRAs work by adding a DNA barcode 
to each putative regulatory element. The reporter gene is then inserted between the 
enhancer element and the barcode, resulting in the barcode being transcribed on the 3’ end 
of the reporter gene. These barcodes can be quantified with RNA-sequencing and regulatory 
elements driving stronger reporter gene expression will have a greater number of barcodes 
relative to the amount of input DNA. Different MPRA variations have emerged including 
STARR-seq, which places the regulatory element downstream of the reporter gene, allowing 
a direct readout of the element rather than a linked barcode.  
Saturation mutagenesis experiments using this technology have recovered known 
disease-associated variants, for example in the TERT promoter (unpublished work from 
Nadav Ahituv) and to test for causal variants in eQTL studies from a large number of SNPs in 
linkage disequilibrium59. Beyond testing variations in wild-type sequence, these assays can 
be used to understand the ‘grammar’ of non-coding elements at a more fundamental level, 
by building functional sequences from scratch, and systematically altering or destroying 
synthetic sequences10,57,60. These assays have a number of drawbacks – in particular, the 
enhancer or promoter is being tested outside of its native context, either in an episome or 
integrated into the genome by a lentivirus. Furthermore, not all tissues or cellular models 
are amenable to transfection. Greater detail on the rapid evolution of the experimental 
techniques and applications of MPRA to interrogate enhancer and promoter function is 
included in the Introduction to Chapter 4. 
 In order to test the impact of genetic changes in their native genetic context, several 
methods have been pioneered using programmed guide-RNAs and the genome-editing 
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enzyme Cas9. Gasperini et. al use pairs of programmed guide-RNAs to delete thousands of 
kilo-base sized genomic regions61. Their first application of the method was applied to a 
housekeeping gene, HPRT1, which has little distal regulatory sequence, but in principal this 
method has the potential to test the impacts on cellular fitness or gene expression from 
deletion of coding or non-coding sequence.  
Cas9 cutting can be paired with a repair template, allowing more precise edits such 
as single base pair changes via homology directed repair (HDR). However, the double-strand 
break (DSB) induced by the CRISPR enzyme most often resolves by non-homologous end-
joining (NHEJ) usually resulting in small deletions at the cut site. Recent work by Findlay et. 
al has shown that performing the edits in a cell-line with LIG4, an important gene in the 
NHEJ pathway, knocked out results in lowered efficiency in NHEJ and a greater proportion of 
DSBs proceeding via HDR. Findlay et. al created more than 96.5% of all possible SNVs in two 
exons of the BRCA1 gene, paving the way for CRISPR-based alternatives to the massively 
parallel reporter assays discussed above62. 
Cellular models may not reveal the full spatial and temporal complexity of enhancer 
activity on an organismal level. Mouse transgenesis assays use a GFP reporter construct 
driven by the putative enhancer of interest to test for tissue-specific enhancer activity. To 
date, more than 2,800 putative enhancers have been tested and results made available 
through the VISTA browser63, with more than 1,500 testing consistently positive in at least 
one tissue. Beyond transgenesis assays, mouse knockouts can reveal the function of 
evolutionarily conserved enhancers in vivo. ARX is an essential neuronal transcription factor 
in the human and mouse brain with at least two enhancers (hs119 and hs121) that control 
expression in the ventral forebrain. These enhancers are ultraconserved, exhibiting >97% 
identity between human and mouse.24 Homozygous deletion of either hs119 or hs121 show 
subtle phenotypic changes including subtle changes in body weight and density of 
cholinergic neurons. However, deletion of both ultraconserved enhancers shows a dramatic 
reduction in both body weight and cholinergic neurons64. 
Taken together, these technologies provide a detailed overview of the functional 
non-coding sequence across the genome for hundreds of different cellular contexts and 
time-points. An overview of each of these techniques is described in Table 1 which includes 
the type of elements/interactions tested, the approximate throughput (number of genomic 
elements tested in a typical experiment).  Projects such as ENCODE29, The Roadmap 
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Epigenome Project40, and FANTOM65 have focused on building an atlas of reference 
epigenomes and functional non-coding elements in primarily healthy tissues and cellular 
contexts. As the role of non-coding elements in common and Mendelian disease becomes 
increasingly apparent, these technologies can be applied to understand the mechanism of 
gene mis-regulation in these diseases. 
 
Name of technique Element/interaction assayed 
Number of elements tested in a 
typical experiment 
DNase-seq Open chromatin Genome-wide 
ATAC-seq Open chromatin Genome-wide 
ChIP-seq 
Protein-occupancy (commonly 




between DNA elements Genome-wide 
Reporter Assays 
Ability of putative regulatory 
element to drive gene expression 100s of loci 
Mouse Transgenesis Assays 
Ability of putative regulatory 
element to drive gene 
expression, with tissue specificity. 10s of loci 
Massively Parallel Reporter 
Assays (MPRAs) 
Activity of putative 
enhancer/promoter to drive gene 
expression >10,000 loci 
CRISPR-inactivation 
Assessing the impact repressing a 
genomic element >10,000 loci 
CRISPR-editing 
Assessing the impact of 
deletion/alteration of a genomic 
element. >10,000 loci 
 
Table 1 Overview of established and emerging techniques in non-coding genome annotation. 
 
Section 1.2: The role of non-coding variation in Mendelian disease 
Section 1.2.1. The contribution of protein-coding variation to Mendelian disease 
 
The overwhelming majority of established genetic causes of Mendelian disease are 
caused by protein-altering single-nucleotide variation, small insertions/deletions (indels), or 
larger copy number variations (CNVs). Clinical microarrays and gene panels have been used 
extensively to test for diagnostic protein-altering variation in Mendelian disease, particularly 
in developmental disorders. As the cost of genome-sequencing has continued to decline, 
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whole exome sequencing, which allows for targeted sequencing of protein-coding regions, 
has proven to deliver a higher diagnostic yield66,67. Across a broad category of Mendelian 
disorders, diagnostic yield is approximately 25-30%, but the actual diagnostic yield differs 
substantially between different disease groups68. For example, RASopathies, a collection of 
disorders resulting from mutations in the RAS-MAP kinase pathway, have diagnostic rates of 
over 60% whereas developmental disorders, which suffer from the issue of phenotypic 
similarity across a wide range of potential causal genes, have a diagnostic yield of 25-30%68-
70. 
Study design can also influence diagnostic yield. For example, sequencing of parent-
offspring trios has been shown to greatly improve the diagnostic yield compared to 
sequencing the proband-only71,72. In the past few years, hundreds of novel Mendelian 
disease genes have been identified using exome sequencing, improving the diagnostic yield 
even further73. In the case of severe developmental disorders, Wright et. al estimate that 
implementing parent–offspring whole-exome sequencing as a first-line diagnostic test 
would diagnose approximately 50% of patients74. 
McRae et. al estimated that 42% of undiagnosed severe developmental disorder 
cases harboured damaging de novo mutations in protein-coding genes70. Of this estimated 
42%, ~25% could be robustly linked to a known or novel developmental disorder gene while 
the remaining ~17% were found in genes not yet robustly linked to developmental 
disorders. Beyond the contribution from de novo mutations in genes with a monoallelic 
disease mechanism, Martin et. al estimated the contribution of protein-altering variation in 




Figure 2 Diagnoses in the DDD project broken down by variant class. De novo mutations in protein-coding 
genes make up the largest fraction of diagnoses (25%), and analyses suggest that a substantial fraction of 
the missing diagnoses (~17%) will come from genes not yet robustly associated to DD. As of this writing, 
~45% of the DDD cases likely lack a highly penetrant protein-coding variant contributing to their disorder. 
 
Beyond developmental disorders, other severe Mendelian diseases have a high rate 
of unsolved cases, despite large-scale exome sequencing projects. In pulmonary arterial 
hypertension (PAH) heterozygous mutations in the coding sequence BMPR2 are found in an 
estimated 80% of familial cases and 20% of sporadic cases76. However, sporadic cases 
greatly outnumber familial cases; in a study of 1,048 individuals affected with PAH, 5.5% 
reported a family history77. Mutations in BMPR2 and other recently reported novel genes 
were found in just 23.5% of cases77. Thus, a substantial fraction of individuals remain 
without a cause in the protein-coding regions, even in large and well-powered studies of 
Mendelian Diseases (Figure 2). These results have motivated the search for causal variation 
outside of protein-coding genes. 
Section 1.2.2. Regulatory variation in Mendelian phenotypes 
 
 The importance of the non-coding genome in complex disease is well established - 
the vast majority of disease-associated single nucleotide polymorphisms (SNPs) lie in 
intergenic or intronic regions78,79. Fine-mapping studies have shown that in most cases 
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associations with a non-coding SNP cannot simply be accounted for by linkage with a coding 
variant on the same haplotype. Analysis of forty coding SNPs associated with Type-II 
Diabetes showed that a large fraction of associations (13/40) are actually ‘false leads’ that 
are likely driven by a nearby non-coding SNP80. In Mendelian disorders, the role of 
enhancers or other non-coding elements is less clear. There have been a number of 
regulatory elements linked to Mendelian disorders through targeted re-sequencing and 
pedigree analyses. Lettice et. al identified a set of single nucleotide variants in evolutionarily 
conserved sites in a regulatory element located 1Mb from the target gene, Shh, responsible 
for polydactyl81. Inherited single nucleotide variants as well as whole-element deletions in 
SOX10 enhancers have also been shown to reduce SOX10 expression, contributing to 
isolated Hirschprung disease82. Weedon et. al describe a set of six different recessive 
variants in an enhancer located 25kb from PFT1A that disrupt transcription factor binding 
sites for FOXA2 and PDX1, abolishing enhancer activity and causing pancreatic agenesis83. A 
single nucleotide variant in an ultraconserved element regulating the expression of PAX6, a 
critical gene in eye development, has also been shown to cause Aniridia. Other examples of 
point mutations and small insertions/deletion in non-coding elements that have been 
causally linked to human disease are described in a review by Mathelier et. al84. 
 In addition to point-mutations and small insertions/deletions, larger-scale copy-
number variations and rearrangements of regulatory sequence have been shown to cause 
Mendelian disorders. Loss of function can be caused by deletion of an enhancer, as in the 
SOX10 case described above resulting in isolated Hirschsprung disease82, as well as in Pierre-
Robin syndrome85,86 , a condition marked by malformations of the cranial skeleton. Genomic 
rearrangements or disruptions of topologically associated domains (for example, by deletion 
of a CTCF binding site) can cause enhancers to regulate a gene they do not normally 
regulate. This phenomenon is termed ‘enhancer adoption’ and has been implicated in 
brachydactyl type A287 (a shortening of the digits) as well as sex-reversal due to a gonad-
specific gain of function of SOX988. A number of studies in which copy number variation and 
rearrangements of non-coding cis-regulatory elements contribute to Mendelian disorders 
by disrupting or altering gene regulation are reviewed by Malte Spielmann and Stefan 
Mundlos89.  
Nearly all of these well-established examples of regulatory causes of Mendelian 
disease share the common characteristic of being non-syndromic. In each of the cases, a 
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single organ or organ system is affected, reflecting the tissue-specificity of the enhancer 
element whose function is being perturbed. It is unclear whether this is a common 
characteristic of Mendelian disease caused by variants in regulatory regions, or a by-product 
of ascertainment based on recognisable phenotypes. Furthermore, unlike loss-of-function 
mutations in protein-coding genes that may only impact the amount of functional protein 
produced, mutations in regulatory elements have the potential to cause more complex mis-
regulation. Thus, the impact of variation in regulatory elements may not be directly 
comparable to changes in the protein-coding sequence. 
 
Section 1.2.3 The role of regulatory variation in cancer and neurodevelopmental disorders 
 
There have been reports of recurrent somatic mutations in regulatory regions in 
several cancer types using whole genome sequence data from The Cancer Genome Atlas 
(TCGA)90,91. These studies included nearly 500 whole genome sequences of tumours and 
matched normal tissue and primarily identified mutations in promoter sequences as well as 
3’ UTRs and 5’ UTRs. The strongest signal, in the TERT promoter, comprises mutations that 
show substantial overexpression of a luciferase reporter as well as RNA levels of the TERT 
transcripts in the cancerous tissue90,91. Further work using a combination of whole genome 
sequencing and chromatin immunoprecipitation sequencing (ChIP-exo) highlighted 
disruption of CTCF and cohesin binding sites in colorectal cancer which contribute to 
genomic stability and establishment/maintenance of TAD boundaries92. 
Expanding these analyses to nearly 1,000 tumour whole genomes with matching 
transcriptomes, Zhang et. al recapitulated the variants resulting in overexpression in the 
TERT promoter and discover novel regulatory elements regulating the expression of 
DAAM1, MTG2, and HYI93. Their approach leverages the matched transcriptomes to identify 
‘somatic eQTLs’ linking regulatory elements to putative target genes. This is a promising 
new approach for disorders where RNA transcript levels can be measured in the relevant 
tissue, or where accurate cellular models can be derived, for example, by reprogramming 
induced pluripotent stem cells (iPSCs). 
There is substantial evidence for protein-coding DNMs contributing to autism 
spectrum disorder (ASD), albeit at a lower contribution than in severe developmental 
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disorders94. Thus, there has been a similar motivation to assess the contribution of DNMs in 
the non-coding genome to ASD. For example, Turner et. al reported a nominally significant 
enrichment for de novo mutations in autism cases compared to unaffected siblings in 3’ 
UTRs, promoters, and conserved transcription factor binding sites95 using data from whole 
genome sequenced trios. However, independent analysis of the same cohort from Werling 
et. al find no significant enrichment and show that without appropriate correction for 
multiple statistical tests, plausible associations can be observed in both cases and controls96.  
Thus, the contribution of variation in the non-coding genome to developmental 
disorders and other rare disorders is not clear. The Deciphering Developmental Disorders 
study has nearly an order of magnitude more cases than the ASD studies discussed above, 
and included approximately 4 megabases of regulatory sequence in the exome capture. This 
study design may afford greater power to test for DNM burden, albeit in a more limited set 
of non-coding annotations. This study will be covered in detail in Chapter 2. The dramatic 
increase in the number of whole genome sequenced individuals affords an opportunity to 
identify non-coding elements under purifying selection across the genome in a disease-
agnostic manner. Analyses based on more than 25,000 deep whole genomes using 
population genetics methods to identify selectively constrained non-coding elements will be 
covered in detail in Chapter 3. Finally, methods for assaying the function of non-coding 
elements and the impact of genetic variation in these elements can be used to delineate 
benign from damaging variation in these non-coding elements and to understand their 
function. Chapter 4 includes results from a series of MPRA experiments and mouse 
transgenesis assays including non-coding mutations identified in developmental disorder 
cases. 
 
1 International Human Genome Sequencing, C. Finishing the euchromatic sequence of 
the human genome. Nature 431, 931-945, doi:10.1038/nature03001 (2004). 
2 Lindblad-Toh, K. et al. A high-resolution map of human evolutionary constraint using 
29 mammals. Nature 478, 476-482, doi:10.1038/nature10530 (2011). 
3 Ponting, C. P. & Hardison, R. C. What fraction of the human genome is functional? 
Genome Res 21, 1769-1776, doi:10.1101/gr.116814.110 (2011). 
4 Lunter, G., Ponting, C. P. & Hein, J. Genome-wide identification of human functional 
DNA using a neutral indel model. PLoS Comput Biol 2, e5, 
doi:10.1371/journal.pcbi.0020005 (2006). 
5 Smale, S. T. & Kadonaga, J. T. The RNA Polymerase II Core Promoter. Annual Review 
of Biochemistry 72, 449-479, doi:10.1146/annurev.biochem.72.121801.161520 
(2003). 
 15 
6 Shlyueva, D., Stampfel, G. & Stark, A. Transcriptional enhancers: from properties to 
genome-wide predictions. Nat Rev Genet 15, 272-286, doi:10.1038/nrg3682 (2014). 
7 Banerji, R., Schaffner. Expression of a Beta-Globin Gene is Enhanced by REmote SV40 
DNA Sequences. Cell (1981). 
8 Meader, S., Ponting, C. P. & Lunter, G. Massive turnover of functional sequence in 
human and other mammalian genomes. Genome Res 20, 1335-1343, 
doi:10.1101/gr.108795.110 (2010). 
9 Villar, D. et al. Enhancer evolution across 20 mammalian species. Cell 160, 554-566, 
doi:10.1016/j.cell.2015.01.006 (2015). 
10 Smith, R. P. et al. Massively parallel decoding of mammalian regulatory sequences 
supports a flexible organizational model. Nature Genetics 45, 1021-1028, 
doi:10.1038/ng.2713 (2013). 
11 Dixon, J. R. et al. Topological domains in mammalian genomes identified by analysis 
of chromatin interactions. Nature 485, 376-380, doi:10.1038/nature11082 (2012). 
12 Ganji, M. et al. Real-time imaging of DNA loop extrusion by condensin. Science 360, 
102-105, doi:10.1126/science.aar7831 (2018). 
13 Beagrie, R. A. et al. Complex multi-enhancer contacts captured by genome 
architecture mapping. Nature 543, 519-524, doi:10.1038/nature21411 (2017). 
14 Benabdallah, N. S. & Bickmore, W. A. Regulatory Domains and Their Mechanisms. 
Cold Spring Harb Symp Quant Biol 80, 45-51, doi:10.1101/sqb.2015.80.027268 
(2015). 
15 Benabdallah, N. S. et al. PARP mediated chromatin unfolding is coupled to long-
range enhancer activation. bioRxiv, doi:10.1101/155325 (2017). 
16 Hardison, R. C. & Taylor, J. Genomic approaches towards finding cis-regulatory 
modules in animals. Nat Rev Genet 13, 469-483, doi:10.1038/nrg3242 (2012). 
17 Tickle, C. & Towers, M. Sonic Hedgehog Signaling in Limb Development. Front Cell 
Dev Biol 5, 14, doi:10.3389/fcell.2017.00014 (2017). 
18 Nord, A. S. et al. Rapid and pervasive changes in genome-wide enhancer usage 
during mammalian development. Cell 155, 1521-1531, 
doi:10.1016/j.cell.2013.11.033 (2013). 
19 Shin, H. Y. et al. Hierarchy within the mammary STAT5-driven Wap super-enhancer. 
Nature Genetics, 1-10, doi:10.1038/ng.3606 (2016). 
20 Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 
934-947, doi:10.1016/j.cell.2013.09.053 (2013). 
21 Hay, D. et al. Genetic dissection of the alpha-globin super-enhancer in vivo. Nature 
Genetics 48, 895-903, doi:10.1038/ng.3605 (2016). 
22 Frankel, N. et al. Phenotypic robustness conferred by apparently redundant 
transcriptional enhancers. Nature 466, 490-493, doi:10.1038/nature09158 (2010). 
23 Osterwalder, M. et al. Enhancer redundancy provides phenotypic robustness in 
mammalian development. Nature 554, 239-243, doi:10.1038/nature25461 (2018). 
24 Bejerano, G. et al. Ultraconserved elements in the human genome. Science 304, 
1321-1325, doi:10.1126/science.1098119 (2004). 
25 Kleinjan, D. A. & Van Heyningen, V. Long-Range Control of Gene Expression: 
Emerging Mechanisms and Disruption in Disease. Am. J. Hum. Genet 76, 8-32, 
doi:10.1086/426833 (2005). 
26 Siepel, A. et al. Evolutionarily conserved elements in vertebrate, insect, worm, and 
yeast genomes. Genome Research 15, 1034-1050, doi:10.1101/gr.3715005 (2005). 
 16 
27 Sandelin, A. et al. Arrays of ultraconserved non-coding regions span the loci of key 
developmental genes in vertebrate genomes. BMC Genomics 5, 99, 
doi:10.1186/1471-2164-5-99 (2004). 
28 Birney, E. et al. Identification and analysis of functional elements in 1% of the human 
genome by the ENCODE pilot project. Nature 447, 799-816, 
doi:10.1038/nature05874 (2007). 
29 Consortium, E. P. An integrated encyclopedia of DNA elements in the human 
genome. Nature 489, 57-74, doi:10.1038/nature11247 (2012). 
30 Crawford, G. E. et al. Genome-wide mapping of DNase hypersensitive sites using 
massively parallel signature sequencing (MPSS). Genome Res 16, 123-131, 
doi:10.1101/gr.4074106 (2006). 
31 Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. 
Transposition of native chromatin for fast and sensitive epigenomic profiling of open 
chromatin, DNA-binding proteins and nucleosome position. Nature Methods 10, 
1213-1218, doi:10.1038/nmeth.2688 (2013). 
32 Liu, C. L. et al. Single-nucleosome mapping of histone modifications in S-cerevisiae. 
Plos Biol 3, 1753-1769, doi:10.1371/journal.pbio.0030328 (2005). 
33 Bannister, A. J. et al. Spatial distribution of di- and tri-methyl lysine 36 of histone H3 
at active genes. J Biol Chem 280, 17732-17736, doi:10.1074/jbc.M500796200 (2005). 
34 Creygthon, C., Welstead, Kooistra, Carey, Steine, Hanna, Lodato, Frampton, Sharp, 
Boyer, Young, Jaenisch. Histone H3K27ac separates active from poised enhancers 
and predicts developmental state. PNAS (2010). 
35 Young, M. D. et al. ChIP-seq analysis reveals distinct H3K27me3 profiles that 
correlate with transcriptional activity. Nucleic Acids Res 39, 7415-7427, 
doi:10.1093/nar/gkr416 (2011). 
36 Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. & Cavalli, G. Genome 
regulation by polycomb and trithorax proteins. Cell 128, 735-745, 
doi:10.1016/j.cell.2007.02.009 (2007). 
37 Barski, A. et al. High-resolution profiling of histone methylations in the human 
genome. Cell 129, 823-837, doi:10.1016/j.cell.2007.05.009 (2007). 
38 Johnson, D. S., Mortazavi, A., Myers, R. M. & Wold, B. Genome-wide mapping of in 
vivo protein-DNA interactions. Science 316, 1497-1502, 
doi:10.1126/science.1141319 (2007). 
39 Landt, S. G. et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE 
consortia. Genome Research 22, 1813-1831, doi:10.1101/gr.136184.111 (2012). 
40 Consortium, R. E. et al. Integrative analysis of 111 reference human epigenomes. 
Nature 518, 317-330, doi:10.1038/nature14248 (2015). 
41 Ernst, J. & Kellis, M. Discovery and characterization of chromatin states for 
systematic annotation of the human genome. Nature Biotechnology 28, 817-825, 
doi:10.1038/nbt.1662 (2010). 
42 Kheradpour, P. & Kellis, M. Systematic discovery and characterization of regulatory 
motifs in ENCODE TF binding experiments. Nucleic Acids Res 42, 2976-2987, 
doi:10.1093/nar/gkt1249 (2014). 
43 Zhou, J. & Troyanskaya, O. G. Predicting effects of noncoding variants with deep 
learning-based sequence model. Nature Methods 12, doi:10.1038/nmeth.3547 
(2015). 
 17 
44 Dixon, A. L. et al. A genome-wide association study of global gene expression. Nat 
Genet 39, 1202-1207, doi:10.1038/ng2109 (2007). 
45 Stranger, B. E. et al. Population genomics of human gene expression. Nat Genet 39, 
1217-1224, doi:10.1038/ng2142 (2007). 
46 Morley, M. et al. Genetic analysis of genome-wide variation in human gene 
expression. Nature 430, 743-747, doi:10.1038/nature02797 (2004). 
47 Consortium, G. T. et al. Genetic effects on gene expression across human tissues. 
Nature 550, 204-213, doi:10.1038/nature24277 (2017). 
48 Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. Nat Genet 45, 
580-585, doi:10.1038/ng.2653 (2013). 
49 Grundberg, E. et al. Mapping cis- and trans-regulatory effects across multiple tissues 
in twins. Nat Genet 44, 1084-1089, doi:10.1038/ng.2394 (2012). 
50 Gaffney, D. J. et al. Dissecting the regulatory architecture of gene expression QTLs. 
Genome Biol 13, R7, doi:10.1186/gb-2012-13-1-r7 (2012). 
51 Dekker, R., Dekker, Kleckner. Capturing Chromosome Conformation. Science (2002). 
52 Lieberman-Aiden, E. et al. Comprehensive mapping of long-range interactions 
reveals folding principles of the human genome. Science 326, 289-293, 
doi:10.1126/science.1181369 (2009). 
53 Jager, R. et al. Capture Hi-C identifies the chromatin interactome of colorectal cancer 
risk loci. Nat Commun 6, 6178, doi:10.1038/ncomms7178 (2015). 
54 Davies, J. O. et al. Multiplexed analysis of chromosome conformation at vastly 
improved sensitivity. Nat Methods 13, 74-80, doi:10.1038/nmeth.3664 (2016). 
55 Hughes, J. R. et al. Analysis of hundreds of cis-regulatory landscapes at high 
resolution in a single, high-throughput experiment. Nat Genet 46, 205-212, 
doi:10.1038/ng.2871 (2014). 
56 Dewet, J. R., Wood, K. V., Deluca, M., Helinski, D. R. & Subramani, S. Firefly 
Luciferase Gene - Structure and Expression in Mammalian-Cells. Mol Cell Biol 7, 725-
737, doi:Doi 10.1128/Mcb.7.2.725 (1987). 
57 Melnikov, A. et al. Systematic dissection and optimization of inducible enhancers in 
human cells using a massively parallel reporter assay. Nature Biotechnology 30, 271-
277, doi:10.1038/nbt.2137 (2012). 
58 Patwardhan, R. P. et al. High-resolution analysis of DNA regulatory elements by 
synthetic saturation mutagenesis. Nature Biotechnology 27, 1173-1175, 
doi:10.1038/nbt.1589 (2009). 
59 Tewhey, R. et al. Direct Identification of Hundreds of Expression- Modulating 
Variants using a Multiplexed Reporter Resource Direct Identification of Hundreds of 
Expression-Modulating Variants using a Multiplexed Reporter Assay. Cell 165, 1519-
1529, doi:10.1016/j.cell.2016.04.027 (2016). 
60 Kheradpour, P. et al. Systematic dissection of regulatory motifs in 2000 predicted 
human enhancers using a massively parallel reporter assay. Genome Research, 800-
811, doi:10.1101/gr.144899.112 (2013). 
61 Gasperini, M. et al. CRISPR/Cas9-Mediated Scanning for Regulatory Elements 
Required for HPRT1 Expression via Thousands of Large, Programmed Genomic 
Deletions. Am J Hum Genet 101, 192-205, doi:10.1016/j.ajhg.2017.06.010 (2017). 
62 Findlay, G. M. et al. Accurate functional classification of thousands of BRCA1 
variants with saturation genome editing. bioRxiv, doi:10.1101/294520 (2018). 
 18 
63 Visel, A., Minovitsky, S., Dubchak, I. & Pennacchio, L. A. VISTA Enhancer Browser - A 
database of tissue-specific human enhancers. Nucleic Acids Research 35, 88-92, 
doi:10.1093/nar/gkl822 (2007). 
64 Dickel, D. E. et al. Ultraconserved Enhancers Are Required for Normal Development. 
Cell 172, 491, doi:10.1016/j.cell.2017.12.017 (2018). 
65 Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. 
Nature 507, doi:10.1038/nature12787 (2014). 
66 Ng, S. B. et al. Targeted capture and massively parallel sequencing of 12 human 
exomes. Nature 461, 272-U153, doi:10.1038/nature08250 (2009). 
67 Yang, Y. et al. Clinical whole-exome sequencing for the diagnosis of mendelian 
disorders. N Engl J Med 369, 1502-1511, doi:10.1056/NEJMoa1306555 (2013). 
68 Rehm, H. L. Evolving health care through personal genomics. Nat Rev Genet 18, 259-
267, doi:10.1038/nrg.2016.162 (2017). 
69 Cizmarova, M. et al. New Mutations Associated with Rasopathies in a Central 
European Population and Genotype-Phenotype Correlations. Ann Hum Genet 80, 50-
62, doi:10.1111/ahg.12140 (2016). 
70 Mcrae, J. F. et al. Prevalence and architecture of de novo mutations in 
developmental disorders. Nature 542, 433-438, doi:10.1038/nature21062 (2017). 
71 Retterer, K. et al. Clinical application of whole-exome sequencing across clinical 
indications. Genet Med 18, 696-704, doi:10.1038/gim.2015.148 (2016). 
72 Lee, H. et al. Clinical Exome Sequencing for Genetic Identification of Rare Mendelian 
Disorders. Journal of the American Medical Association 312, 1880-1887, 
doi:10.1001/jama.2014.14604 (2014). 
73 Chong, Jessica X. et al. The Genetic Basis of Mendelian Phenotypes: Discoveries, 
Challenges, and Opportunities. The American Journal of Human Genetics 97, 199-
215, doi:10.1016/j.ajhg.2015.06.009 (2015). 
74 Wright, C. F. et al. Making new genetic diagnoses with old data: iterative reanalysis 
and reporting from genome-wide data in 1,133 families with developmental 
disorders. Genet Med, doi:10.1038/gim.2017.246 (2018). 
75 Martin, H. C. et al. Quantifying the contribution of recessive coding variation to 
developmental disorders. bioRxiv, doi:10.1101/201533 (2017). 
76 Lane, K. B. et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta 
receptor, cause familial primary pulmonary hypertension. Nature Genetics 26, 81-84 
(2000). 
77 Graf, S. et al. Identification of rare sequence variation underlying heritable 
pulmonary arterial hypertension. Nature Communications 9, doi:ARTN 1416 
10.1038/s41467-018-03672-4 (2018). 
78 Hindorff, L. a. et al. Potential etiologic and functional implications of genome-wide 
association loci for human diseases and traits. Proceedings of the National Academy 
of Sciences of the United States of America 106, 9362-9367, 
doi:10.1073/pnas.0903103106 (2009). 
79 Maurano, M. T. et al. Systematic Localization of Common Disease-Associated 
Variation in Regulatory DNA. Science 337, 1190-1195, doi:10.1126/science.1222794 
(2012). 
80 Mahajan, A. et al. Refining the accuracy of validated target identification through 
coding variant fine-mapping in type 2 diabetes. Nat Genet 50, 559-571, 
doi:10.1038/s41588-018-0084-1 (2018). 
 19 
81 Lettice, L. A. et al. A long-range Shh enhancer regulates expression in the developing 
limb and fin and is associated with preaxial polydactyly. Human Molecular Genetics 
12, 1725-1735, doi:10.1093/hmg/ddg180 (2003). 
82 Lecerf, L. et al. An impairment of long distance SOX10 regulatory elements underlies 
isolated Hirschsprung disease. Hum Mutat 35, 303-307, doi:10.1002/humu.22499 
(2014). 
83 Weedon, M. N. et al. Recessive mutations in a distal PTF1A enhancer cause isolated 
pancreatic agenesis. Nature Genetics 46, 61-64, doi:10.1038/ng.2826 (2014). 
84 Mathelier, A., Shi, W. & Wasserman, W. W. Identification of altered cis-regulatory 
elements in human disease. Trends in Genetics 31, 67-76, 
doi:10.1016/j.tig.2014.12.003 (2015). 
85 Gordon, C. T. et al. Long-range regulation at the SOX9 locus in development and 
disease. J Med Genet 46, 649-656, doi:10.1136/jmg.2009.068361 (2009). 
86 Gordon, C. T. et al. Identification of Novel Craniofacial Regulatory Domains Located 
far Upstream of SOX9 and Disrupted in Pierre Robin Sequence. Hum Mutat 35, 1011-
1020, doi:10.1002/humu.22606 (2014). 
87 Dathe, K. et al. Duplications Involving a Conserved Regulatory Element Downstream 
of BMP2 Are Associated with Brachydactyly Type A2. Am J Hum Genet 84, 483-492, 
doi:10.1016/j.ajhg.2009.03.001 (2009). 
88 Amiel, J., Benko, S., Gordon, C. T. & Lyonnet, S. Disruption of long-distance highly 
conserved noncoding elements in neurocristopathies. Ann N Y Acad Sci 1214, 34-46, 
doi:10.1111/j.1749-6632.2010.05878.x (2010). 
89 Spielmann, M. & Mundlos, S. Looking beyond the genes: the role of non-coding 
variants in human disease. Human Molecular Genetics 25, 157-165, 
doi:10.1093/hmg/ddw205 (2016). 
90 Melton, C., Reuter, J. a., Spacek, D. V. & Snyder, M. Recurrent somatic mutations in 
regulatory regions of human cancer genomes. Nature Genetics, doi:10.1038/ng.3332 
(2015). 
91 Weinhold, N., Jacobsen, A., Schultz, N., Sander, C. & Lee, W. Genome-wide analysis 
of noncoding regulatory mutations in cancer. Nature Genetics 46, 1160-1165, 
doi:10.1038/ng.3101 (2014). 
92 Katainen, R. et al. CTCF/cohesin-binding sites are frequently mutated in cancer. 
Nature Genetics, 818-821, doi:10.1038/ng.3335 (2015). 
93 Zhang, W. et al. A global transcriptional network connecting noncoding mutations to 
changes in tumor gene expression. Nature Genetics 50, 613-+, doi:10.1038/s41588-
018-0091-2 (2018). 
94 Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum 
disorder. Nature 13, 216-221, doi:10.15154/1149697 (2014). 
95 Turner, Tychele N. et al. Genome Sequencing of Autism-Affected Families Reveals 
Disruption of Putative Noncoding Regulatory DNA. The American Journal of Human 
Genetics 98, 58-74, doi:10.1016/j.ajhg.2015.11.023 (2016). 
96 Werling, D. M. et al. An analytical framework for whole-genome sequence 
association studies and its implications for autism spectrum disorder. Nature 










The Deciphering Developmental Disorders Study 
 
The Deciphering Developmental Disorders (DDD) study is a collaboration 
between the National Health Services (NHS) Regional Genetics Centres in the United 
Kingdom and Ireland and the Wellcome Trust Sanger Institute which has enrolled 
nearly 14,000 patients with severe developmental disorders (DD)1. Patients enrolled 
in the DDD study do not have a molecular diagnosis for their disorder after testing by 
clinical microarray, single-gene tests, or gene panels by a senior clinical geneticist in 
the NHS. The sheer number of genes implicated in DD (2,045 as of this writing 
https://decipher.sanger.ac.uk/ddd#ddgenes), and the often-overlapping phenotypes 
from different genes (for example, intellectual disability or developmental delay) 
have made diagnosing this class of rare disorders very challenging. The rate of 
molecular diagnosis for these disorders has been estimated to be between 20% and 
60% dependent on a number of factors, including the specificity of the clinical 
presentation and the technology used to detect mutations, underscoring the need 
for greater understanding in the underlying genetic architecture and improvements 
in diagnosis2. 
Successful molecular diagnosis may provide opportunities for treatment. A 
number of metabolic disorders, provided they are correctly diagnosed, are amenable 
to treatment by vitamin or mineral supplementation. In Duchenne Muscular 
Dystrophy, exon-skipping therapies have been used in clinical trials to restore the 
open-reading frame of the DMD gene. Approaches such as these may be amenable 
to other developmental disorders, and successful diagnosis is a critical first step to 
understanding the mechanisms underlying these disorders, and conducting clinical 
trials. Furthermore, knowing the likely genetic cause of the disorder is essential for 
counselling families considering having more children. For example, the recurrence 
risk for a family whose child carries a de novo mutation (DNM) in a dominant 
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developmental disorder gene is far lower than for a family where the child has 
inherited a rare and damaging genetic variant from each parent in a recessive 
developmental disorder gene. 
The DDD study has performed exome sequencing on approximately 14,000 
affected individuals. Nearly 10,000 of the affected individuals were recruited as full 
trios (mother, father, and child). The trio study design allows for detection of both 
rare recessive variants and de novo mutations, which are more challenging to detect 
from singleton affected patients. A subset of patients were also tested using array 
CGH, which allows for detection of large copy number variations (CNVs). The 
affected individuals and parents enrolled in the study have undergone systematic 
phenotyping using the Human Phenotype Ontology3 as well as growth parameters 
including height, weight, and head circumference, and developmental milestones.  
Large copy-number variations, rare genetic variants, and de novo mutations 
disrupting protein-coding genes have been identified as likely causal in nearly one-
third of patients. The majority of these diagnosis are from de novo mutations in 
protein-coding genes. In the first 4,000 DD trios analysed, 25% of patients carried a 
likely causal de novo mutation in a known developmental disorder gene, and an 
additional 17% were predicted to carry pathogenic mutations in genes not yet 
robustly associated to developmental disorder4. However, after accounting for 
pathogenic de novo mutations and inherited variants, the majority of the individuals 
in the DDD study remain undiagnosed. For this reason, I sought to explore the 
contribution of de novo mutations outside of the protein-coding sequence. 
 
Assaying non-coding sequence in the Deciphering Developmental Disorders Study 
The majority of disease-associated common SNPs lie in intergenic or intronic 
regions, albeit with low effect sizes. In severe Mendelian disorders, rare sequence 
and structural variants in relatively few regulatory elements have been causally 
linked to Mendelian disorders5-7 (reviewed in Chapter 1, and Mathelier et. al, 2015, 
Zhang and Lupski, 2015, and Spielmann and Mundlos, 2016). These pathogenic 
regulatory variants can act by loss-of-function8-11 or gain-of-function12,13 and most 
act dominantly, with a few exceptions14. These regulatory elements can lie far from 
the gene they regulate. For example, sequence variants in an evolutionarily 
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conserved regulatory element located 1Mb from its target gene, SHH, can cause 
polydactyly12. As a consequence, it can be challenging to identify the gene whose 
regulation is being perturbed by an associated regulatory variant15-17. Moreover, the 
contribution of highly penetrant mutations in regulatory elements to genetically 
heterogeneous rare diseases, such as neurodevelopmental disorders, has not been 
firmly established. 
To assess the contribution of variation outside the coding regions to severe 
DD, more than 6,000 putative regulatory elements were included in the exome 
capture. These elements were derived from three major categories: 4,307 highly 
evolutionarily conserved non-coding elements18, 595 experimentally-validated 
enhancers19, and 1,237 putative heart enhancers20, together covering 4.2Mb of 
sequence (see Methods). 
 
Variant effect prediction in the non-coding genome 
 A number of computational tools have been developed that combine 
evolutionary conservation, chromatin modifications in different tissues, transcription 
factor binding sites, and other genomic features to predict the impact of variation 
genome-wide. Combined Annotation Dependent Depletion uses a support vector 
machine (SVM) to predict pathogenicity of coding and non-coding variation and has 
proved to be a powerful tool in the coding regions, particularly for improved 
stratification of missense variation21. FATHMM-MKL also uses an SVM to predict the 
pathogenicity of variation genome-wide, but instead of combining all features into 
one model, constructs a kernel for each different feature group (Histone 
modifications, TF binding sites, Open Chromatin, evolutionary conservation, GC 
content, amongst others)22. 
 In contrast to CADD and FATHMM-MKL, which attempt to model 
pathogenicity genome-wide, Genomiser addresses the more precise use-case of 
variant prioritisation in Mendelian disease23. Genomiser relies on a set of 453 non-
coding variants previously associated with Mendelian disorders, collected through 
literature review and in some cases, computational prediction. Genomiser employs a 
similar set of features to CADD and FATHMM-MKL, including evolutionary 
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conservation, histone modifications, and open chromatin data and uses a Random 
Forest model to make pathogenicity predictions. 
 Other methods have been developed to predict disruptions to TFBS, and 
integrate these disruptions with evolutionary conservation data to infer 
pathogenicity. One such method, DeepSEA uses a convolutional neural network 
(CNN) to predict TF binding intensity based on sequence context alone, using peak 
intensity from the ENCODE project to train the model24. While this method has been 
shown to outperform motif-based predictions of TF-binding, neural networks and 
other machine learning models that predict on sequence data alone are more 
challenging to interpret than models with structured feature sets. 
 CADD, Fathmm-MKL, Genomiser, and other non-coding variant effect 
predictors have purported to improve variant effect prediction for non-coding 
variation, but the utility of these scores has not been robustly verified in the non-
coding genome to the same degree as tools such as Variant Effect Predictor25 (VEP), 
SIFT26, PolyPhen27, or CADD21 which are used in interpretation of coding variation. 
This difference is in large part due to the paucity of disease associated regulatory 
variation to verify the models. In the case of Genomiser, which was trained using 
curated disease variants, testing on an independent set of disease-linked variants 
will not be possible until more variants independent of the training set have been 
reported. Furthermore, effect sizes in the non-coding genome may be smaller in 
general, as suggested by the greater burden of non-coding variation in common 
disease, making the detection of damaging variation more difficult. 
 An alternative approach to validate the utility of these models is to use 
selective constraint, which can be inferred from the allele frequency of variation in 
modern humans. Sites under negative selection will on average harbour fewer 
variants, and variants at lower allele frequencies, than sites evolving neutrally28-30 
This approach has been successfully applied in the coding regions of the genome—
CADD, SIFT, and PolyPhen scores show a strong correlation with pathogenicity 
predictions and inferred strength of purifying selection30. In this chapter, the 
mutability adjusted proportion of singletons (MAPS30) method is used to assess the 
relationship between non-coding variant effect predictors and selective constraint as 
a proxy for their potential in non-coding variant prioritisation. The topic of variant 
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effect prediction and selective constraint in the non-coding genome is explored in 




Recruitment in the Deciphering Developmental Disorders (DDD) project 
At the time of this analysis, 7,930 trios (mother, father, affected child) were 
recruited through NHS Clinical Genetics Centres in the U.K. and Ireland and had been 
sequenced. The families gave informed consent for participation and the study has 
research ethics approval (10/H0305/83, granted by the Cambridge South Research 
Ethics Committee and GEN/284/12, granted by the Republic of Ireland Research 
Ethics Committee). DECIPHER was used to collect and store clinical data including 
family history, growth measurements, developmental milestones, and structured 
phenotypic descriptions (using the Human Phenotype Ontology3). Saliva was 
collected from all family members, and blood was collected from affected probands 
and DNA was extracted for sequencing. 
 
Sequencing in the DDD Cohort 
Genomic DNA was extracted from patient saliva and sheared into 150bp fragments. 
Libraries were created following standard Illumina paired-end protocols in the 
Wellcome Trust Sanger Institute sequencing facility. SureSelect RNA baits were used 
to do the exome pulldown. Enriched libraries were sequenced on Illumina HiSeq at 
the Wellcome Trust Sanger Institute using 75-base paired-end sequencing. 
 
Alignment, Variant Calling, and Quality Control 
Mapping of short-read sequences was carried out using the Burrows-Wheeler 
Aligner31 (BWA; version 0.59) algorithm with the GRCh37 1000 Genomes Project 
phase 2 reference. The Genome Analysis Toolkit32 (GATK; version 3.1.1) and 
SAMtools33 (version 0.1.19) were used for sample-level BAM improvement. Ensembl 
Variant Effect Predictor (VEP25) based on Ensembl gene build 76 was used to 
annotate variants and, in coding regions, the transcript with the most severe 
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consequence was selected.  I identified a trinucleotide specific error mode 
(GTN->GGN) that introduced false positives which was corrected by strict strand 
filtering (FS < 20). I determined the number of variants called per individual, and 
excluded unaffected parents with variant counts on the extremes of the distribution 
(top 1% and bottom 1%). Across the 7,080 unaffected parents that passed quality 
control filters, I identified 1,520,250 unique variants in the targeted non-coding 
elements and coding regions. 
 
De novo mutation calling 
De novo mutations were called as described in McRae et al, 2017, excluding SNVs 
and indels with posterior probability <0.00781 as annotated by DeNovoGear34. 
 
Defining targeted non-coding elements 
The placental mammal 28-way phastCons score35 was used to select the top 4,432 
conserved non-coding elements with no overlap with RefSeq genes (downloaded 
from UCSC on August 4th, 2010). Using the VISTA enhancer browser19, all 622 
putative enhancers with evidence of in vivo activity in developing mouse embryos 
were downloaded on August 3rd, 2010. At the time the capture was designed, the 
observation had been made that heart enhancers are depleted among ultra-
conserved elements20. As heart defects are the largest group of non-CNS 
abnormalities in the DDD cohort ultra-conserved elements were supplemented with 
an early annotation of heart enhancers. These putative heart enhancers were kindly 
provided by Axel Visel based on ChIP-seq of p300 in human fetal heart described in 
May et. al, 2012 in GRCh36 coordinates, mapped over to GRCh3736. Collectively, 
these elements cover approximately 4.6 megabases of total sequence. First, 
elements were filtered to exclude any targeted sequences with less than 10x 
coverage across the DDD data set. Second, any elements previously annotated to be 
non-coding, but classified as protein-coding in Gencode v1937 were removed. Finally, 
any elements less than 50bp in length were excluded. After filtering, 4,307 




Defining intronic control sequences 
The exome baits designed to capture the coding regions frequently have 
considerable overlap with non-coding intronic regions. To define a set of putative 
well-covered introns, a 10bp buffer was added upstream and downstream of all 
gencode v19 coding sequence (to avoid classifying any critical splice sites in the 
control introns) and this coding sequence was subtracted from the exome probes. 
Furthermore, any introns within known developmental disorder genes (the DDG2P 
gene set38) were excluded. This set of control introns filtered to include only 
elements 30bp in length or larger with >30x coverage. 
 
Evolutionary conservation using phastcons and phylop 
The degree of evolutionary conservation across vertebrates at the element level was 
calculated using the phastcons vertebrate 100-way score. Scores were retrieved in R 
using the Bioconductor39 package phastCons100way.UCSC.hg1935 (Siepel et. al, 
2005). 
 
PhyloP scores represent the –log10 p-value that a given nucleotide is evolving 
neutrally40 (Pollard et. al, 2010). I used a tabix file of pre-computed PhyloP 
vertebrate 100-way scores for every site in the genome in order to annotate the 
DNMs observed in exome-negative probands, exome-positive probands and the 
simulated null model. 
 
Functional genomic annotation using the Roadmap Epigenome Project data 
Data from DNase hypersensitivity assays (broadPeak set, FDR 1%) were downloaded 
from the Roadmap Epigenome Project41 ftp site 
(http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/broadPeak/) 
in order to predict regulatory function and tissue-specificity in the enhancers and 
conserved noncoding elements. The GenomicRanges Bioconductor39,42 package was 
used to intersect DHS peaks with the elements sequenced in this analysis. All code 




Chromatin state predictions (chromHMM 15-state model43) for 111 different tissue 
types were downloaded from the Roadmap Epigenome Project41 (REP) ftp site 
(http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/Chmm
Models/coreMarks/indivModels/default_init/). I considered a CNE to be inactive in a 
given tissue if it was completely contained within a chromHMM segment described 
as Quiescent, Heterochromatin, or Polycomb Repressed ("9_Het", "13_ReprPC", 
"14_ReprPCWk", and "15_Quies") in the 15-state model. Using the GenomicRanges42 
Bioconductor package and coding sequence from gencode v19, I calculated the 
distance of each active and broadly inactive element to the nearest exon or 
transcription start site. All code used in this analysis can be found at 
https://github.com/pjshort/DDDNonCoding2017. 
 
Trinucleotide mutation rate model with CpG-methylation status 
The germline mutation rate model described in Samocha et. al, 2014 based on tri-
nucleotide context44 was adapted to include a correction at CpG sites for 
methylation status. This method models the null mutation rate at a given site as a 
Poisson rate parameter that is dependent on the tri-nucleotide context, where the 
second base is mutated. I fit a linear model to the ratio of observed/expected 
variants at MAF <0.1% in CpG sites based on their methylation status in embryonic 
stem cells. For all CpG sites, I corrected the tri-nucleotide mutation rate based on the 
methylation status to produce a methylation-aware mutation rate model. As the 
sum of Poisson random variables is Poisson, the rate parameter for a given element, 
or set of elements, can be determined by summing the mutation rate for each 
individual site. Simulated mutations were based on the same tri-nucleotide mutation 
framework and implemented in an R software package: 
https://github.com/pjshort/DenovoSim. 
 
Statistical testing for mutational burden 
The p-value for the number of observed de novo mutations compared to expected is 
calculated in R as:  
 
ppois(n_obs - 1, lambda = mu, lower.tail = FALSE)  
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where n_obs is the number of observed mutations within an element and mu is the 
mutability of the element(s) being tested (under the null model described above) 
multiplied by the number of probands. The burden testing I performed across 
subsets of elements and phenotypes included multiple nested hypotheses that were 
accounted for with a conservative Bonferroni-adjusted p-value threshold based on 
the number of explicit and implicit tests. 
 
Gene-target prediction 
I used four different methods of gene target prediction to link CNEs and enhancers 
to putative target genes.  
 
The first method, Genomicus, predicts gene targets based on evolutionary 
conservation with nearby genes. Genomicus determines the extent to which each 
CNE is within the same syntenic block with nearby genes across a number of 
vertebrate species and predicts one or more targets16. The Genomicus method 
produces at least one prediction for 90% of CNEs (approximately 1/3 of these are the 
closest gene). 
 
The second method, described in Shooshtari et. al, 2016, compares DNase 
hypersensivity at each CNE to expression of nearby genes in 56 different tissues 
(using RNA-seq) to search for CNE-gene pairs that show a correlation between 
DNase signal and gene expression45. This method produces statistically significant 
predictions for only 28% of CNEs in our set and is likely underpowered to detect 
elements that are active in specific tissues or timepoints. 
 
The third method is to link CNEs to putative target genes using chromatin interaction 
data (Hi-C) in two different regions of the fetal brain derived from Won et. al, 201646. 
Using Hi-C data is the most direct and tissue specific of all of the prediction methods 
used, but the prediction is sparse (26% of CNEs with evidence for fetal brain activity 
have a predicted target). 
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The fourth method used is a simple heuristic to choose the gene with the closest TSS 
(for intergenic elements) or the gene containing the element (for introns). Choosing 
the closest gene allows us to make a prediction for 100% of elements, but 
comparison with chromatin conformation and DHS-based methods has shown that 
the closest gene is likely the target 7% and 12% of cases45,47. 
 
I used the Genomicus, DHS, and Hi-C predictions to generate aggregated predictions 
which I considered ‘high confidence’ if predicted by at least two of the three 
methods. 
 
To assess the pair-wise concordance, I took the set of CNEs for which at least one 
gene target was reported in both methods and tested how frequently both methods 
identified the same gene within the set of predicted targets. 
 
Transcription factor binding site analyses 
The JASPAR2016 and TFBSTools Bioconductor packages48 were used to retrieve 
position weight matrices for 454 human transcription factors (TFs). Analyses in this 
chapter focus on the 202 TFs predicted to be expressed in the brain (cortex-
expressed from GTEx dataset49). 
 
A custom R package called ‘denovoTF’ (https://github.com/pjshort/denovoTF) was 
written to predict any change in TF binding at sites where DNMs were observed or 
simulated. This analysis works by scanning the reference and alternative sequence 
for all 202 PWMs and comparing predicted binding events on both sequences. By 
comparing the potential binding affinity for ref and alt sequences, I can predict loss 
of binding (alt binding < ref binding), gain of binding (alt binding > ref binding), and 
silent (no difference). ‘Silent’ DNMs fall into two classes: those for which binding is 
predicted on both reference and alternate, but strength of binding is unchanged, 
and those which do not lie in a predicted TF binding site. 
 
The analysis of motif enrichment (AME) tool from the meme suite was used to 
identify a subset of PWMs that was significantly enriched in the fetal brain active 
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elements50. Comparing the fetal brain active CNEs to the fetal brain inactive CNEs 
returned a set of 90 transcription factors, of which 45 were expressed in the brain 
and had PWMs available in JASPAR201648. This analysis was performed on the 
meme-suite web server using the following command: 
 
ame --verbose 1 --oc . --control meme_chromHMM_fb_inactive_all.fasta --bgformat 
1 --scoring avg --method ranksum --pvalue-report-threshold 0.05 
meme_chromHMM_fb_active_all.fasta db/JASPAR/JASPAR_CORE_2016.meme 
 
In order to test for enrichment of loss of binding or gain of binding events in the 
observed DNMs, I compared predicted impact on TF binding in observed DNMs to 
1,000 simulations of mutations across the 2,613 fetal brain active elements for 6,147 
probands. 
 
Power calculations at different study sizes 
I used the tri-nucleotide null model described previously in order to estimate our 
power to detect disease-associated elements. Parameters impacting power include 
the fold enrichment for disease-causing mutations in the DDD cohort (proportional 
to the incidence of severe developmental disorders with a genetic basis in the 
population), the proportion of mutations within a true disease-associated element 
expected to be pathogenic, the penetrance of such mutations, the size/mutability of 
the elements tested, and the number of trios analysed. In order to estimate the 
power across different study sizes, I fixed the remaining parameters as follows: 120-
fold enrichment for disease-causing mutations, proportion of mutations expected to 
be pathogenic at 8% (lower bound estimate for coding regions), penetrance at 100%, 
and the elements tested were the 2,613 fetal brain active conserved non-coding 




Estimating the genome-wide burden of DNMs in fetal brain active elements 
contributing to severe DD 
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First, I intersected all targeted non-coding sequence, irrespective of original class, 
with fetal brain DHS peaks. I used the phastcons100 score (scores retrieved in R 
using the Bioconductor package phastCons100way.UCSC.hg1935 (Siepel et. al, 2005) 
to rank these elements by evolutionary conservation. The ratio of 
observed/expected DNMs was computed with a sliding window across the elements 
(window size of 1000 elements, shift of 100 elements). This approach resulted in a 
median of 62 DNMs expected in each bin (minimum 51, maximum 68) which was 
compared to the observed number of DNMs. I fit a logistic regression to the excess 
observed/expected in each window, setting any window with observed less than 
expected to have excess of zero. I used the logistic regression fit on the CNEs 
sequenced in our analysis to predict the burden of DNMs in this genome-wide set. 
 
Modelling the likelihood of different proportions of elements and sites with 
monoallelic disease mechanism given observed data  
In order to test the likelihood of different models of dominant disease mechanism 
within the non-coding space I adapted the power calculation framework described 
above to test the probability of observing our data across two different parameters: 
the number of elements (out of 2,613) with a dominant disease mechanism and the 
proportion of mutations expected to be pathogenic. I tested the likelihood of 
observing 286 DNMs, 25 recurrently mutated elements, and zero elements at 
genome-wide significance while systematically varying two parameters: the 
proportion of mutations expected to be pathogenic parameter from 0.01% to 10.0% 
in increments of 0.01% and the proportion of elements with true disease-
associations (from 0 to 2,613 in increments of 5). In this analysis, the remaining 
parameters were held constant: 120x enrichment for pathogenic mutations, 
penetrance at 100%, testing 2,613 fetal brain active conserved non-coding elements, 




Results Section 2.1: Assessing the role of de novo mutations in regulatory 
elements in severe DD 
Results Section 2.1.1. Modelling the germline mutation rate in the non-coding 
genome 
 Assessing the contribution of de novo mutations (DNMs) to developmental 
disorders relies on an accurate null model of the germline mutation rate in the 
absence of disease association. Local sequence context has been shown to have a 
significant influence on the per-base mutation rate44. For example, CpG 
dinucleotides have an approximately 10x greater mutation rate than other 
dinucleotides due to spontaneous deamination when the C is methylated. This 
spontaneous deamination results in a high rate C to T transitions, and is reflected in 
an overrepresentation of polymorphisms at CpG sites, and a higher rate of 
DNMs30,44,51,52. 
A well-established mutation rate model incorporating the sequence one base 
upstream and downstream of a nucleotide of interest, referred to as the ‘triplet 
context’, has been shown to significantly outperform sequence-agnostic models in 
predicting the number of DNMs or level of rare variation in a protein-coding gene. 
This model has been used extensively in assessing the burden of DNMs in the autism 
spectrum disorder (ASD) patients and DD patients53, and to predict the level of 
expected rare variation in protein-coding genes in order to detect genes under 
purifying selection30. 
 However, the widely used tri-nucleotide mutation rate model does not 
account for methylation status. Unmethylated CpGs have a substantially lower 
mutation rate. As a result, loci with high levels of methylation relative to the 
genome-wide average for CpG dinucleotides would have a higher than expected 
mutation rate. Conversely, loci with low levels of methylation at CpG dinucleotides 
(for example, promoters) would have a much lower mutation rate than predicted by 
the trinucleotide model. Thus, I adapted this tri-nucleotide model to include CpG 
methylation genome-wide. There is a strong correlation between the observed 
number of rare variants at CpG sites and their methylation levels in either embryonic 
stem cells (ESCs) or sperm (Figure 1A). This methylation-aware model better 
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accounts for levels of rare variation observed in the set of non-coding elements 
sequenced in DDD (Figure 1B).  
 
 
Figure 1 Methylation-aware mutation rate model. (a) Methylation proportion at a given CpG site 
in Embryonic Stem Cells (ESC) and sperm correlates with observed rare variation in gnomAD. (b) 




Results Section 2.1.2. Selective constraint acting on non-coding elements 
I reasoned that if the non-coding elements sequenced in DDD were 
contributing to severe developmental disorders, there should be evidence for 
negative selection in these elements. I first assessed how much purifying selection 
had skewed allele frequencies in non-coding elements using the mutability-adjusted 
proportion of singletons (MAPS) metric30 in 7,080 unrelated, unaffected DDD 
parents. I tested six different element classes: introns, heart enhancers, validated 
enhancers, conserved non-coding elements (CNEs), protein-coding genes, and 
known DD-associated genes. The validated enhancers from the VISTA enhancer 
browser vary across the spectrum of evolutionary conservation, while the heart 
enhancers are poorly conserved, consistent with previous reports20, and the CNEs 
show high levels of evolutionary conservation (Figure 2A).  The introns and heart 
enhancers show little evidence of purifying selection, while the experimentally-
validated enhancers and CNEs are constrained to a similar degree to protein-coding 
genes, but less than known DD-associated genes (Figure 2B), consistent with 
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Figure 2 Selective constraint in targeted non-coding elements. (a) Evolutionary conservation score 
(phastcons10035) for CNEs (n=4,307), experimentally validated enhancers (n=595), and putative 
heart enhancers (n=1,237). (b) Strength of selection (MAPS metric, mean and 95% CI represented 
by dot and bars) in targeted non-coding elements compared to protein-coding regions, where 
‘Exonic’ refers to all variation within protein coding exons. Stratification based on 
synonymous/non-synonymous consequence displayed on the same row to illustrate power of even 
a simple discriminator. Introns and putative heart enhancers show little evidence of purifying 
selection while CNEs show selection on par with all genes, but less than known DD genes. (c) Using 
CADD to stratify coding and non-coding variants observed in unaffected parents differentiates 
neutral variation from weakly and strongly constrained sites in coding regions, but fails to identify 
non-coding variation with selection pressure on par with protein-truncating variants (stop gained). 
(d) Sites overlapping a DNase I hypersensitive site (DHS) in at least one tissue are under stronger 
purifying selection than sites not overlapping a DHS. 
 
Statistical power to detect functionally relevant variants in protein-coding 
genes is strengthened considerably by stratification of variants by their likely impact 
on the encoded protein and variant deleteriousness metrics such as CADD21. I 
computed the MAPS within bins of CADD scores encompassing 1,520,250 variants in 
unaffected DDD parents to assess whether CADD was predictive of selective 
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strength of purifying selection enabled differentiation between variants that are 
neutral (synonymous sites), weakly constrained (missense variants), and highly 
constrained (protein-truncating variants). In CNEs, CADD differentiates neutral 
variation from variation under weak constraint (comparable to missense variants), 
but failed to identify highly deleterious variants with selective constraint on a par 
with protein-truncating variants (Figure 2C). Other deleteriousness metrics were 
assessed, but none were more informative than CADD (Figure 3).  
I used DNase I hypersensitivity sites (DHS) in 39 tissues and chromHMM 
genome segmentation predictions in 111 tissues41 to predict tissue activity for the 
targeted non-coding elements. Of the 4,307 CNEs sequenced, 4,046 (93.9%) were 
active in at least one of the 111 surveyed tissues while 261 (6.1%) were inactive or 
repressed in all tissues. Variants within a DHS peak in at least one tissue were under 
stronger purifying selection than variants not overlapping a DHS peak (p = 0.019), 
but I did not identify significant differences in selective constraint between different 
tissues (Figure 2D). 
The non-coding elements sequenced in this study are not representative of 
regulatory elements genome-wide, and the MAPS metric used here is not the only 
method for detecting selective constraint. Evidence of selective constraint in the 
non-coding genome is explored in greater detail in Chapter 3 using genome-wide 
assays of putative regulatory function and deep whole genome sequences to test for 




Figure 3 Assessment of variant deleteriousness metrics and selective pressure in conserved non-
coding elements. Dots and bars represent the point estimate and 95% confidence interval, 
respectively for MAPS and proportion singletons. (a) Fathmm-MKL and (b) Genomiser separate 
benign variation (low MAPS score) from likely damaging variation (high MAPS score), but do not 
identify any classes of variation under strong selective constraint. (c) Validation of Figure 2C in 
main text using whole genome data from UK10K project. While CADD can identify coding variation 
under strong selective constraint (as measured by the proportion of singletons), CADD is unable to 
identify strongly constrained non-coding variants. (d) There was no significant difference in 
strength of purifying selection measured by MAPS between sites predicted to result in loss, gain, or 
no change of transcription factor binding. 
 
 
Results Section 2.1.2. Fetal brain active ultra-conserved non-coding elements are 
enriched for mutations in exome-negative probands with neurodevelopmental 
phenotypes 
 
To assess the contribution of DNMs in regulatory elements sequenced in the 
DDD families, I identified candidate de novo single nucleotide mutations in 7,930 
trios using DeNovoGear (see Methods). I identified 1,691 ‘exome-positive’ 
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known DD-associated gene, with the remaining 6,239 being ‘exome-negative’. Using 
the methylation-aware mutation model, I compared the numbers of observed and 
expected DNMs in the targeted non-coding elements in these individuals. No 
significant DNM enrichment was observed in exome-positive probands in the 
targeted non-coding elements, demonstrating that the mutation model is reasonably 
well-calibrated and that a large proportion of exome-positive cases likely represent 
Mendelian syndromes caused by high-penetrance protein-coding mutations (Figure 
4A). I note that the number of exome-positive individuals affords only limited power 
to reject modest mutation enrichment in the non-coding elements. Based on these 
results, I chose to focus on the 6,239 exome-negative individuals for subsequent 
analyses. 
 
Figure 4 Non-coding mutations in exome-positive and exome-negative probands. Red diamonds 
indicate observed counts, while black circles and bars indicate expected count and 95% CI. (a) In 
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the 1,691 ‘exome-positive’ probands, there is no evidence for a burden of de novo mutations in 
any of the non-coding element classes tested. (b) Enrichment of DNMs across element classes and 
functional annotations in exome-negative probands (n=6,239). Targeted CNEs showed a modest 
enrichment for DNMs (422 observed, 388 expected, p = 0.04) while heart enhancers, 
experimentally-validated enhancers, and control introns matched the null model. Observed 
enrichment is specific to CNEs predicted to be active in the fetal brain and to patients with 
neurodevelopmental disorders (238 observed, 194 expected, p = 1.2e-3). Confidence intervals and 
p-values derived from a Poisson distribution. 
 
 I found that the CNEs are nominally significantly enriched for DNMs (422 
observed, 388 expected, p = 0.04), whereas experimentally-validated enhancers (153 
observed, 156 expected, p = 0.605), heart enhancers (86 observed, 86 expected, p = 
0.514), and intronic controls (901 observed, 919 expected, p = 0.728) were not 
enriched (Figure 4B). 
Given the preponderance of individuals with neurodevelopmental disorders 
in our cohort but broad range of the tissue activity of the targeted CNEs, I focused on 
CNEs active in fetal brain. I observed a strong significant enrichment of DNMs within 
2,077 fetal brain DHS peaks in CNEs (177 observed, 138 expected, p = 8.1e-4) but no 
enrichment in sites in CNEs falling outside of fetal brain DHSs (245 observed, 249 
expected, p = 0.608) (Figure 4B). I also used chromHMM43 predictions of fetal brain 
activity and again identified a significant enrichment of DNMs in the 2,613 fetal brain 
active CNEs (Figure 4B). Moreover, the DNMs observed in fetal brain active CNEs in 
exome-negative probands were at more highly conserved sites (Wilcoxon rank sum 
test on PhyloP 100-way score40, p = 7.5e-4) compared to DNMs observed in exome-
positive probands (Figure 5). 
The excess of DNMs observed in fetal brain active CNEs is concentrated 
exclusively within the 79% of exome-negative probands with neurodevelopmental 
phenotypes (fetal brain DHS peaks: 147 observed, 109 expected, p = 3.1e-4, fetal 
brain active by chromHMM: 238 observed, 194 expected, p = 1.2e-3), with no 
significant enrichment observed in those without neurodevelopmental phenotypes 
(fetal brain DHS: p=0.413; fetal brain active by chromHMM: p=0.681) (Figure 4B). 
The highly significant and specific enrichment of DNMs in fetal brain active CNEs in 
exome-negative probands with neurodevelopmental disorders is robust to 
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Bonferroni correction for thirteen explicitly and implicitly tested hypotheses (Figure 
6A). The fold-enrichment of DNMs is consistent with DNMs in fetal brain active CNEs 




Figure 5 Evolutionary conservation of mutated base in conserved non-coding elements. DNMs in 
exome-negative probands show a greater degree of evolutionary conservation (measured by 
PhyloP score) compared to DNMs observed in exome-positive probands in two classes: fetal brain 
active CNEs (median 1.57 exome-positive, 2.85 exome-negative, n=368 mutations) and missense 
changes (median 3.43 exome-positive, 3.98 exome-negative, n = 6244 mutations). 
 
 Having identified a signal of DNM enrichment only within CNEs active in fetal 
brain, I re-evaluated the experimentally-validated enhancers with functional 
evidence for activity in fetal brain (N=383, 64%) and observed a nominally significant 
enrichment for DNMs only within the top quartile of evolutionary conservation (18 
observed, 9 expected, p = 0.01) (Figure 6B). This result is suggestive that even for 
experimentally validated fetal brain enhancers, DNM enrichment is concentrated 
within elements with strong evolutionary conservation. 
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Figure 6 Hypothesis test enumeration and enrichment for mutations in highly conserved fetal 
brain active enhancers. (a) We corrected for thirteen tests in order to account for the nested 
hypotheses based on element class and phenotype in this analysis. (b) Evolutionarily conserved 
fetal brain active enhancers (n=106) are enriched for DNMs in exome-negative probands. 
 
 In addition to methylation at CpG sites, other genomic features have been 
previously associated with mutagenicity. To test whether the enrichment for 
mutations I observe is a result of hypermutability rather than disease association, I 
tested four genomic features previously associated with mutagenicity56 for 
enrichment in non-coding elements with DNMs. I found no evidence that these 
genomic features were enriched in non-coding elements with DNMs (H3K27me3 χ2-
test p=0.4809, H3K9me3 χ2-test p=0.1966, replication timing57 Figure 7A, 
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recombination rate58 Figure 7B). To test for any as yet unknown factors causing 
differential mutability, I compared the levels of rare variation in fetal brain active 
and inactive CNEs in 7,509 deep whole genomes from the gnomAD consortium and 
found no evidence for a higher germline mutation rate in fetal brain active elements 
(Figure 7C, D). These results indicate that the enrichment of DNMs in regulatory 
elements in exome-negative probands is not likely to be the result of 
hypermutability not captured by the mutation rate model. 
 
 
Figure 7 Genomic factors influencing mutation rate in non-coding elements. (a) Elements with de 
novo mutations observed in our study are not enriched in late-replicating regions or (b) in regions 
with higher recombination rate. (c) Levels of rare variation in deep whole genomes (n=7,509 non-
Finnish Europeans) were used to estimate power to detect a hypermutability of 1.1X, 1.2X, or 1.3X. 
(d) The level of rare variation in the fetal brain active elements (n=2613, labelled FB(+)) is slightly 
lower than the fetal brain inactive elements (n=1694, labelled FB(-)), consistent with similar 




I next sought to estimate what proportion of the fetal brain active CNEs  
sequenced in the DDD patients act as enhancers. I compared a set of 617 high 
confidence brain enhancers from the VISTA enhancer database to two orthogonal 
enhancer annotations, FANTOM559 and EnhancerAtlas60. The high confidence 
enhancers from the VISTA database were also identified as enhancers in the 
FANTOM5 or EnhancerAtlas datasets, 12% and 36% respectively, providing an 
estimate for the sensivitity of these two datasets. Applying the same test to the 
CNEs, 6% of the fetal brain active CNEs were identified as enhancers by FANTOM5 
and 28% were identified as enhancers by EnhancerAtlas. Taken together, these 
results suggest that at least half and possibly up to three quarters of CNEs are acting 
as enhancers. 
In principle, linking regulatory elements to the gene(s) they regulate may 
improve power (by grouping distinct elements, and by combining burden of 
regulatory and coding mutations). Furthermore, predicting the target gene(s) for a 
given regulatory element may provide greater insight into mechanisms of 
pathogenic mutations in regulatory elements. I assessed four different methods for 
gene target prediction: Genomicus35 (based on evolutionary synteny), correlation 
between DNase accessibility and gene expression36, Hi-C in fetal brain33, and 
choosing the closest gene. Genome annotations are rapidly evolving and the 
sensitivity and specificity of gene target prediction methods is not yet known. 
However, independent eQTL, eRNA and Hi-C data all suggest that the closest gene is 
often not the target of non-coding regulatory variation32-34. Across the four methods 
tested, the proportion of fetal brain active CNEs for which a target gene was 
predicted was 28% (fetal brain Hi-C), 48% (DHS-RNA correlation), 91% (evolutionary 
synteny), and 100% (closest gene). The pairwise-concordance between any two 
methods (given that both methods make a prediction) was between 17% and 35% 
(Figure 8A). Intersecting multiple independent methods may provide higher 
confidence predictions, but comes at a cost of sensitivity and therefore power. I did 
not identify any enrichment for DNMs in elements predicted to target known DD 
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genes, likely dosage sensitive genes (pLI metric22), or genes differentially expressed 
in the brain (Figure 8B). Gene target predictions using fetal brain Hi-C were 
performed by Hyejung Won, a collaborator in the Geschwind Lab at UCLA. 
 
 
Figure 8 Gene target prediction for targeted non-coding elements. (a) Pairwise concordance 
between four different gene target prediction methods is low. (b) Using predicted targets from 
fetal brain Hi-C data, elements with an observed DNM in an exome-negative probands (n=286) do 
not show any bias toward any of the gene sets consistently implicated in neurodevelopmental 
disorders. Dots and bars represent the point estimate and 95% confidence interval, respectively. 
 
I hypothesized that the mutations observed in DDD patients may be altering 
transcription factor binding. To this end, I assessed the impact of DNMs on a set of 
45 transcription factor binding motifs enriched in fetal brain active CNEs (see 
Methods), and observed a nominally significant enrichment for DNMs predicted to 
increase binding affinity which did not survive multiple hypothesis correction (Figure 
9). Given the number of DNMs identified, and the relative immaturity of in silico 
predictions of the impact of non-coding variation, it is not currently possible to 
determine precise mechanisms by which these DNMs contribute to DDs. 
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Figure 9 Predicted transcription factor binding site disruption. (a-d) Comparing predicted change 
in transcription factor binding for observed DNMs compared to null mutation model. Empirical p-
values derived from comparison with mutations simulated from the null mutation model. 
 
Results Section 2.1.3. Recurrently mutated regulatory elements 
 Observing mutations independently in multiple different families has led to 
the discovery of dozens of novel developmental disorder-associated protein-coding 
genes4 . I applied the same approach to the set of targeted non-coding elements to 
test for recurrently mutated non-coding elements (two or more DNMs in unrelated 
individuals). I observed a significant excess of recurrently mutated elements in the 
fetal brain active CNEs and evolutionarily conserved enhancers compared to the 
expectation under the null mutation model (31 observed, 15 expected, p = 9.3e-5) 
(Figure 10A). However, no individual element exceeds a conservative genome-wide 
significance threshold of p<1.91e-5 (Bonferroni-correction for independent tests on 
2,613 fetal brain active elements) (Figure 10B). Nonetheless, the set of thirty-one 
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recurrently mutated elements provides a source of elements for medium and high-
throughput functional assays, albeit with a high false-discovery rate (FDR of 
approximately 50%). I tested these thirty-one recurrently mutated using a saturation 
mutagenesis massively parallel reporter assay in order to gain a better 
understanding of the nucleotide-level patterns underlying these elements. 
Furthermore, a subset of these elements with robust evidence for fetal brain 
enhancer activities were tested in mouse knockout studies in collaboration with 
Evgeny Kvon, Diane Dickel, Len Pennachio, and Axel Visel. These results are 
discussed in detail in Chapter 4, and these assays and other potential functional 
follow-ups are detailed in the Discussion of this chapter. 
 
 
Figure 10 Recurrently mutated elements. (a) Approximately two-fold enrichment of recurrently 
mutated non-coding elements. Grey histogram shows distribution of expected number of 
recurrently mutated fetal brain active non-coding elements under the null model and vertical line 
indicates observed number. (b) Enrichment test of individual non-coding elements. No element 
was significant at a genome-wide threshold of P < 1.9 ´ 10-5 (Bonferroni correction for testing 
2,613 fetal brain active elements). Inset plots for three elements show the nearest exon or 
transcription start site, location of DNMs (red markers) with any predicted transcription factor 
binding site disruptions (gain of binding in blue, loss of binding in red), location of rare variants in 
unaffected parents (grey markers), evolutionary conservation (blue, higher indicates more 
conserved), and fetal brain DNase I hypersensitivity (male in pink, female in blue). 
 
I used chromHMM43 to assign the recurrently mutated CNEs to a predicted 
chromatin state. I observed the greatest excess of DNMs in CNEs predicted to be 
enhancers (N=9) or strongly/weakly transcribed (N=8) (Figure 11). Five of the eight 
transcribed recurrently mutated elements fall in close proximity to exons, but are 
not in protein-coding transcripts and show evidence for involvement in alternative 
splicing (BCLAF1, SRRT, SLC10A7, and MKNK1) or as a 3’ UTR (CELF1). The full set of 
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recurrently mutated elements is described in Supplementary Table 1 (Appendix 1) 
and the location of DNMs relative to population variation and additional annotations 
is shown in Supplementary Figure 1 (Appendix 1). 
 
Figure 11 chromatin state of the recurrently mutated elements. chromHMM was used to 
annotate each of the recurrently mutated elements with a predicted chromatin state. The 
recurrently mutated elements showed an enrichment for enhancers and transcribed elements. 
 
Increased power to detect locus-specific enrichments of DNMs could be 
gained from aggregating DNMs across elements regulating the same target gene(s). 
However, as described above, gene target prediction is lacking in coverage and 
accuracy. CNEs have been shown to cluster together within the genome61 and are 
enriched around developmentally important genes61. An alternate approach, 
analogous to aggregating distinct exons into a single gene, is to cluster regulatory 
elements based on their location in genomic space. Therefore I applied hierarchical 
clustering on the 2,613 fetal brain active CNEs to identify 356 clusters (Methods). I 
found an excess of recurrently mutated clusters, defined as two or more elements 
with at least one DNM in each element (11 observed, 6 expected, p = 0.016), but did 
not find any element clusters with a significant excess of DNMs at a genome-wide 
significance threshold. 
	 48	
Results Section 2.2: Extrapolating results from targeted regulatory elements 
to genome-wide estimates 
Results Section 2.2.1. Estimate of proportion of probands carrying a pathogenic 
mutation in a regulatory element genome-wide. 
While only 4.2Mb of non-coding sequence was analysed in this cohort, there 
is more than 80Mb of non-coding sequence overlapping DNase I hypersensitive sites 
in the fetal brain. Unlike the set of elements I targeted, which is biased toward highly 
evolutionarily conserved elements, the vast majority of open chromatin regions in 
the fetal brain are poorly evolutionarily conserved (Figure 12A). Thus, the results 
from the DDD project is biased towards highly evolutionarily conserved elements, 
but also includes elements with lower levels of evolutionary conservation. In the 
targeted elements in this study, all of the observed DNM enrichment is concentrated 
in the highly conserved elements and I see no evidence for enrichment in poorly 
conserved regions, even though a large fraction of the poorly conserved regions 
have strong evidence for enhancer activity in mouse transgenesis assays. 
To extrapolate the excess of DNMs I observed in the targeted non-coding 
elements to a genome-wide estimate, I modelled the enrichment of DNMs in the 
targeted non-coding elements as a function of evolutionary conservation and 
extrapolated to non-coding elements genome-wide (Methods). Factoring in the 
distribution of evolutionary conservation of fetal brain DHS peaks genome-wide, I 
predicted a genome-wide excess of 88 DNMs (95% CI: 48-140), corresponding to 
1.0% - 2.8% of exome-negative cases carrying pathogenic mutations in regulatory 
elements (Figure 12A) in contrast to 13.4% and 28.4% carrying protein-truncating 
variants and missense variants estimated by McRae et. al, 2017 (Figure 12B). This 
estimate does not include small insertions or deletions due to a low number of 
observations in this study and the lack of a well-calibrated mutation model for small 
insertions and deletions. Furthermore, the lack of signal in poorly conserved 
elements should not be considered definitively negative – the targeting strategy in 
this analysis focused on highly evolutionarily conserved elements and comparable 
numbers of affected trios with deep whole genome sequencing will provide a more 
	 49	




Figure 12 Genome-wide estimate of DNM burden. (a) Logistic regression used to model the 
genome-wide contribution of dominant-acting DNMs in fetal brain DNase hypersensitive sites in 
non-coding elements as a function of level of evolutionary conservation using a sliding window 
approach including 1,000 elements in each bin (see Methods). Dashed lines indicate the upper and 
lower 95% CI. The barplot shows the fetal brain active DHS peaks genome-wide (in megabase of 
total sequence) at a given level of evolutionary conservation. (b) The proportion of probands 
carrying a pathogenic de novo SNV in a fetal brain active regulatory element (1-2.8%) is far lower 
than the proportion carrying a pathogenic de novo protein-truncating variant (PTV) (~13.4%) or de 
novo missense variant (~28.4%). 
 
 
Results Section 2.2.2. Power calculations and estimation of fraction of bases 
contributing to severe DD when mutated 
 
The significant excess of recurrently mutated elements, but absence of 
individual non-coding elements with a genome-wide significant enrichment of DNMs 
is indicative of low power. This was initially surprising, as in a study comprising 4,293 
trios, roughly half the sample size of this analysis, McRae et. al discovered 94 
robustly associated protein-coding genes4. However, a large fraction of the 
difference in power can be attributed to the smaller size of CNEs compared to 
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protein-coding genes and the lack of nucleotide-level variant effect prediction in the 
non-coding genome. The CNEs sequenced in this analysis are a median of 600bp in 
length, while protein-coding genes are median of 1800bp. Furthermore, variant 
effect predictor (VEP) reliably stratifies likely damaging from benign variation in 
protein-coding genes, while no such tool exists in non-coding elements. Down-
sampling gene length to 600bp and masking protein consequence annotation results 
in an 80% drop in empirical power for the 94 genes passing the genome-wide 
significance threshold in McRae et. al, 2017 (Figure 13A). However, even after down-
sampling genes in size and masking the predicted consequence of individual 
mutations, I still discover more than 20 genes at a genome-wide significance 
threshold (Figure 13A). 
Beyond element length and consequence annotation, the proportion of sites 
that, when mutated, result in a severe developmental disorder with a dominant 
mechanism may differ between non-coding elements and protein-coding genes. At 
least 8% of mutations in protein-coding genes are predicted to cause loss of function 
due to protein-truncation44,62, and many variants may result in missense changes 
causing full or partial loss of function. The fact that I do not discover any genome-
wide significant CNEs at this sample size suggests that the proportion of DNMs in 
CNEs that are pathogenic and highly penetrant must be substantially lower than 8%. 
I modelled the likelihood of observing 286 DNMs, 25 recurrently mutated 
CNEs, and zero CNEs at genome-wide significance across different values for the 
number of fetal brain active CNEs (out of 2,613) and the proportion of mutations in 
those elements that are pathogenic with a dominant mechanism for 
neurodevelopmental disorders (see Methods). The maximum likelihood model is one 
in which 3.5% of mutations within approximately 100 elements are pathogenic with 
a dominant mechanism. However, there is considerable uncertainty around this 
point estimate (Figure 13B), with the credible interval including scenarios whereby 
tens of elements have ~5-7% of mutations being pathogenic or thousands of 
elements have <1% of mutations being pathogenic. Our results support a model in 
which most sites in highly conserved non-coding elements are reasonably tolerant to 
heterozygosity. This result implies that the extreme sequence conservation in these 
elements may be maintained by selection against lower-effect size heterozygotes, 
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compound heterozygotes, or oligogenic selection reflecting full or partial 
redundancy between multiple regulatory elements. 
 
Figure 13 Power calculations estimates of genetic architecture in non-coding elements. (a) 
Estimating the reduction in power due to size differences between non-coding elements and genes 
(median 600bp vs. 1800bp) and ignoring VEP annotations used to stratify benign from likely 
damaging variants. Dots and bars represent the point estimate and 95% confidence interval, 
respectively. (b) Credible intervals for the proportion of fetal brain active conserved elements and 
proportion of sites within those elements with a dominant mechanism for developmental 
disorders.  Based on our observation of zero non-coding elements at genome-wide significance in 
6,239 exome-negative probands, very few sites within these elements (<5%) are likely to 
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contribute to developmental disorders through a highly penetrant dominant mechanism. (c) Power 
calculations for disease-associated non-coding element discovery. Without annotation or tools to 
discriminate pathogenic from benign variants in non-coding elements (grey), more than 100,000 
trios are required to achieve 40% power. With annotation or tools to fully discriminate likely 




In summary, I have demonstrated that de novo mutations in regulatory elements 
contribute to severe neurodevelopmental disorders. This significant excess of DNMs 
is only observed in highly evolutionary conserved elements that are active in the 
fetal brain. I observed a 1.3-fold excess of DNMs within DHS peaks in these 
regulatory elements, suggesting that a minority of such DNMs are pathogenic. 
Moreover, our modelling suggests that there are few, if any, regulatory elements in 
which >4% of mutations cause neurodevelopmental disorders with a dominant 
mechanism. Our data are consistent with only 0.15% of mutations within fetal brain 
active CNEs being highly penetrant for neurodevelopmental disorders (Appendix 1, 
Figure S7A), likely considerably lower than the proportion of dominant pathogenic 
mutations in protein-coding regions. As a consequence, this class of pathogenic non-
coding DNMs is only likely to account for a small proportion (<5%) of ‘exome-
negative’ individuals and robustly identifying disease-associated regulatory elements 
will present a greater challenge than protein-coding genes.  
This estimate does not include the potential contributions from indels. While 
the indel mutation rate is approximately 10-fold lower than the SNV mutation rate, 
indels have been suggested by evolutionary studies to be more deleterious than 
single nucleotide changes in non-coding regions63. I also did not quantify the 
contribution of large copy number variations in regulatory elements. Deletion of 
enhancer elements as well as enhancer adoption due to genomic rearrangements 
have been previously associated with severe disorders. Whole genome sequencing 
of affected trios will allow us to better detect this class of variation in order to 
accurately quantify the contribution of structural variants in non-coding elements to 
severe DD. 
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Our study design focuses on highly conserved elements and fetal-brain active 
elements and is relatively uninformative with respect to pathogenic ‘gain-of-
function’ DNMs within elements that show no wildtype activity in fetal brain, and are 
not highly evolutionarily conserved. While our findings have focused on the highly 
conserved elements, I do not consider our observations to be definitively negative 
about the role of less highly conserved fetal brain enhancers in neurodevelopmental 
disorders, or the role of heart enhancers in CHD (due to the low proportion of 
subjects with CHD). The field of regulatory element annotation has progressed 
tremendously over the past six years since this study design was initially conceived. 
Therefore, a comprehensive analysis of the contribution of variation within all 
classes of non-coding elements to neurodevelopmental disorders is likely to require 
whole genome sequencing (WGS) of many tens of thousands, if not hundreds of 
thousands of parent-proband trios (Figure 13C).  
A few recently published studies using whole genome sequencing in trios 
with Autism Spectrum Disorder have produced mixed results. One challenge of 
interpreting WGS data is the vast universe of hypotheses that could be tested, and 
thus how to account appropriately for multiple hypothesis testing. Turner et al. 
recently reported a nominally significant enrichment (p = 0.03) of de novo SNVs and 
private copy number variants in fetal brain DHS or at sites with PhyloP conservation 
score of >4, within 50kb of known autism-associated genes in WGS from 53 
individuals with autism64. Caution should be exercised in interpreting findings based 
on: small sample sizes relative to that required for well-powered analyses (as 
discussed above) and analyses requiring multiple, arbitrary, levels of variant 
stratification (e.g. gene set, genomic proximity threshold, and conservation score). 
WGS-based analyses need to account for all explicit and implicit hypothesis testing. 
Sanders et. al, analysed a larger data set using an unbiased method to test for 
enrichment of mutations in more than 50,000 different annotations and found little 
evidence for enrichment of DNMs in non-coding annotations.   
The disease-associated elements identified in this analysis primarily act either 
as enhancers or to regulate alternative splicing, but establishing the precise 
mechanism for each element has proved challenging. Our analyses highlight an 
urgent need for improved tools to stratify benign and damaging variants within non-
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coding elements and annotate gene targets for regulatory elements. Improvements 
in annotation of functional non-coding elements and nucleotides within these 
elements will dramatically increase power to detect highly-penetrant disease-
associated non-coding variation, for example, increasing power more than ten-fold 
from 8% to 83% in 40,000 trios (Figure 13C).  
Functional characterisation of increasing numbers of robustly-associated, 
highly-penetrant, regulatory variants in cellular and animal models will be critical in 
moving from a descriptive to a more predictive understanding of non-coding 
variation in the human genome. There are a number of experimental tools available 
to better understand the impact of mutations in regulatory elements. Massively 
parallel reporter assays (MPRAs) can be used to assess the function of tens of 
thousands of putative regulatory elements in parallel. Whereas mouse transgenesis 
assays or mouse knock-in models can assay particular variants in great detail, MPRAs 
provide far greater throughput allowing every base within an element to be assessed 
for allele specific expression. Results from a set of MPRA experiments in elements 
harbouring DNMs in the DDD patients are detailed in Chapter 4. While MPRA allows 
for very high throughput characterisation of regulatory element function, mouse or 
zebrafish assays can reveal spatiotemporal mis-regulation that may not be apparent 
in reporter assays. Results from a collaborative study contrasting expression patterns 
between wildtype and mutated alleles in mouse embryos is also discussed in detail 
in Chapter 4. 
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Chapter 3: Mutation rate and selective constraint in the non-coding genome 
 
Introduction 
Heterogeneity in the human germline mutation rate 
 Identifying associations between de novo mutations and disorders such as Autism 
Spectrum Disorder (ASD) or Developmental Disorders (DD) relies on a well-calibrated model 
of the underlying mutation rate, particularly if a large number of unaffected siblings or 
healthy trios are unavailable. Many methods for detecting positive and negative selection 
also rely on well-calibrated models of the germline mutation rate1,2. Assuming a 
homogeneous mutation rate across the whole genome can confound tests of purifying 
selection, increasing the false positive rate in hypomutable regions, and the false negative 
rate in hypermutable regions. 
 Historically, the mutation rate in humans has been inferred by comparing divergence 
between closely related species, for example other great apes3. These evolutionary methods 
have a number of drawbacks, including the difficulty in deconvoluting changes in mutational 
processes, generation times, and selective pressure. Furthermore, evolutionary measures 
have difficulty in distinguishing changes due to mutations from changes due to 
recombination-associated events such as biased gene conversion2,4.  
The rapid decline in sequencing cost has resulted in the sequencing of thousands of 
human exomes and whole genomes in recent years and rare variation in these individuals 
has also been used to model the germline mutation rate. These studies have focused on 
rare and putatively neutral sites (e.g. synonymous sites with minor allele frequency < 0.1%) 
where the mutational origin is likely recent and selection has had little time to act5,6. Under 
these assumptions, rare synonymous variation will closely reflect the underlying mutational 
processes6,7. 
Furthermore, increasing numbers of whole exome and whole genome sequenced 
trios have allowed more direct estimates of the germline mutation rate. Trio sequencing 
data has the advantage of measuring de novo variation directly, but at current sample sizes, 
the number of mutations observed is still low, approximately 100,000 de novo mutations in 
the largest study as of writing. 
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Trio sequencing studies also allow for the parent-of-origin to be determined for a 
large fraction of mutations. Using these data, the contribution of maternal and paternal age 
to the SNV mutation rate has been quantified8. Subtly different mutational spectra in the 
maternal and paternal germline have also been characterised, including an enrichment for 
C>T mutations with increasing paternal age, and increasing C>G mutations with maternal 
age with particularly striking maternal-biased hotspots in a small number of sub-
chromosomal segments8,9. These maternal-biased hotspots coincide with large 
hypermutable regions in the genome, most strikingly apparent on chromosomes 2,7,8,9, 
and 16. Thus, trio sequencing data can be used to estimate the total human mutation rate, 
but may not be sufficient to detect heterogeneity, except on a megabase scale.  
Studies using de novo mutations, rare variants, as well as evolutionary comparisons 
to detect heterogeneity in the underlying mutation rate have identified a number of 
genomic features associated with mutation rate and spectra. Local sequence context has 
been shown to have a significant influence on the per-base mutation rate. SNV mutation 
models incorporating triplet context (the base before and after the mutating base) capture 
variation in the mutation rate and have been used extensively in rare disease studies and 
models of selective constraint7. Extending beyond the triplet context, pentamer (5-bases) or 
heptamer (7-bases) context centred on the nucleotide of interest further improve modelling 
of DNMs and rare variants5.  
Beyond sequence context, other features related to cellular processes and 
chromatin modifications have been linked to mutation rate heterogeneity. Later replicating 
regions of the genome have been shown to accumulate a greater number of mutations10. A 
number of mechanisms have been proposed for this phenomenon, including exhaustion of 
the pool of dNTPs, causing polymerase stalling and that later replicating regions lack 
sufficient time to undergo mismatch repair. Increased recombination rate has also been 
linked to increase SNP density and mutation rate11,12. The proposed mechanism for this 
relationship is the mutagenic effect of double strand breaks, which are required for 
recombination. Two chromatin marks characteristic of repression, H3K27me3 and 
H3K9me3, have also been suggested to influence the germline mutation rate5, perhaps by 
reducing accessibility of the DNA repair machinery. Transcription factor binding has also 
been suggested to influence mutation rate13. 
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Despite analyses implicating different genomic features and sequence features in 
germline mutation rate heterogeneity, there are no widely used models incorporating these 
features together. Furthermore, the heterogeneity in the germline mutation rate has not 
been fully explained by the features studied to date, motivating continued work in 
characterising factors contributing to variation in the germline mutation rate. 
 
Measuring selective constraint in the human genome 
Putative functional DNA can be identified by using alignments between multiple 
species to detect orthologous segments and testing the divergence of these segments 
relative to a neutral model of evolution. Based on this approach, the majority of putative 
functional sequence is thought to be non-coding14. A small set of these elements show 
extreme sequence conservation and were originally dubbed ‘ultra-conserved’15. These 
evolutionary methods have also suggested that non-coding sequence may be more 
intolerant to small insertions and deletions than single-nucleotide changes16. 
More recently, different population genetics methods have been applied to large 
sets of exome and whole genomes sequences to detect selective constraint in humans. In 
sites or regions undergoing purifying selection, there will be a greater proportion of 
observed rare alleles compared to sites or regions evolving neutrally. These shifts in the 
variant frequency spectrum (VFS) have been quantified using different methods including 
the proportion of singletons (the number of polymorphic sites observed once in a 
population sample of unrelated individuals divided by the total number of observed 
polymorphic sites) as well as methods such as RVIS that quantify the difference between 
two allele frequency distributions6,17,18. As sample sizes have increased beyond tens of 
thousands of individuals, the assumptions of the infinite sites model have been broken for 
some classes of variation with high mutation rates (e.g. CpG sites) and measures of selection 
based on the variant frequency spectrum have required revision6. The mutability adjusted 
proportion of singletons (MAPS) is an extension of the proportion of singletons measure 
that corrects for biases due to hypermutability6. 
Yet another way to quantify purifying selection is to compare the number of 
observed rare variants to the number of expected variants under a neutral model. This 
approach has been applied to protein-coding genes to identify genes intolerant of protein 
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truncating variation6. Using a germline mutation rate model, the expected number of 
protein-truncating variants can be determined for each gene in the absence of selection. 
Genes with few observed variants relative to the number expected are annotated as loss of 
function intolerant. The degree of intolerance can be quantified as a ratio of observed 
divided by expected with an associated Z-score, or using a mixture model to identify genes 
with a high ‘probability of loss of function intolerance’ (pLI)6. The pLI score has been utilised 
in a number of different contexts to prioritise disease causing variants. For example, 
Kosmicki et. al show that the enrichment for damaging DNMs in ASD and DD patients can be 
explained almost entirely by enrichment in genes with pLI > 0.9, which represent only ~17% 
of all genes19. This approach has also been applied to identify protein-coding genes or gene 
sub-regions that are intolerant to missense variation20.  
Using data from approximately 10,000 deep whole genome sequences, Di Iulio et. al 
developed the ‘context dependent tolerance score’ (CDTS), to measure selective constraint 
genome-wide. Like the pLI and MAPS scores, which use the triplet sequence context to 
correct for heterogeneity in the germline mutation rate, the CDTS model uses the heptamer 
sequence context. However, the CDTS method suffers from a few potential drawbacks, most 
notably failure to model germline mutation rate heterogeneity and background selection21 
(the loss of heterogeneity or depression of allele frequencies at a site due to selection on 
nearby sites due to linkage). The pLI and MAPS scores also do not account for mutation rate 
heterogeneity beyond sequence context, but failing to account for mutation rate 
heterogeneity in coding regions is likely less impactful due to greater similarity in features 
such as replication timing and recombination rate compared to non-coding regions22. 
Both the evolutionary methods and the population genetics methods described 
above rely on a well-calibrated model of neutral evolution or the germline mutation rate. 
The risk of a mis-specified mutation rate causing false positive or false negative rates can be 
mitigated in protein-coding genes by testing for enrichment or depletion of variation in 
synonymous variants alongside missense or protein-truncating variants6. In the event that a 
gene has a higher mutation rate than predicted under the mutation rate model, this will be 
apparent as an increased number of synonymous sites. While these mutation rate 
differences are not modelled explicitly, genes with great deviations in synonymous rates can 
be flagged for removal or further analysis. In non-coding elements, it is more challenging to 
identify likely benign variation that can be assumed to be shaped almost entirely by 
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mutation and not selection. As a result, negative selection will be confounded by 
hypomutability. In the case of the CDTS score discussed above, non-coding regions in the 
highest percentile CDTS score are highly enriched for promoter marks, which Di Iulio et. al 
interpret as evidence of strong purifying selection on promoters. However, promoters are 
enriched for CpG sites which are highly mutable when methylated, but CpG sites are often 
hypomethylated in promoters. As a result, a model based only on sequence and not 
incorporating methylation status will greatly overestimate the mutation rate, leading to a 
false positive prediction of constraint.  
Detecting selectively constrained non-coding elements has the potential to greatly 
improve the signal-to-noise ratio in disease association studies in non-coding elements. 
However, identification of constrained elements relies critically on a robust germline 
mutation rate model, and a sufficient number of deep whole genome sequences to ensure 
power to detect modest selective constraint. The analyses I describe in this chapter make 
use of over 28,000 deep whole genome sequences and more than 1,500 whole genome 
sequenced trios to construct an improved model of germline mutation rate and apply this 
model to detect selective constraint genome-wide.  
Methods 
De novo mutations from 1,548 healthy trios 
De novo mutations (DNMs) from 1,548 healthy trios described in Jonsson et. al 2017 were 
downloaded from the online supplementary information: 
https://www.nature.com/articles/nature24018#supplementary-information. These DNMs 
were lifted over from GRCh38 to GRCh37 using the UCSC LiftOver tool (https://genome-
store.ucsc.edu/) and filtered to include only single nucleotide changes, leaving a total of 
100,714 de novo SNVs. The DNMs were intersected with the regions used to build the model 
in Samocha et. al, 2014. These observed number of DNMs per triplet were compared to the 
fraction of triplets in the reference genome to determine the per triplet mutation rate.  
 
Quality control of allele frequency data from 15,000 whole genome sequenced individuals 
from the genome aggregation database (gnomAD) and 13,000 individuals from the 
BRIDGE consortium 
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The gnomAD consortium (http://gnomad.broadinstitute.org/about) runs a unified 
bioinformatics pipeline on a large number of exome and whole genome sequencing samples 
and provides access to allele frequency data and other meta-data including depth of 
coverage across samples. Depth of coverage was included as a covariate for in the mutation 
rate model and all analyses related to selective constraint. All sites with low-quality variants 
(defined by the gnomAD random forest model) were flagged as low-quality, and the 
proportion of variants called as low quality in a given element was also included as a 
covariate. 
 
The BRIDGE project also runs a unified bioinformatics pipeline for whole genome sequence 
data in a collection of rare disease cohorts. Coverage for every base as well as variant 
quality metrics provided were available, and as with the gnomAD sites, depth of coverage 
and the proportion of low quality variants was included as a covariate in the mutation rate 
model and all analyses related to selective constraint. 
 
All analyses in the selective constraint section were run on the full set of 28,000 deep whole 
genome sequences from unrelated individuals as well as a subset of 15,000 whole genome 
sequenced from non-Finnish Europeans defined by principal components analysis. The 
number of rare variants in 50kb bins genome-wide was highly correlated between the full 
set of individuals compared to using only the non-Finnish Europeans (r^2 = 0.93, p < 2.2e-
16). As a result, I performed all analyses with the full set of 28,000 individuals as the greater 
number of individuals improves power to detect depletion or enrichment for rare variation. 
 
Tri-nucleotide mutation rate table based on 100,714 observed mutations 
A custom R script was used to determine the trinucleotide sequence context for 100,714 de 
novo SNVs identified in 1,548 healthy trios. These de novo SNVs were used to construct a 
table describing the empirical mutation rate for each of 96 possible trinucleotide changes 
(e.g CCG -> CTG is one such change where CCG is the reference sequence and a C to T DNM 
is observed). 
 
Genomic features included in the germline mutation rate random forest regression model 
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To model the variation in mutation rate due to genomic features, annotations in different 
functional categories were assembled: 
- Recombination rate 
The 1000 genomes Phase 3 recombination map23 
Recombination rate in the male germline24.  
Recombination rate in the female germline24. 
 
- Replication timing 
Replication timing in lymphoblastoid cell lines25. 
Replication timing in embryonic stem cells26. 
 
- Chromatin features 
ATAC-seq data in human spermatogonial stem cells27 
ATAC-seq data in human embryonic stem cells27 
Embryonic stem cell H3K9me3, H3K27me3, H3K4me3, H3K4me1, H3K36me3, 
and H3K9ac from the Roadmap Epigenome Project28 
Ovary H3K9me3, H3K27me3, H3K4me3, H3K4me1, H3K36me3, and H3K9ac from 
the Roadmap Epigenome Project28 
CTCF binding sites from the ENCODE project29 
 
Modelling genome-wide regional variation in mutation rate using random forest 
regression 
The expected variation in sites predicted to be evolving neutrally based on the PhyloP score 
(PhyloP < 1 and PhyloP > -1) was calculated in 50kb bins genome-wide using the 
trinucleotide mutation rate model from Samocha et. al with the correction for CpG 
methylation status described in Chapter 2. Dividing the observed variation in these 50kb 
bins by the expected variation yielded the observed/expected ratio based on sequence 
context alone. 
 
In order to determine the contribution to variation in observed/expected ratio from 
genomic and technical features, a random forest regression model was used. Seventy-
percent of the data was used for hyperparameter tuning and model selection using 10-fold 
 66 
cross validation. The remaining thirty percent of data was held out to evaluate the model. 
The model was also evaluated on a completely independent set of de novo mutations 1,548 
trios described in Jonsson et. al, 2017. 
 
Measuring selective constraint using rare single nucleotide variants 
A linear model was trained to predict number of observed variants given the mutation rate 
of a genomic segment using only sites with PhyloP between -1 and 1 in the ENCODE 
Ancestral Repeat sequences with >25x coverage in BRIDGE and gnomAD and >80% high 
quality variant calls in BRIDGE and gnomAD. Given a new genomic element, set of elements, 
or set of sites, the mutation rate was determined from the mutation rate model discussed 
above and the number of expected variants was generated using this linear model. Dividing 
the observed number of variants by the number of expected variants yields the 
observed/expected ratio. 
 
Measuring selective constraint using rare indels 
The number of rare indel variants per megabase (indels per megabase, or IPM) was first 
calculated for the ENCODE Ancestral Repeat sequences with >25x coverage in BRIDGE and 
gnomAD and >80% high quality variant calls in BRIDGE and gnomAD. The number of de novo 
indel calls per megabase (dnIPM) in 1,548 DECODE trios was also determined.  
 
Given a new set of genomic elements of interest, for example DHSs, the IPMDHS can be 
determined as above. The IPMDHS is then multiplied by dnIPMAR /dnIPMDHS and the 
observed/expected value is:  
 dnIPMARdnIPMDHS ∗ IPMDHS	IPMAR  
 
Including the de novo indel rates is critical, as elements with dnIPMDHS < dnIPMAR will appear 
under selective constraint, when in fact the paucity of rare variants is due to differences in 
mutation rate. Due to the relatively small number of observed de novo indels, Indel 
constraint is only feasible for element sets with a sufficient number of observations. For this 
work, only element sets with at least 100 expected mutations under the neutral model were 
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included, limiting the noise introduced by the mutation term to approximately 20%, 
assuming the rate of indels follows a Poisson distribution. 
 
Evolutionary conservation using PhyloP and PhastCons 
PhastCons scores describing degree of evolutionary conservation at the element level in 





PhyloP scores represent the –log10 p-value that a given nucleotide is evolving neutrally31 
(Pollard et. al, 2010). A tabix file of pre-computed PhyloP vertebrate 100-way scores and 
primate 46-way scores were used to annotate rare variants and de novo mutations. 
 
ENCODE open chromatin clusters 
All of the ENCODE V3 DNase I hypersensitive peaks were overlapped to generate singly-




Simulations to determine the power to detect selective constraint in non-coding elements  
Random segments of the required size (10bp, 20bp, 100bp, 200bp) were selected from the 
ENCODE V3 DNase I hypersensitivity sites and the mutation rate and expected amount of 
rare variation under a neutral model was calculated. To simulate selective constraint, the 
amount of observed variation was sampled from a Poisson distribution with lambda = 
0.8*expected. This simulated constraint is approximately equal to the deficit of variation 
observed in the average protein-coding exon, thus is a conservative estimate if constrained 
non-coding elements are less constrained, on average, than protein-coding exons. The 
observed/expected ratio and Z score was calculated from the simulated observed count and 
the expected count. The proportion of elements with Z < -2.58 was recorded as the power 
to detect a true association. This Z-score results in a false discovery rate of approximately 
10%, under the assumption of ~5% of the genome under selective constraint, as a Z-score of 
 68 
less than or equal to -2.58 would be achieved under the null model in ~1/200 tests (false 
positive rate of 0.005). 
 
Conserved transcription factor binding sites  
Conserved transcription factor binding sites based on the Transfac database were 
downloaded from the UCSC genome browser (http://rohsdb.cmb.usc.edu/GBshape/cgi-
bin/hgTables?db=hg19&hgta_table=tfbsConsSites). This set includes any binding sites that 
successfully align in human, mouse, and rat and are predicted to bind based on position 
weight matrices in the Transfac Matrix Database (v7.0). 
 
Analysing selective constraint stratified by number of active tissue groups 
Non-coding elements defined by DNase hypersensitive sites were annotated with a 
predicted chromatin state in each of the following ten tissue groups from the Roadmap 
Epigenome Project data: 
- Embryonic stem cells (Roadmap IDs: "E002", "E008", "E001", "E015", "E014", 
"E016", "E003", "E024") 
- Blood (Roadmap IDs: "E062", "E034", "E045", "E033", "E044", "E043", "E039", 
"E041", "E042", "E040", "E037", "E048", "E038", "E047") 
- Hematopoietic Stem Cell and B Cell (Roadmap IDs: "E029", "E031", "E035", 
"E051", "E050", "E036", "E032", "E046", "E030") 
- Mesenchymal Cells (Roadmap IDs: "E026", "E049", "E025", "E023") 
- Epithelial Cells (Roadmap IDs: 
"E055","E056","E059","E061","E057","E058","E028","E027") 
- Adult Brain (Roadmap IDs: "E071", "E074", "E068", "E069", "E072", "E067", 
"E073", "E070") 
- Adult Muscle (Roadmap IDs: "E100", "E108","E107") 
- Adult Heart (Roadmap IDs: "E104", "E095", "E105", "E065") 
- Fetal Tissues (Roadmap IDs: E082", "E081", "E080", "E083", "E084", "E085", 
"E086", "E088", "E089", "E090", "E092", "E093", "E017") 
- Smooth Muscle (Roadmap IDs: "E078", "E076", "E103", "E111") 
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An element was considered active in a tissue group if it was annotated as an enhancer in 
any of the constituent tissues (Roadmap IDs above). The obs/exp ratio was calculated for 
elements grouped by the number of tissue groups they were active in (from 0 to 10). 
 
Results Section 3.1: Modelling the human germline mutation rate 
Results Section 3.1.1. Improved modelling of the human germline mutation rate. 
 
 The reduction in cost of whole genome sequencing has led to adoption of this 
technology in a number of different research efforts worldwide. Many of these efforts are 
focused around generating diagnoses in rare or common disease, but whole genome 
sequence data is also of general utility to address questions in population genomics. With 
this goal in mind, researchers at the genome aggregation database (gnomAD) have collected 
data from dozens of such studies and processed the raw data through a unified quality 
control and variant calling pipeline. To date, data from more than 15,000 deep whole 
genome sequences have been released by the gnomAD consortium. The latest gnomAD 
release (r2.0.2) was downloaded for use in these analyses. This release includes allele 
counts at each polymorphic site and metadata including depth of coverage. The BRIDGE 
consortium has sequenced more than 13,000 deep whole genomes from individuals with 
different rare diseases and in some cases, unaffected family members. Allele counts from 
the BRIDGE and gnomAD data were combined and annotated with depth of coverage and 
variant call quality (see Methods). I also downloaded high-quality de novo mutations from 
1,548 whole genome sequenced healthy trios8 in order to validate analyses on the germline 
mutation rate derived from rare variant data (see Methods). 
 The widely used germline mutation rate model from Samocha, 2014 described 
previously relies on a 96-row table that describes the mutation rate from one triplet 
sequence to another7. This table was derived using polymorphism data in orthologous 
chimp and human sequence. As it has been shown that there have been changes in triplet-
specific mutation rates between humans and other great apes, as well as within human 
populations32,33, I reasoned that building this table directly from high-quality DNMs would 
be more accurate. To build this table, I intersected the DNMs with the same set of regions 
used to build the original mutation rate table (see Methods). 
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The triplet mutation rates derived from de novo mutations differed slightly from 
those derived from evolutionary estimates, notably in the rate of mutations at CpG sites. 
The DNM-based triplet model modestly but significantly outperforms the triplet model 
derived from polymorphisms in orthologous sequence in predicting the observed number of 
variants with MAF < 0.1% in 2kb bins genome-wide (r2 = 0.61 compared to r2 = 0.64). As 
described in Chapter 2, the addition of CpG methylation status also improved the model fit. 
A number of additional genomic features have been previously associated with 
differences in rare variant density and divergence over evolutionary time, specifically 
replication timing, recombination rates, and H3K9me3, with conflicting evidence for 
H3K27me34,5,10. As a previous study by Carlson et. al, used rare variant data from just 3,000 
individuals to test potential mutation-associated germline features, I reasoned that with 
over 28,000 deep whole genomes as well as mutations from whole genome sequenced 
trios, an analysis to test association across a wide range of potential associated features 
would have much greater power. Furthermore, Carlson et. al was descriptive, but did not 
provide a model to predict the mutation rate given a sequence and set of genomic 
features5. Such a model integrating known sequence-associated variation in mutation rate 
with genomic features would be a useful tool in disease-association studies, population 
genomic models of selection, and for identifying ‘mutational outliers’ that are not well-
explained by known mutation-associated futures which may provide insight into novel 
mutational mechanisms. 
 I reasoned that rare variants in deep whole genome sequences could be used to 
assess variation in the germline mutation rate independent of selection by focusing only on 
sites that are likely to be evolving neutrally. While our understanding of the ‘regulatory 
code’ does not allow for identification of benign sites to the same degree of certainty as in 
protein-coding genes, I reasoned that nucleotide level evolutionary conservation could be a 
useful proxy. I annotated every base genome-wide with the PhyloP score (see Methods). 
Sites with PhyloP greater than one (referred to as ‘conserved sites’ going forward) had on 
average 25% fewer variants than sites with PhyloP less than 1 and greater than -1 (referred 
to as ‘neutrally evolving sites’ going forward). There was no significant difference in the 
mutation rate between conserved sites and neutral sites, indicating that the deficit of 
variation observed in the conserved sites is likely the result of purifying selection. Taken 
together, these results imply that, in the aggregate, sites predicted to be evolving neutrally 
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by PhyloP are under minimal purifying selection and can be used to quantify the background 
mutation rate. 
 I compiled data from twenty-six different sources representing established or 
potential mutation-associated genomic features including replication timing, recombination 
rate, and chromatin marks from the male and female germline (see Methods). I also 
included technical covariates including depth of coverage, presence of low complexity 
repeats34, and variant quality to quantify the amount of variation that is attributable to 
technical sources rather than variation in mutation rate. Finally, I included the proportion of 
polymorphisms observed split across the six different 1mer possibilities (C>T, C>A, C>G, T>A, 
T>C, T>G). Including this feature was motivated by the observation that a subset of highly 
hypermutable regions of the genomes are enriched for C>G mutations which are high bias 
toward maternal-origin8,9. Unlike other genomic features, associations with this feature may 
not necessarily have a clear mechanistic interpretation, but are nonetheless useful to model 
mutation rate heterogeneity, or generate hypotheses for the source of mutational 
heterogeneity based on known mutational signatures, for example those found in the 
Cosmic database (https://cancer.sanger.ac.uk/cosmic).  
 I then split the genome into non-overlapping segments and annotated these 
segments with the number of observed rare putatively neutral variants, and the number 
expected given the mutation rate based on sequence context alone. The ratio of observed 
to expected variation was fit using a random forest regression (RFR) on a randomly selected 
subset of the two-kilobase segments (the ‘training’ set). The performance of the model was 
then tested on a held-out subset (the ‘test’ set) (see Methods). I hypothesized that different 
genomic features may influence the mutation rate at different length scales. Thus, a 
separate model was trained for input segments of size 2kb, 10kb, 50kb, 200kb, and 1Mb.  
Incorporating genomic features substantially improved prediction of rare variation 
over sequence context and technical covariates alone across all of the different length 
scales, with the largest length scales showing the greatest improvement (Figure 1A), as 
variation in sequence context plays a larger role for smaller regions, while genomic features 
dominate over larger length scales where sequence context becomes more homogeneous 




Figure 1 Modelling heterogeneity in the germline mutation rate. (a) Correlation between different model features. (b) adding genomic features and polymorphism nucleotide 
signatures (1mer) improves prediction of level of rare variation in different sized genomic bins. (c) Random forest regression feature importance shows decreasing importance of 
sequence context at larger length scales, and increased importance of chromatin features. (d) adding genomic features to mutation rate model improves prediction of de novo 
mutation rates. 
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Figure 2A shows the observed/expected values in 2kb bins across chromosome 8 for 
the model incorporating sequence context and technical covariates compared to the model 
incorporating sequence context, technical covariates, and genomic features. As the model 
was trained using rare variant data, which may not accurate reflect the underlying mutation 
rate, I sought to validate this model using 100,714 de novo SNVs from 1,548 healthy trios6. 
De novo SNVs will more closely reflect the mutation rate independent of selection, but are 
fewer in number than rare variants, motivating the choice to train using rare variant data, 
and validate using the DNMs. To validate the model performance, I ordered all of the 2kb 
bins genome-wide based on their predicted deviation from the mutation rate based on 
sequence context alone. Splitting the ordered bins into deciles, the expected number of de 
novo mutations was estimated for each bin using the sequence context-based model as well 
as the model including genomic features. The model including genomic features was a 






Figure 2 Visualising and validating the improved germline mutation rate model. (a) Observed over 
expected ratios across chromosome 2. Calculating the expectation from the sequence context only (red 
dots) and using the genomic features and sequence context (blue dots). (b) All 2kb elements genome-wide 
ordered by their observed enrichment of rare variation predicted rare variant enrichment. The enrichment 
of de novo mutations in each bin was calculated using the model based on sequence context only (red dots) 
and the model using genomic features and sequence context (blue dots). The mutation rate model 
incorporating genomic features was a closer fit to the observed number of de novo mutations. 
 
Results Section 3.1.2. Genomic features associated with hypermutability 
This random forest regression approach detailed in Section 3.1.1. identified significant 
associations between the rate of rare likely neutral variation and a number of different 
genomic features (Figure 1C). This analysis recapitulated several known mutagenic features. 
Increase in recombination rate by one standard deviation was associated with an increase in 
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mutation rate of approximately 0.5% - 1%. Replication timing had a modest but significant 
effect (increase in mutation rate of 0.2% per standard deviation increase in replication 
timing). In somatic tissues, replication timing has been observed as one of the primary 
determinants of mutation rate, whereas these results suggest that replication timing has a 
significant, but overall modest effect on variation in mutation rate in the germline.  
I observed a strong positive correlation between the proportion of C>G polymorphisms 
and the mutation rate (mutation rate increase of 4.6% per standard deviation increase in 
C>G proportion), consistent with striking sub-chromosomal mutation hot-spots identified 
previously on chr2, chr7, chr8, chr9, and chr168,9. Re-analysing the DNMs from Jonsson et. al 
shows that regions with strong enrichment for maternal biased C>G also exhibit a maternal 
bias for other mutation signatures, and a paternal bias for C>T mutations. The DNM counts 
in two megabase bins on chromosome 8, which has a mutational hotspot on the first 40 
megabases of the chromosome, are shown in Figure 3A, B (enrichment for rare variation is 






Figure 3 Hypermutable elements with C>G polymorphism signature. (a) De novo single nucleotide 
variants of maternal origin and (b) paternal origin in 2Mb bins across chromosome 8 stratified by the 
reference and alternate base to illustrate the difference in mutational signature between maternal 
and paternal derived mutations.   
Even after removing chromosomes 2,7,8,9, and 16 which show large regions of extreme 
enrichment for C>G polymorphisms, we detect an association between this feature and 
increased mutation rate on other chromosomes, indicating that the phenomenon 
underlying these extreme events may be pervasive across the genome. Previous work 
describing this phenomenon has posited a role for recombination in generating these 
hotspots. I found a significant enrichment for maternal as well as paternal recombination 
hotspots in hypermutable elements with C>G polymorphism rates in the top decile, 
supporting previous work suggesting a role for recombination in these mutational hotspots. 
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I next sought to take a more unbiased approach to identify patterns underlying these 
hypermutable elements. I supplied maternal and paternal phased mutations to Raheleh 
Rahbari, a collaborator in the Voet group at the Wellcome Trust Sanger Institute, who 
performed non-negative matrix factorisation to detect mutation signatures separately in the 
maternally and paternally phased DNMs. DNMs of maternal and paternal origin both 
showed a strong contribution from Signature 1 (spontaneous deamination of 5-
methylcytosine) and Signature 5 (unknown etiology) which were shown to predominate in 
the Germline by Rahbari et. al, 2016. The maternally phased DNMs also showed a strong 
contribution from Signature 3 (which has been linked with double strand break repair), 
supporting the hypothesis that double strand breaks in the maternal germline, perhaps due 
to recombination, are contributing to the enrichment for DNMs, particular C>G changes, in 
these regions. In contrast, there was no evidence for Signature 3 in the paternally phased 
DNMs or in DNMs in regions of the genome not enriched for C>G polymorphisms.  
An inverse relationship between RNA expression level and mutation rate has been 
reported in somatic tissues based on analysis of whole-genome sequenced tumours and 
matched normal tissues by The Cancer Genome Atlas (TCGA)35,36. However, analyses in the 
germline based on evolutionary divergence and more recently, analysis of whole exome 
sequenced trios has suggested the opposite effect, whereby higher expression is associated 
with a higher mutation rate37. I tested the relationship between density of rare variation 
and RNA expression levels in the testis based on the GTEx data set. Consistent with previous 
reports in the germline, I detected a strong positive relationship between increased 
expression and density of rare variation as well as de novo mutations. Notably, this 
relationship was only evident in coding sequence, not in the non-coding intronic sequence. 
Protein-coding exons on the most highly expressed decile of transcripts had approximately 






Figure 4 Association between mutation rate and expression in the ovaries and testis. Protein-coding 
exons were split into deciles based on transcript levels in ovary and testis from the GTeX project. 
Observed de novo mutations were compared to the expectation, generated using the random forest 
regression mutation rate model and show a positive correlation between transcript level and 
observed mutation rate that is not captured in the existing model. 
 
It is possible that this apparent hypermutability in coding sequence could actually be 
explained by a fraction of mutations in highly expressed genes in the testis conferring a 
selective advantage by increasing spermatogonial stem cell proliferation or sperm motility. I 
reasoned that if this was the case, there would be an enrichment for non-synonymous 
changes relative to synonymous changes in the highly expressed genes compared to the 
lowly expressed genes. I compared the fraction of DNMs predicted to be protein-truncating, 
missense, and synonymous in each transcription decile and did not find any evidence for 
higher-than-expected rates of missense or protein-truncating mutations compared to 
synonymous changes that might suggest this observation was driven by a selective 
advantage in sperm or sperm progenitors. 
After incorporating known and suspected mutation-associated genomic features into 
the mutation rate model, there were still genomic regions with a significant excess of rare 
variation. These genomic regions were also enriched for de novo mutations, indicating that 
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sources of technical variation. Thus, while the mutation rate model developed here is an 
improvement on the existing model based on sequence context alone, there is still 
opportunity for improvement, particularly in modelling finer scale variation in mutation 
rate. CTCF binding has been shown to be associated with increased mutation rate13 and 
other transcription factors may have also increase the mutation rate when bound. Better 
understanding of mutation rate heterogeneity in the germline will be possible as tens of 
thousands of whole genome trio sequencing data sets become available – these next steps 
are discussed in greater detail in the Discussion. 
 
Results Section 3.2: Measuring selective constraint in regulatory elements genome-
wide 
Results Section 3.2.1. Patterns of purifying selection in non-coding elements genome-wide 
 
 The degree of selective constraint on a non-coding sequence can be expressed as a 
ratio of observed variation divided by expected, with elements under stronger constraint 
having lower observed/expected ratios. The germline mutation rate model discussed in 
section 3.1.1 was used to calculate the mutation rate for approximately 46,000 
Human/Chimp Ancestral Repeats. A linear regression was fit to predict the observed 
number of rare single nucleotide variants in likely neutrally evolving bases given the 
mutation rate in these neutral bases. This approach is analogous to the approach taken in 
Lek et. al, 2016 in the coding regions using synonymous variation, which is expected to be 
under little purifying selection, to calibrate the model. 
 This model was applied to 1.7 million DNase I hypersensitive sites, 22,000 3’ UTRs, 
28,000 5’ UTRS, 15,000 promoters, 88,000 exons from long non-coding RNAs (lncRNAs) and 
182,000 exons from protein-coding genes. I first assessed evidence of selective constraint 
for rare variants in these elements regardless of any annotation of evolutionary constraint 
or variant effect on the nucleotide level (Figure 5A). Protein-coding exons showed the 
greatest degree of selective constraint, with a median depletion of 28% (observed/expected 
ratio = 0.72). The DNase hypersensitive sites showed evidence for a modest, but statistically 
significant depletion of approximately 5.5% (observed/expected ratio = 0.945). The 5’ UTRs, 
3’ UTRs, and promoter sequence were not significantly different from the ancestral repeats. 
This was an unexpected result, but may be due to a small fraction of the nucleotides within 
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these elements being selectively constrained, or potentially an underestimate of the 
mutation rate leading to a false negative call. Of note, a previous publication from Di Iulio 
et. al reported a striking level of selective constraint in promoters: 23-fold enrichment in the 
top 1% of elements genome-wide compared to the genome-wide average, whereas protein-
coding exons were only 12-fold enriched. As mentioned previously, Di Iulio et. al do not 
model variation in the germline mutation rate21.  This analysis does account for CpG 
methylation status, amongst other genomic features – as promoter elements have 
hypomethylated CpGs, failure to account for this feature in a sequence-context based 
model would drastically overestimate the mutation rate and lead to incorrect predictions of 
extreme selective constraint. 
Long non-coding RNAs (lncRNAs) are typically identified in RNA sequencing data as 
transcripts with little protein-coding potential, and are often transcribed at much lower 
levels than protein-coding genes. There are relatively few lncRNAs with well-understood 
functions. Some examples include XIST, which is involved in the X-inactivation process38,39, 
and MALAT1, which has been implicated as a lung cancer driver40. Assessing selective 
constraint in 15,904 lncRNA genes defined by the GENCODE consortium (v24), I find 
evidence for a significant depletion of rare variation in lncRNAs (Figure 5A). 
Small insertions and deletions (indels), while rarer than SNVs, may have a greater 
functional impact than SNVs and therefore shed greater light on functional and non-
functional regions of the genome16. However, while considerable progress has been made in 
modelling the single nucleotide mutation rate in the germline, modelling the rate of indels 
has posed a greater in challenge. This challenge is in part due to the greater complexity of 
these mutations, which vary may vary in size and, in the case of insertions, the sequence 
inserted. Furthermore, the mutation rate for indels is also ~10-fold lower than single-
nucleotide variation, resulting in a smaller number of de novo mutations to train and 
validate new models. Thus, while there are several models of the indel mutation rate in 
development, some of which make use of convolutional neural networks using DNA 
sequence as an input, no well-validated models exist to date. While the lack of a validated 
indel mutation rate model makes predicting indel constraint for any individual element 
challenging, estimating constraint in the aggregate for different element classes (for 
example, protein-coding exons, non-coding RNA exons, and DNase hypersensitive sites) can 
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still be achieved by using de novo indels from the 1,548 DECODE WGS trios to account for 
any underlying heterogeneity in the indel mutation rate (see Methods). 
 The protein-coding exons showed a very strong depletion for indels compared to the 
other element classes analysed, consistent with strong purifying selection against frameshift 
variation reported previously. Of the non-coding elements assessed, the lncRNAs, CNEs, 3’ 
UTRs, and 5’ UTRs showed the greatest degree of indel constraint, followed by promoters 
and ENCODE open chromatin peaks (Figure 5A).  
Evolutionary studies have suggested that insertions and deletions may be more 
deleterious than single nucleotide variants in regulatory elements16. All of the element sets 
with sufficient de novo indels to accurately assess the indel mutation rate had a 
substantially greater degree of indel constraint than SNV constraint. This result has 
important implications for how constraint is assessed, as constraint methods based on 
indels may have greater power to detect constrained non-coding elements, despite being 
fewer in number. Furthermore, this result suggests that while de novo indels may be rarer 
than de novo SNVs, they may be more pathogenic and therefore have a non-trivial 
contribution to severe Mendelian disorders akin to frameshift mutations in coding regions 
that, despite their low mutation rate, contribute to an outsized fraction of diagnoses in 





Figure 5 SNV and indel constraint in non-coding and coding elements. (a) observed over expected ratio for 
SNVs and indels in non-coding element sets and protein-coding exons. While the number of indel 
observations limits precise estimates, point estimates of indel constraint suggests stronger constraint 
against indels than SNVs. (b) Exons and 3’ UTRs of genes with pLI > 0.9 (likely intolerant of heterozygous loss 
of function) show a greater degree of indel constraint than genes with pLI <= 0.9. 
 
The exome aggregation consortium (ExAC) profiled loss of function mutations in 
more than 60,000 individuals and identified a depletion for loss of function mutations, 
including protein-truncating variants and splice variants. In this study, a subset of genes with 
a high probability of loss of function intolerance (pLI > 0.9) were identified. These genes 
have a high overlap with known haploinsufficient genes (in which loss of a single copy of the 
gene causes a severe phenotype). It has been proposed that high pLI genes require RNA 
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expression above a particular threshold in order to maintain a critical function. Thus, genetic 
variation outside of the coding sequence causing reduction in expression may also be under 
selective constraint. To this end, I hypothesized that in addition to constraint on changes to 
the protein-coding sequence, there would be greater constraint on proximal regulatory 
elements such as promoters, 3’ UTRs, and 5’ UTRs in high PLI genes compared to other 
genes with less evidence for dosage sensitivity. I found a significant depletion in variation in 
protein-coding exons of high pLI genes compared to exons of genes with pLI < 0.9, 
consistent with previous reports6. I found evidence for a moderate depletion of rare SNVs in 
3’ UTRs of high pLI genes compared to genes with pLI < 0.9, but did not find any evidence 
for increased selective constraint on promoters or 5’ UTRs of high pLI genes.  
This result contradicts a relationship between selective constraint in non-coding 
elements and pLI score of the nearest protein-coding genes reported by Di Iulio et. al. 
However, as discussed previously, Di Iulio et. al, fail to account for variation in the germline 
mutation rate which may have biased some of their results. In particular, failure to account 
for variation in CpG methylation status led to a high rate of false positive predictions of 
selective constraint in promoter elements. Promoters of haploinsufficient genes, which have 
a high degree of overlap with high pLI genes, are enriched for CpG islands and have been 
shown to be less mutable41, which could explain the strong enrichment for constrained 
promoters near high pLI genes. 
I also tested the relationship between constraint and gene dosage sensitivity using 
indel constraint. The protein-coding exons of high pLI genes showed a very strong depletion 
for indels compared to exons of genes with pLI < 0.9. There is a strong correlation between 
3’ UTR length and gene dosage sensitivity41 hypothesised to be due in part to a greater 
number of microRNA binding sites required to exert tight transcriptional control in these 
genes. Further work to understand the precise patterns of purifying selection, particularly 
for indels, is warranted in these elements. As with the SNVs, I did not observe any significant 
difference in indel constraint in the 5’ UTRs or promoters of genes with pLI > 0.9 compared 
to genes with pLI < 0.9 (Figure 5B). 
Beyond testing known categories of non-coding element for selective constraint, 
there is great interest in using selective constraint as a method to identify regulatory 
elements that are evolutionarily novel or have adopted a novel function in humans, such as 
human gained enhancers42 (HGEs). Putative HGEs were identified by Reilly et. al by 
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comparing H3K27ac and H3K4me2 levels in human to mouse and macaque. A total of 912 
putative HGEs active in the fetal brain were identified. I observed moderate selective 
constraint on these putative HGEs, but this constraint was not significantly different from 
open chromatin peaks in general. Thus, while these elements do show human specific 
activity, there is little evidence for strong selective constraint that would imply a critical 
novel function. Reilly et. al report that the HGEs identified in their study do not show 
exceptional human specific changes, lending further support that the majority of HGEs may 
be the result of gradual changes in regulatory element function over evolutionary time, and 
have not undergone strong positive selection for a novel and critical function in brain 
development. 
Human accelerated regions (HARS) are another class of regulatory element with 
putatively novel function in humans. HARs are non-coding elements that are highly 
evolutionarily conserved, but have accelerated divergence on the human lineage43,44. It is 
hypothesized that HARs have undergone recent positive selection for new and potentially 
human-specific function. Thus, these elements are of great interest in human evolution, 
developmental biology, and disease studies. HARs were originally described 
contemporaneously by Prabahakar et. al and Pollard et. al in 2006. The two groups relied on 
slightly different methodology, but both sought to identify genomic elements with 
extremely high sequence conservation across different vertebrate species, but a larger than 
expected number of point mutations that have reached fixation on the human lineage. 
HARs, like conserved non-coding elements in general, are enriched near genes involved in 
development45. A small number of HARs have been studied in detail, including HACNS1, an 
enhancer that has acquired 16 different human specific mutations46. HACNS1 is a weak limb 
enhancer in chimpanzee and macaque, but is strong enhancer in humans and is an 
important component of the development of the thumb. Doan et. al also report an 
enrichment for biallelic variants in HARs in Autism cases in consanguineous families47. 
I assessed the selective constraint on HARs using a set of 2,649 putative HARs 
compiled by Capra et. al in a meta-analysis of four different studies45. The selective 
constraint on HARs is greater than that of HGEs and not significantly different from other 
conserved non-coding elements, which are amongst the most highly constrained non-coding 
elements. These results indicate that the majority of HARs are likely to be functional and 
under selective constraint in humans. However, one particular HAR, 2x.HAR.238, has a 
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striking three-fold enrichment for rare variation (Figure 6A,B). 2x.HAR.238 has been shown 
to act an enhancer for GLI2, an important gene in brain development. This element lies very 
close to a recombination hotspot and shows evidence for localised mutational clustering 
(Figure 6C), which I hypothesize may be the source of the hypermutability in this element. 
Thus, the enrichment for variation in 2x.HAR.238 in humans may be due to hypermutability 




Figure 6 Density of rare variation in CNEs, HARS, and DHSs. (a) One human accelerated region (HAR), 
2x.HAR.238, has a very strong enrichment for rare variation. No conserved non-coding elements (CNEs) or 
DNase I Hypersensitive Sites (DHSs) was observed with as extreme of an enrichment for variation. (b) 
Examination of the rare variation in the 2kb sequence upstream and downstream of 2x.HAR.238 reveals 
localised hypermutability in a window of approximately 750bp. (c) Rare variation in 2x.HAR.238 exhibits a 
high degree of clustering. 
There are many more regulatory elements than protein-coding genes in the human 
genome29. Mammalian genes have a median of twelve associated regulatory elements, 
and the number of regulatory elements is positively correlated with higher expression, 
and greater stability of gene expression48. Likewise, large arrays of ultra-conserved 
regulatory elements have been shown to cluster near genes involved in early 
development, and are hypothesized to exert tight control over timing and expression 
levels49. However, the activity of more individual regulatory elements, is often restricted 
to a subset of tissues and developmental time points. It is not clear whether regulatory 
elements that drive expression in a large number of tissues, or those that operate within 
a relatively narrow, but potentially critical, functional window are under stronger 
selective constraint at the sequence level.  
To test this, I used data from the Roadmap Epigenome Project to annotate activity for 
non-coding elements across 10 different tissue groups (see Methods) and found a 
significant correlation between the number of tissues in which an element is predicted to 
be active and the level of selective constraint (Figure 7). In contrast, we did not find 
strong evidence of a relationship between activity in a particular tissue or organ system 
(e.g. the fetal brain) and selective constraint that would imply strong constraint on 







Figure 7 Activity in a greater number of tissues is correlated with increased selective constraint. 
Annotating DNase hypersensitive sites with predicted enhancer activity across ten different tissue 
groups shows a significant correlation between selective constraint and the number of tissues in 




Results Section 3.2.2. Nucleotide-level conservation scores are more informative of 
selective constraint than locus-level scores 
 A large fraction of the human genome—by some estimates more than 80 percent—
is biochemically active in at least one tissue. However, biochemical activity does not 
necessarily imply function or selective constraint. A number of different studies based on 
multispecies alignments suggest that just 3-15%of the genome is subject to purifying 
selection16,50,51. One potential explanation for these potentially contradictory observations is 
that a small fraction of biochemically active segments of the genome are functional and 
under selection at the sequence level, while the majority of biochemically active segments 
are explained by non-specific protein-binding that has no functional consequence. A second 
potential explanation is that a large fraction of biochemically active peaks are indeed 
functional, but this function is driven by a small fraction of nucleotides within these regions 
which are under selective constraint.  
I sought to test these hypotheses on 1.7 million open chromatin regions covering 
nearly 400Mb of sequence outside of protein-coding exons. These regions were defined by 
the ENCODE consortium using DNase I hypersensitivity (DHS) assays in more than 200 
different cell types and primary tissues. In combination with histone modifications and 
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transcription factor binding sites, these open chromatin regions can be used to identify 
enhancers, promoters, and other functional non-coding elements.  
I observed a strong correlation between evolutionary conservation and selective 
constraint in the ENCODE open chromatin peaks using rare variant data from the BRIDGE 
and gnomAD whole genome sequences (Figure 8A), which has been described 
previously17,21,23. However, even within poorly conserved peaks, there are individual 
nucleotides or sets of nucleotides that appear to be evolutionarily conserved within 
primates or vertebrates. To this end, I hypothesized that while these poorly evolutionarily 
conserved peaks do not appear to be under selective constraint in the aggregate, they may 
contain individual nucleotides that are selectively constrained. 
 To test this hypothesis, I selected the subset of nucleotides within the ENCODE open 
chromatin peaks with a PhyloP score greater than one, indicative of evolutionary 
conservation across vertebrates. The evolutionarily conserved nucleotides showed a 
depletion for rare variation regardless of the degree of conservation of the surrounding 
element (Figure 8A). Repeating this analysis using PhyloP scores based on primate multi-
species alignments returned a similar result. Thus, while the open chromatin peaks cover 
nearly 400Mb of sequence, selective constraint is concentrated within a subset of 
approximately 120 Mb of sequence defined by nucleotide-level conservation. This sequence 
is spread throughout the genome, indicating that the elements underlying these peaks may 
be functional, albeit with a small fraction of nucleotides under selective constraint. 
To further explore the relationship between element level constraint (measured by 
PhastCons) and nucleotide level constraint (measured by PhyloP), I annotated every 
nucleotide with the PhastCons100 score of the open chromatin peak in which the 
nucleotide is positioned and the PhyloP score of the nucleotide itself. Analysing the 
depletion of rare variation in a grid comprising deciles of PhyloP100 and PhastCons100 
scores, it is clear that evolutionarily conserved nucleotides, even within poorly conserved 
peaks, are under selective constraint. Furthermore, as PhyloP score increases the degree of 
selective constraint also increases. Taken together, these results indicate that PhyloP score 
is a reasonable proxy for selective constraint in the non-coding genome, even when the 





Figure 8 Nucleotide level conservation is more predictive of selective constraint than element-level 
conservation. (a) There is strong correlation between constraint, measured by the observed over 
expected ratio, and the element level correlation of DNase I Hypersensitive sites, measured by 
PhastCons100. Focusing on the bases with evidence for nucleotide level conservation (PhyloP > 1, 
denoted ‘conserved nucleotides’), it is evident that even in elements with poor element-level 
conservation, there is constraint on conserved nucleotides. (b) All nucleotides in the 1.7 million DHSs 
genome-wide were annotated with nucleotide-level conservation (PhyloP) and element-level 
conservation (PhastCons100). Nucleotides were split into ten equal sized bins for each measure and 
plotted as a grid, showing a clear relationship between nucleotide-level conservation and constraint, 
regardless of the element-level conservation of the surrounding sequence. 
 
I hypothesized that constraint on a small fraction of nucleotides within a DNase peak 
that is poorly evolutionarily conserved could be due to selective constraint on functional 
transcription factor binding sites within those peaks. To test this hypothesis directly, I 
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calculated the selective constraint on a set of over two million TFBSs conserved between 
human, rat, and mouse (based on computational prediction of TFBS) and overlapping an 
open chromatin peak in at least one tissue. These TFBS are between 6bp and 30bp with a 
median size of 14bp. As with individual nucleotides identified by PhyloP score, the 
conserved TFBSs are constrained, even when they lie within poorly conserved open 
chromatin peaks (Figure 9A). 
Testing each conserved transcription factor binding site independently, there is clear 
variation in the patterns of rare variation. A small fraction of the TFBS had greater levels of 
variation than expected. Testing these TFBS independently using de novo mutations from 
1,548 healthy trios, I observed a 1.42-fold enrichment for mutations compared to the 
expectation under a null model (Figure 9B), indicating that this enrichment for rare variation 
is likely driven by hypermutability not captured by the updated model, perhaps due to TF 
binding in germline tissues as has been suggested previously for CTCF13. A more 
comprehensive analysis with greater numbers of whole genome sequenced trios will likely 
reveal a greater number of associations between mutation rate and transcription factor 
binding. On the other end of selective constraint spectrum, a number of transcription factor 
binding sites appear to be under strong selective constraint. The TFBS under the greatest 
degree of constraint is the TATA-box binding protein (TBP) motif, which is ubiquitous in 
mammalian promoters (Figure 9B). As this motif is likely active in a wide range of tissues, 
due to its general role in transcriptional activation, I hypothesize that the difference in 
selective constraint between TFs may be driven in part by their tissue specificity/ubiquity, in 
line with the observations on DHS described earlier (Figure 7), but further work is required 






Figure 9 Constraint in conserved transcription factor binding sites. (a) Observed over expected ratio 
in conserved transcription factor binding sites (TFBS), stratified by the PhastCons100 score (element-
level conservation) of the surrounding DHS peak. Conserved TFBS were selectively constrained to a 
similar degree regardless of the conservation of the peak in which they lie. (b) Different conserved 
TFBS showed different levels of selective constraint. TFBS with an enrichment for rare variation also 
showed an enrichment for de novo mutations, indicating that there is still variability in mutation rate 
that may be due to mutagenicity of TF binding not captured by the mutation rate model developed 
here. 
 
Regulatory elements are more numerous and show greater evolutionary turnover 
compared to protein-coding genes52,53. Furthermore, the nucleotide level patterns denoting 
regulatory sequence are not yet as well understood as protein-coding genes. It has been 
hypothesized that with a sufficient number of deep whole genome sequences, functional 
regulatory elements could be detected by examining patterns of purifying selection and 
overlapping with biochemical signals associated with enhancers, promoters, or other 
regulatory sequence. However, if a relatively small fraction of nucleotides within an active 
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enhancer or promoter are under selective constraint, the power to detect these elements 
will be significantly lower. 
To address this question directly, I calculated the power to detect constrained non-
coding sequence in this manner using 28,000 whole genomes (see Methods). At this sample 
size, there is sufficient power to detect large tracts of constrained non-coding sequence 
(e.g. 200bp or larger, Figure 10). For example, ultra-conserved non-coding elements or 
human accelerated regions where several hundred base pairs are under selective constraint 
could be detected at this sample size. However, as I have shown here, the vast majority of 
regulatory sequence is poorly conserved on an element-level, but likely harbours individual 
nucleotides or sets of nucleotides, perhaps constituting TFBSs, that are under selective 
constraint. Power to detect constrained sequence the size of a TFBS (e.g. 10-20bp) is 
extremely limited; power calculations indicate that upwards of 1 million deep WGS will be 
needed for this approach to succeed (Figure 10). However, the use of computational tools 
and biochemical assays to refine to identify likely TFBS a priori (analogous to using the 





Figure 10 Power calculations for detecting constrained regulatory sequence Rare variation from 25,000 to 
100,000 whole genome sequenced individuals provides substantial power to detect large tracts (e.g. 100bp 
– 200bp) of selectively constrained sequence. Power calculations suggest that greater than 1 million WGS 
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will be required to detect constraint on the level of a single TFBS (10bp-20bp).  
Results Section 3.2.3. Dominance and selection in the non-coding genome 
 
Conservation is the result of selection against fixation of non-ancestral alleles over a 
period of evolutionary time. Selection against fixation can manifest in a number of ways, 
including strong selection against heterozygotes (e.g. in the case of severe dominant 
disorders), weak selection against heterozygotes where the selection coefficient is greater 
than 1/Ne (the effective population size), or via selection against homozygotes, compound 
heterozygotes, or more complex multi-locus models. 
I sought to test how selective constraint in the non-coding genome differs from 
constraint in the protein-coding genome, where patterns of selection and disease 
mechanisms are more well-understood. I annotated every nucleotide in the protein-coding 
exons and ENCODE open chromatin peaks with their PhyloP scores. Comparing the 
observed/expected ratios of protein-coding nucleotides to putative regulatory non-coding 
nucleotides within the same bins of evolutionary conservation reveals a pattern of selective 
constraint in non-coding elements that is more similar to recessive disease genes than likely 
dosage sensitive genes (pLI > 0.9) and known dominant disease genes (Figure 11). This result 
indicates that at the same degree of evolutionary conservation, regulatory elements have 
weaker selection on heterozygotes than protein-coding genes. This result is consistent with 
the limited role for de novo mutations in regulatory elements discussed in Chapter 2, and 
the predominant role for regulatory variation in common/complex disease54,55. However, as 
the ratio of observed to expected variation is most sensitive to detect strong selection 
against heterozygotes, these data alone do not clearly delineate between evolutionary 
conservation in regulatory elements being maintained by weak selection on heterozygotes, 
selection on homozygotes/compound heterozygotes, or oligogenic selection. Recent work in 
population genetics suggests that distinguishing these two modes of selection may be 




Figure 11 Comparing selective constraint in coding and non-coding elements Observed over expected ratio 
for various protein-coding gene sets with different hypothesized strength of selection on heterozygotes 
alongside the observed over expected ratio for DNase Hypersensitive Sites (DHSs). The DHSs show a pattern 
of selective constraint that is most similar to known recessive disease genes, whereas genes with known or 
suspected strong selective pressure against heterozygotes (Monoallelic DDG2P genes, genes with pLI > 0.9) 
show a much greater decrease in rare variation at equivalent levels of evolutionary conservation. 
 
To further explore the strength and dominance of selection in the non-coding 
genome, I computed the mutability adjusted proportion of singletons (MAPS) scores for the 
same element sets, again stratified by PhyloP scores. I also annotated the protein-coding 
variants with a predicted consequence using the variant effect predictor and extracted 
bases predicted to result in synonymous changes, missense changes, and protein 
truncation. The MAPS score of non-coding variants in the top decile of nucleotide 
conservation was similar to missense changes in protein-coding genes genome-wide 
(excluding known developmental disorder genes and genes with pLI > 0.9) and consistently 
lower than loss of function variants (Figure 12). The results from Figures 11 and 12 together 
imply that there is pervasive weak selection on a small subset of evolutionarily conserved 
non-coding sites, and patterns of selection on these sites may be similar to those of 
missense changes in protein-coding exons, the majority of which have been previously 
reported to be weakly deleterious57. Further study is warranted to determine whether 
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disease-causing alleles in regulatory elements are contributing small, additive effects, or are 





Figure 12 Comparing non-coding variation to protein-coding variation. Strength of selection measured 
by proportion singletons compared to nucleotide-level evolutionary conservation for protein-coding 
gene sets and DNase I Hypersensitive sites. Protein-coding variation was annotated with predicted 
effect (stop gained, missense, and synonymous) and plotted with the median PhyloP score for that 
category. As no such prediction is available in the non-coding genome, nucleotides in DHSs were split 
based on PhyloP score for comparison. Strength of selection on evolutionarily conserved nucleotides in 
the DHSs was similar to missense variation and substantially lower than stop-gained variants, regardless 






 A large fraction of the functional DNA in the human genome has been predicted to 
be non-coding. These predictions have relied primarily on evolutionary comparisons which 
may not be able to reveal relatively recent loss or gain of selective constraint.  Furthermore, 
it can be challenging to deconvolute changes in mutational processes, generation times, and 
selective pressure across evolutionary time2.   
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As large numbers of deep whole genome sequences become available, there has 
been great interest in applying population genetics tools to detect regions of the non-coding 
genome under selective constraint. However, the germline mutation rate is very 
heterogeneous and failure to appropriately model this heterogeneity can lead to false 
positives, for example in promoter regions, as well as false negatives in hypermutable 
regions. To this end, I have developed a new germline mutation rate model using thirty-two 
different features including sequence context, histone modifications in germline tissues, 
replication timing, and recombination rate. This model greatly improves prediction of the 
rate of de novo mutations and rare variants over the existing model which relies on 
sequence context alone. This mutation rate model also corroborates previously published 
mutation rate associated features including a recent observation of hypermutable regions 
with a strong bias toward maternal inheritance8,9. Another limitation to this mutation rate 
model was the lack of available chromatin data in oogonial stem cells. Chromatin marks and 
RNA sequencing data from ovary were used, but a tissue that is closer to the germline will 
likely improve the characterisation of factors influencing the maternal germline. The 
relationship between transcription factor binding and mutation rate should also be explored 
in greater detail. Analysis in this chapter on conserved transcription factor binding sites 
revealed an increased mutation rate in a subset of binding sites, in line with previous 
reports of hypermutability in CTCF binding sites in cancer13. Full characterisation the 
transcription factor binding profiles in germline tissues will likely lead to the discovery of 
more mutation-rate associated TF binding events and further improve understanding of 
mutation rate heterogeneity in the germline. 
Using this improved germline mutation rate model, I modelled selective constraint in 
the non-coding genome using whole genome sequence data from 28,000 individuals, nearly 
3-fold greater than previous non-coding constraint metrics. Furthermore, I showed that 
constraint on indels is much greater than SNVs across a number of coding and non-coding 
elements, consistent with previous results based on evolutionary divergence. I found a 
strong relationship between evolutionary conservation and selective constraint, but showed 
that this relationship was driven primarily by conservation on individual nucleotides and 
suggest that a substantial fraction of these sites may lie in conserved transcription factor 
binding sites.   
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While similar methodologies for detective selective constraint methods have been 
applied successfully to find selectively constrained protein-coding genes, the sparsity of 
functional nucleotides in regulatory elements presents a challenge. Power calculations 
suggest that 25,000 individuals provides sufficient power to detect long contiguous tracts of 
constrained sequence, for example ultraconserved non-coding elements, but affords little 
power to detect constrained TFBS within an otherwise poorly constrained element. 
Improvements in variant effect prediction in the non-coding genome such as identification 
of functional transcription factor binding sites and deleterious variation within them will 
improve power to detect constrained non-coding sequence substantially. 
 In the previous chapter, I showed that de novo mutations in highly evolutionarily 
conserved non-coding elements contribute to severe developmental disorders. Based on 
the analyses presented here, I hypothesize that de novo mutations in highly conserved 
bases within poorly conserved, but nonetheless active, regulatory elements may also 
contribute to these disorders. Identifying these functional non-coding bases is a 
considerable challenge and will be critical to improve power to discover pathogenic DNMs 
and rare variation in non-coding elements. Improvements in computational prediction of 
non-coding variant effects could allow for study designs that assign weights a priori based 
on a predicted functional effect (e.g. by PhyloP or a variant deleteriousness metric such as 
CADD), improving power akin to the implicit weighting scheme already used in protein-
coding genes whereby enrichment analyses focus on missense and protein-truncating 
variation58 or explicit weighting schemes such as independent hypothesis weighting59. 
Furthermore, these analyses suggest that constraint against heterozygosity in 
regulatory elements is in general not as strong as in coding regions. This suggests that the 
effect size or dominance of mutations in regulatory elements will be smaller, and there may 
be a greater role for recessive or oligogenic models. Results from large-scale exome-
sequencing studies indicate that a substantial fraction of individuals do not carry protein-
coding variant that is pathogenic with high penetrance60,61. Thus, it is likely that many 
unsolved disorders may be the result of multiple variants in the coding and non-coding 
regions with moderate to modest effect sizes. Approaches to integrate coding and non-
coding variation, for example by analysing matched RNA-sequencing and whole genome-
sequencing data, may be another strategy to interpret non-coding variant effects through 
their impact on transcript levels. This strategy will require sampling of the relevant tissue or 
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cell types, as is already clinical practice in many types of cancer, or in cases where accessing 
the primary tissue is challenging (e.g. the developing brain), the development of cellular 
models or organoids to recapitulate the tissue of interest. 
As whole genome sequencing is completed in tens of thousands of trios in with 
Autism spectrum disorder, developmental disorders, and other Mendelian disorders, there 
will be greater opportunities to explore the role of de novo mutations as well as recessive 
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Chapter 4: Functional characterisation of mutations in ultra-conserved elements 
associated with severe developmental disorders 
 
Introduction 
Methods for assessing enhancer activity using reporter constructs 
 
 While there are robust computational tools to identify putative protein-coding genes 
based on sequence alone, detecting transcriptional enhancers has proved more challenging. 
Large scale collaborations such as the ENCODE project and the Roadmap Epigenome Project 
have experimentally profiled hundreds of different cell types and tissues to identify putative 
enhancers, promoters, and other genomic elements1,2 (these projects are discussed in 
greater detail in Chapter 1). While these projects have identified millions of putative 
regulatory elements across hundreds of different tissues and time points, these data are 
observational, presenting a number of drawbacks. First, regulatory elements active at a 
tissue or time point that is difficult to sample, for example very early embryonic 
development, may not be identified. Second, these efforts have been focused around 
assaying a small number of individuals per tissue/time point, limiting the insight into the 
impact of variation on enhancer function. Thus, while resources such as ENCODE or the 
Roadmap Epigenome Project provide a rich resource for identifying active regulatory 
elements, these resources are unable to predict the impact on regulatory element function 
by the introduction of a genetic variant. 
 Reporter assays are one of the most widely used methods for assessing promoter 
and enhancer activity. Early reporter assays made use of a modified version of the firefly 
luciferase gene in a mammalian expression vector3. Putative promoter or enhancer 
sequence could be inserted upstream of the luciferase gene and luciferase-induced 
fluorescence could be quantified as a proxy for activity. These assays have improved and 
diversified in many ways since their first use. To assess enhancer activity rather than 
promoter activity, the putative enhancer can be inserted into a vector with a minimal 
promoter upstream of the luciferase gene. Shortly after the introduction of the luciferase 
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reporter gene, many other read-outs of enhancer and promoter activity were developed, 
including the use Green Fluorescent Protein4 (GFP) and lacZ staining5,6. 
 Mouse transgenesis assays using lacZ staining have been used to assess the impact 
of regulatory mutations identified in patients7, study the role of ultraconserved regulatory 
elements in brain development8, and characterise ultraconserved regulatory elements that 
have adopted new functions in humans9. Over the past decade, expression patterns in the 
developing mouse embryo from nearly 3,000 putative enhancers have been collected in the 
VISTA database10. While the reporter assays described above are amenable to testing 
dozens of putative enhancers or promoters in a single experiment and provide a powerful 
view into the complexity of enhancer function with respect to tissue and developmental 
time, they are impractical to scale to hundreds or thousands of tests. This limitation has led 
to a number of different high-throughput reporter assay techniques known collectively as 
massively parallel reporter assays (MPRAs). 
 
Massively parallel reporter assays methods and applications 
MPRAs make use of oligo synthesis to generate libraries of tens of thousands of 
putative enhancers or promoter elements to test in a single experiment. Each enhancer is 
assigned to a unique 15-20bp DNA barcode either during the oligo synthesis step11 or added 
after oligo synthesis using PCR12. Paired-end sequencing is then used to identify the 
enhancer-barcode pairs. Next, a reporter gene, typically GFP is inserted between the 
enhancer and the barcode. As a result, the barcode is situated on the 3’ end of the reporter 
gene and included in the gene transcript. This library of barcoded enhancers is then 
transfected into the cell type of interest, the RNA is harvested and reverse transcribed into 
cDNA, and the short barcode fragments are sequenced to quantify the transcriptional 
output of the upstream enhancer. Comparing the transcriptional output to the amount of 
DNA input, the enhancer potential of a putative regulatory sequence can be assessed. This 
approach, which has been applied to detect eQTLs, is described in detail in Tewhey et. al. An 
alternative approach, STARR-seq, does not make use of DNA barcodes. Instead, the 
enhancer is inserted downstream of the reporter gene in the viral vector13. As the viral 
vector is circular, the enhancer can drive expression of the reporter gene, transcribed along 
with the gene, and used as a readout for its own activity. 
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The first application of the MPRA was a proof of concept saturation mutagenesis 
experiment in a synthetic enhancer11. Since this proof of concept, the approach has been 
used in a number of different applications including construction of synthetic enhancers and 
dissection of enhancers with links to disease or interesting evolutionary properties. Tewhey 
et. al used an allele specific expression strategy to compare enhancer activity of the SNPs in 
linkage disequilibrium with the most significantly associated SNP in gene expression 
quantitative trait loci12 (eQTLs). Smith et. al, generated approximately 5,000 synthetic 
enhancers containing twelve different transcription factor binding sites (TFBSs) important 
for function in the liver, arranged with varying degrees of complexity, from testing more 
than 500 sequences with a single TF binding site and more than 2,500 putative enhancers 
with three or more transcription factor binding sites. This work revealed general principles 
of enhancer function consistent with the ‘billboard model’ including increased expression 
correlating with the number and heterogeneity of TFBSs. The authors also demonstrated 
synergistic and antagonistic interactions between different transcription factors (TFs). Ryu 
et. al, recently used a series of MPRA to test 714 putative human accelerated regions, 
conserved non-coding elements with a greater number of human-specific variation than 
expected under a neutral model, for enhancer activity in induced pluripotent stem cell 
derived neuronal progenitors. Different MPRA variations and applications are reviewed in 
Inoue and Ahituv 14. 
After generating MPRA data, statistical methods are needed to quantify the effect of 
individual variation on reporter gene activity relative to a reference sequence. Many of the 
first studies in this field drew on previous work in allele-specific expression (ASE) in RNA-
sequencing to analyse MPRA data11,12,15. However, there are major differences between 
these two types of analysis, most notably that the input DNA sequence in a MPRA 
experiment may not be the same between the reference and alternate alleles, whereas in 
ASE studies, the ratio of DNA from the two alleles is equal. Recently, the QuASAR-MPRA 
approach was developed which incorporates plasmid proportions and uses a beta-binomial 
distribution model variance16. Applying this method to previously published data12,16 
indicates that this approach reduces false positives while improving power to detect ASE in 
MPRAs. Other statistical methods have been developed for different types of analysis. For 
example, Sharpr-MPRA was designed to analyse data from oligonucleotides densely tiled 
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across a larger regulatory element to make inferences about which nucleotides are 
functional within the regulatory sequence17. 
While mouse transgenesis assays and MPRAs have proved to be powerful tools, they 
come with important caveats to consider. In the case of MPRAs, the activity of a putative 
enhancer or promoter will depend on the cell type or tissue in which the assay is conducted, 
not least due to the expression of different transcription factors in different cell types 15. 
Likewise, gathering sufficient RNA to maintain library complexity requires high transfection 
efficiency or a large amount of cellular material to balance out low transfection efficiency. 
These technical limitations may limit the choice of cell types considerably and potentially 
bias studies toward cell lines that are experimentally tractable but less biologically relevant. 
Moreover, many experimental approaches involve the reporter gene being expressed in an 
episomal context (i.e. not integrated into a chromosome), and it has been suggested that 
integration into the genome, using a lentiviral vector, provides a more biologically realistic 
context18. It is currently challenging to synthesise elements longer than approximately 
150bp. In the case where the true functional sequence is longer than 150bp, a MPRA may 
not faithfully represent in vivo function. For these reasons, no individual functional assay 
should be considered conclusive, either of enhancer function or the impact of genetic 
variation on enhancer function. Integrating data from evolutionary genetics, medical 
genetics, and multiple experimental approaches is likely to provide greatest insight into 
gene mis-regulation as a mechanism for disease. 
This MPRA data discussed in this Chapter are derived from a pilot project designed 
as a follow-up to the results presented in Chapter 2. Specifically, I sought to test the 
evidence for enhancer activity of the CNEs sequenced in the DDD project, assess the impact 
of SNVs and indels in these CNEs, and to compare the impact of patient mutations to 
common and rare variation observed in unaffected individuals. Sebastian Gerety and Matt 
Hurles contributed a substantial amount of work and oversight in the study design and 
Sebastian Gerety and Holly Ironfield performed all of the wet-lab experiments generating 





MPRA oligo design 
Reference sequence was included in the oligo synthesis for the following element sets:  
 
1. Conserved non-coding elements and enhancers with at least one DNM (SNV or indel) 
in 7,930 probands (n = 767 unique sites) from Short et. al, 2018. 
 
2. Control elements assayed in U87 cells and neural progenitor cells - 90 elements with varying evidence for biochemical activity in Neural Progenitor 
Cells (30 low, 30 medium, 30 high from data kindly provided by Barak Cohen and 
Brett Maricque, described in Maricque et. al 2016). 
 
3. Positive control regulatory elements - Three high-confidence neural cis-regulatory elements, derived from data kindly 
provided by Barak Cohen and Brett Maricque, from a LV-MPRA assay in neural 
progenitor cells described in Maricque et. al, 2016, chr2:72898217-72898346, 
chr17:44916284-44916413, and chr3:71241866-71241995 in GRCh37 
coordinates. 
 
The following subset of elements were selected for saturation (all possible SNV changes) 
 
1. Recurrently mutated fetal brain active elements from Short et. al, 2018 
-     64 unique sites across 31 elements 
 
2. Positive controls - Three high-confidence neural cis-regulatory elements, derived from data kindly 
provided by Barak Cohen and Brett Maricque, from a LV-MPRA assay in neural 
progenitor cells described in Maricque et. al, 2016, chr2:72898217-72898346, 




The following elements were selected and variants were synthesized with non-overlapping 
5bp deletions across the entire element: 
 
1. Conserved non-coding elements and enhancers with at least one DNM (SNV or indel) 
in 7,930 probands (n = 767 unique sites). 
 
2. Positive controls - Three high-confidence neural cis-regulatory elements, derived from data kindly 
provided by Barak Cohen and Brett Maricque, from a LV-MPRA assay in neural 
progenitor cells described in Maricque et. al, 2016, chr2:72898217-72898346, 
chr17:44916284-44916413, and chr3:71241866-71241995 in GRCh37 
coordinates. 
 
All of the oligonucleotides for this experiment were synthesized by Agilent Technologies 
using a 244K array. Oligos are 180bp long, within 15bp of adapter sequence on the 5’ and 3’ 
end, and 150bp of genomic context in between. 
 
Four different adapters were designed in order to allow for sub-pooling of the library to 















The POOL_A adapter sequences were the same as the adapter used in Tewhey et. al, 2016, 
which did not employ any sub-pooling strategy. 
 
The four separate adapter sequences were used to define four different pools: 
Pool 1 - first 22 recurrently mutated elements (lexicographical ordering) in exome-negative 
probands (ref, saturation, and tiling indels) 
Pool 2 - second 21 recurrently mutated elements (lexicographical ordering) in exome-
negative probands (ref, saturation, and tiling indels) 
Pool 3- remaining 21 recurrently mutated elements (lexicographical ordering) in exome-
negative probands (ref, saturation, and tiling indels) 
Pool 4 – remaining 703 elements with single DNM (ref, tiling indels from exome-positive and 
exome-negative) 
 
One of each of the three positive controls from Maricque et. al, 2016 were included in each 
pool. The 90 common controls were included in all three pools to allow for normalization 
and comparison between pools. 
 
Reference Testing (4 oligos) - Wildtype sequence in the forward direction with the DNM centered at +25bp, 
+75bp, and +125bp. - Wildtype sequence in the reverse direction with the DNM centered at +75bp. 
 
Saturation mutagenesis (453 oligos) - 150bp of reference genomic sequence, with DNM at position +75, every position in 
sequence changed to three possible alt SNVs. (450 oligos) - 150bp of reference genomic sequence, with DNM at position +25, only site where 
DNM is located is changed to alt. (1 oligo) - 150bp of reference genomic sequence, with DNM at position +125, only site where 
DNM is located is changed to alt. (1 oligo) - 150bp of reversed reference genomic sequence, with DNM at position +75, only site 
where DNM is located is changed to alt. (1 oligo) 
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- If there is a variant present in addition to the DNM within the 150bp window, one 
extra oligo is generated including both the variant and DNM to analyse the full 
haplotype. 
 
Tiling indels (30 oligos) - 5bp deletions beginning at position +0, +5, +10, …, +145, with respect to the DNM at 
position +75bp. 
 
All oligos were generated using the oligo_design.R script in the MPRA_ddd project: 
https://github.com/pjshort/MPRA_ddd/ 
 
In total, 56,688 oligos were generated: - 3,068 oligos were generated with four different ref sequences (767 unique DNMs, 
see above for different ref sequences). - 363 sequences were generated with ref in the forward direction (90 common 
controls with each of four adapters, plus 3 positive controls with one adapter each). - 30,150 oligos were generated with a single nucleotide of wild-type sequence 
changed (64 unique DNMs in recurrent elements + 3 positive controls, 450 oligos 
each). - 7 oligos where child has other common or rare variants within 150bp oligo in 
addition to the observed DNM. - 23,100 oligos were generated with a 5bp deletion of wild-type sequence (767 unique 
DNMs, 3 positive controls, 30 oligos each. 
 
 
Adding barcodes and pool adapters to oligos 
In order to easily identify individual oligo plasmids, 20bp barcodes were added by PCR to 
the oligo pools.  Primers were designed to specifically amplify each subpool, adding a 3' 20-
base random barcode to each fragment, and the necessary overlaps with the target vector 
to perform Gibson cloning.  For pools A-D, these were forward primers #430-433, and 
reverse primers #434-437.  For each pool (A-D), 300 uL PCR reactions (spread across a 96 
well plate as 6 X 50ul reactions) were run using 6ng of oligo library template.  Q5 NEB 
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polymerase was used, and all reactions were done at 15 cycles: this gave us sufficient 
material for downstream cloning while avoiding over-amplification and potential bias in the 
oligo pool. The resulting PCR products were treated with ExonucleaseI (NEB) to remove 
unincorporated barcode primers, and then purified using standard SPRI bead methods 
(Ampure, Agilent). 
 
Creating the MPRA vector library 
The plasmid backbone used in this analysis (pGL4:23:∆xba∆luc) was provided by Ryan 
Tewhey and is the same backbone used in Tewhey et. al, 2016. This vector was prepared by 
PCR, incorporating sequence overlapping the library oligos (#525 and 526), thus enabling 
the use of Gibson assembly.  1 microgram(ug) of vector was combined with 1 ug of purified 
oligo in a 40ul Gibson assembly reaction, using standard conditions.  The gibson reactions 
were purified using standard SPRI bead isolation, eluting in 20ul of elution buffer (EB, 
Qiagen).  10ul of this eluate was electroporated into 100 ul of high efficiency 
electrocompentent bacterial cells (C3020K, NEB) using recommended protocols and 
parameters: 0.1mm cuvettes (Biorad), with settings of 2KV,200 ohm,25uF.  After recovery, 
cells were plated on large 22.5cm X 22.5cm agar/ampicillin plates at around 2 million CFU 
per plate.  Plating density was confirmed by serial dilution, plating, and counting.  After 
overnight at 37 degrees, the cells from the plates were harvested in LB broth, and plasmid 
DNA was prepared using two Qiagen PLUS Midiprep columns (Qiagen) per subpool.  This 
yielded around 250ug per subpool.  
 
These oligo-barcode libraries were sequenced in order to determine the oligo-barcode pairs 
for downstream analyses.  This was done as described in Tewhey et. al, with modifications, 
using paired end 150bp Illumina chemistry.   
 
 To generate the final MPRA libraries, containing an open reading frame downstream of the 
oligo/elements, we cut 15ug of each pool DNA with Sgf1 followed by SPRI bead purification.  
We generated PCR amplicons containing the GFP ORF (primers #426-450), and ligated 2ug 
of this to 2ug of the cut vector pool using Gibson assembly. These reactions were purified 
using SPRI beads, re-cut with AsiSI, and purified using SPRI beads.  The reactions were then 
electroporated into high efficiency electrocompetent bacterial cells as described above.  
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After recovery, these transformed cells were grown in LB+Carbenicillin for 9 hours, 
harvested, and purified using Qiagen PLUS maxiprep columns (4 columns per pool).  The 
initial electroporation was also serially diluted and plated on LB/agar+AMP plates to 
estimate yield.  Each electroporated pools each gave around 8 X 108 CFUs. 
 
Transfection into HeLA and Neuroblastoma cell lines 
The Neon Transfection System (ThermoFisher Technologies) was used to transfect HeLA 
cells and SHSy5y human neuroblastoma cells (https://www.lgcstandards-
atcc.org/Products/All/CRL-2266.aspx) in triplicate.  We electroporated 5 million cells with 30 
ug of plasmid pool DNA per replicate, using 100uL NEON tips.  For HELA, we used 1005 
Volts, 35ms pulse, with 2 pulses.  For SHSy5y cells, we used 1200 volds, 20ms pulse, for 3 
pulses.  Cells were recovered into standard growth media, and allowed to grow for two 
days.  The presence of GFP expression was confirmed by epifluorescence microscopy.  Cells 
were then trypsinized, spun down and snap frozen for RNA extraction. 
 
RNA taqSeq library preparation 
RNA extraction from cell pellets was done using RNeasy columns (Qiagen).  All RNA samples 
were DNAse treated (TURBO DNA-free Kit, Thermofisher) to remove any residual plasmid 
DNA.  cDNA was synthesised using 2.5 ug of total RNA, and a primer specific to the plasmid-
derived 3' UTR (primer #543), thus ensuring enrichment for plasmid-derived transcripts 
(SuperScript IV First-Strand Synthesis System, Thermofisher).  To introduce 15bp unique 
molecular identifiers (UMIs), we performed a second strand synthesis (primer extension 
reaction) using a primer that annealed 125 bases upstream of the barcode, and included 15 
random bases in addition to Illumina partial adaptor sequences for library construction 
(primer #539).  After SPRI bead purification, these uniquely labeled cDNA molecules were 
then amplified in two rounds of 15 cycles of PCR, to progressively add the necessary 
Illumina adaptors (primers #544,535), then index barcodes (Illumina 11bp index set, PE 1.0).  
Purified library DNA was then subjected to 25bp paired-end sequencing on an Illumina 
HiSeq4000 to identify barcode expression (3' end) and UMI identity (5' end).  Each replicate 
gave around 165 million read-pairs.   
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The plasmid library DNA was sequenced in an identical manner, starting with primer 
extension step using plasmid DNA and UMI containing primer (primer #539).  These plasmid 
counts provide the DNA input amounts with which we normalise element expression. 
 
Linking elements to barcodes with 150bp paired-end sequencing data 
First, I fused the 150bp paired-end reads to a single read using the FLASH19 with the 
following flags:  
flash -r 150 -f 220 -s 10 PoolA_R1.fastq.gz PoolA_R2.fastq.gz -o PoolA.Mar2018.Lane1 
 
This will output the extended fragments as PoolA.Mar2018.Lane1.extendedFrags.fastq. 
 
Next, the fused reads were aligned to the reference oligos using BWA mem20 version 0.7.13: 
 
bwa mem -v 0 ddd_noncoding_MPRA.refs_and_controls.dups_removed.fasta 
PoolA.Mar2018.extendedFrags.fastq > PoolA.Mar2018.sam 
 
A custom python script was written using pysam to reconstruct the element sequence from 
the alignment and populate a table of element-barcodes pairs. 
 
Counting UMI-labelled barcodes from 25bp paired-end sequencing data  
A custom python script was written using pysam to extract the barcode and UMI from the 
25bp paired-end sequences and populate a table of unique barcode-UMI pairs with the total 
number of reads observed for each pair.  
 
In order to correct for sequencing errors in the barcodes, any barcodes not matching a 
previous element-barcode, the edit distance was calculated for all known element-barcode 
pairs. If a barcode was within two edits of a known barcode from the previous step, it was 
corrected to this barcode. If there were multiple matching barcodes, the count was 
excluded. 
 
Calculating normalised expression values in HeLa and Neuroblastoma and testing 
correlation between replicates 
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Elements were split into four different sub-pools (as described above) and each sub-pool 
was tested in HeLa and Neuroblastoma in three independent biological replicates. For each 
sub-pool and replicate, normalised expression was calculated as the ratio between RNA and 
DNA, normalised by the total number of RNA and DNA UMIs sequenced: 
 𝑒𝑥𝑝𝑟%&%'%() = 	 RNAelement	/RNA56578DNAelement	/DNA56578 
  
Spearman rank correlation was used to assess the correlation of normalised expression 
values across different experimental replicates. 
 
 
Results Section 4.1: Assessing disease-associated enhancer activity using massively 
parallel reporter assays 
 
Results Section 4.1.1. Design of a MPRA experiment to assess enhancer activity of 
elements harbouring de novo mutations in patients 
 
 In Chapter 2, I demonstrated an enrichment for damaging de novo mutations 
(DNMs) in evolutionarily conserved non-coding elements and I showed that a substantial 
fraction of these elements are likely acting as enhancers. However, determining the precise 
effect of these regulatory DNMs remains a substantial challenge. This hampers the 
discovery of novel genetic associations and in resolving variants of unknown significance in 
patient genomes. Putative pathogenic variants in regulatory elements have been assayed 
previously using zebrafish models, mouse transgenesis assays, and mouse knock-ins. 
However, these experimental assays can only test tens of variants due to prohibitive cost or 
experimental complexity. Massively parallel reporter assay (MPRAs) allow traditional 
reporter assays to be scaled to test tens of thousands of variants in a single experiment. 
Thus, patient DNMs within the elements of interest can be tested alongside population 
variation as well as variants that have not yet been observed, providing insight not only into 
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the impact of specific mutations discovered in patients, but also, potentially, a systematic 
overview of nucleotide-level functional importance within an element. 
 The primary aim of this experiment was to serve as a pilot experiment to shape 
future studies using MPRAs as a tool to evaluate putative pathogenic regulatory variation. I 
chose to focus on the elements that were most likely to be harbouring pathogenic 
regulatory variants based on the analysis in Chapter 2. While conserved non-coding 
elements are depleted for genetic variation, they still harbour rare and common variation 
that is found in healthy individuals, and one of the goals of this pilot was to compare 
putative pathogenic variation found in patients to variants observed in healthy individuals. I 
also sought to compare the impact of SNVs and deletions in these elements, with the 
hypothesis that deletions would be more disruptive to element function. Published work 
has shown a higher impact from deletions than SNVs, albeit in the context of a synthetic 
enhancer. If deletions do cause a more pronounced effect, they may also be a more efficient 
way of determining which regions in an enhancer are critical for function.  
As part of the pilot project, I also ran the experiment in HeLa cells as well as 
neuroblastoma cells. While HeLa cells are experimentally tractable and have been used in 
previous MPRA work, they may not contain the relevant TFs for expression of elements 
likely to be active in neural tissues. In contrast, Neuroblastoma expresses many of the 
essential neuronal markers21, but has lower transfection efficiency than HeLa cells. Thus, an 
essential part of the pilot project was determining whether we can observe cell type-specific 
enhancer activity, and whether choice of cell type dramatically impacts any conclusions. 
 To this end, I designed a series of MPRA experiments testing 56,688 different 
enhancer sequences based on results from Chapter 2. These 56,688 sequences included 
thirty-one genomic elements with DNMs observed in multiple families. A total of 64 
independent DNMs were identified in these recurrently mutated elements. These 64 DNMs 
were included in the analysis with 150bp of genomic sequence (74bp upstream and 75bp 
downstream). These 64 elements were also synthesized with every possible SNV change 
from the reference sequence throughout the 150bp element. In the case that two DNMs fall 
within 150bp, a saturated element was programmed for each DNM and thus the DNMs 
would be evaluated twice in different contexts—once in the center of a saturated element, 
and a second time in the oligo centred on the other DNM. To mitigate the risk of false 
negatives due to the 150bp element centred on the DNM would be non-functional, I also 
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included the wild-type sequence of the element with the DNM at the 25th base, at the 125th 
base, and at the 75th base with the element in reverse orientation. 
A total of 767 elements, including the 64 selected for saturation SNV editing, with a 
DNM observed in one patient were synthesized with the reference sequence as well as five 
base pair deletions tiled across the element (see Methods). Control elements assayed in a 
previously published MPRA conducted in U87 glioblastoma cell line and neural progenitor 
cell line were also included11,22 (see Methods). The experimental workflow for this analysis 
was based on Tewhey et. al, but included adaptations to the protocol most notably the 
addition of unique molecular identifiers (UMIs) to ensure all sequencing steps are reflective 
of the original input material and not subject to overcounting or PCR biases. This work was 
led by Sebastian Gerety in the laboratory and I worked on the experimental design, 
bioinformatics, and statistical analysis. An overview of the experimental design and 




Figure 1 Overview of the MPRA method adapted to include UMIs. 		
 The oligo synthesis design included 28,800 SNVs and 23,010-thousand five base pair 
deletions in non-coding elements with mutations observed in patients with severe 
developmental disorders (see Methods). However, oligo synthesis is error-prone and as a 
result a far greater diversity of variation was observed than what was originally designed. In 
particular, 22% of oligonucleotides had a one base pair deletions and 7% had large deletions 
(>20bp). By comparing the sequencing reads spanning the same element-barcode pairs, I 
determined that these deletions were likely present in the oligo-synthesis step, not as a 
sequencing error. Figure 2A shows the distribution of actual observed deletions sizes 
relative to the reference compared to what was expected based on the array design. 
However, due to the quasi-random nature of the deletions, the vast majority of ‘non-





Figure 2 Linking elements to barcodes. (a) Oligo-synthesis is error-prone and introduces non-
programmed variation. One base pair deletions are the most common error mode, but large deletions 
(>20bp) are also common. (b) Most programmed oligonucleotides are present with tens to hundreds 
of different barcodes in the input DNA, while non-programmed variation is at a much lower 
abundance in the library. 		
Previous MPRA work has not, to my knowledge, addressed the issue of errors in 
oligo-synthesis directly. Instead, they have used approximate string matching to match non-
programmed variation to expected variation within a stated error tolerance (typically two 
edits)12. In cases where barcodes are synthesized on the oligo rather than ligated in a 
separate step, synthesis errors cannot be easily separated from sequencing errors11,15. In 
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either case, pooling data from oligonucleotides sharing the same programmed edit but with 
different non-programmed edits may introduce noise to the experiment. For this reason, I 
chose to begin by strictly filtering to ensure that any inferences made about variant effect 
were due to the precise programmed variation and not due to error-prone oligo synthesis. I 
successfully recovered barcodes for 27,146/28,800 (94.2%) of SNV-containing sequences 
and 21,238/23,010 (92.3%) of 5bp deletion-containing sequences. Of the 64 elements 
selected for saturation, 61/64 elements had near complete saturation (median 447/450 
SNVs recovered), while 3/64 elements were very poorly represented (Figure 3A). These 
three elements had long runs of repeated sequence. These elements had a high error rate 
during oligo synthesis and were also observed at lower abundance, indicative of low PCR 
efficiency. Due to these technical limitations, these three elements were excluded from 
further analyses. The programmed deletions were also well-represented in the library. Of 
the 767 elements selected for tiling 5bp deletions, >80% of elements had at least 27/30 




Figure 3 Proportion of programmed SNVs and deletions. (a) 61/64 elements selected for saturation 
had nearly all of the 450 expected SNVs observed after the barcoding step. (b) of the 767 elements 
 121 
selected for tiling 5bp deletions, recovery of observed deletions was also very high.  	
The expression of a putative regulatory element in a massively parallel reporter 
assay is calculated by dividing the observed RNA levels after transfection by the input DNA 
levels. Previously published MPRA studies have calculated normalised expression based on 
dividing the proportion of sequenced reads matching element-associated barcodes in the 
cDNA by the proportion of those barcodes in the original library DNA library used in 
transfections12. One concern with this approach is that performing PCR before sequencing 
may result in PCR biases confounding expression estimates as well as redundant sequencing 
of the same original DNA molecule in cases where the amount of starting material is low. 
This has been observed in bulk RNA-sequencing23 and single cell RNA sequencing24, and 
these biases have been addressed using unique molecular identifiers (UMIs), but this 
approach has not yet been applied to MPRA to my knowledge. In order to test and 
potentially correct for overcounting the same DNA molecule, the protocol described in 
Tewhey et. al was adapted by Sebastian Gerety in the Hurles Lab to include incorporation of 
UMIs to each DNA molecule prior in the plasmid library prior to PCR amplification and 
sequencing as well as to each cDNA molecule harvested from HeLa and neuroblastoma cell 
lines prior to sequencing (Figure 1). 
I found that in the cDNA pools, each individual molecule was sequenced, on average, 
just over three times, implying that the complexity of input material used in sequencing was 
too low. Without the use of UMIs, it would be difficult to know whether the amount of 
input material was sufficient. In the case of low input material, counting sequencing reads 
rather than UMIs would result in an artificially high level of certainty around estimates of 
variant effect due to overestimate of the denominator (input DNA) and numerator (output 
RNA) in estimates of allele specific expression (ASE). In the case of abundant input material, 
I expect that the UMIs will reduce the variance between independent controls by reducing 
the noise due to sequencing the same original molecule twice, due to sampling with 
replacement. For these reasons, I used the UMI counts, rather than the total read counts, in 
all analyses going forward. 
The choice of cellular system used in MPRA has shown to impact the regulatory 
activity of putative enhancer sequence22. For this reason, I chose to test the enhancer 
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elements in both HeLa cells and neuroblastoma cells. HeLa cells are more easily transfected 
and have been used extensively in MPRAs, but are lacking in many of the tissue-specific 
transcription factors important for activity of developmental enhancers. I sought to test the 
robustness of the assay in HeLa and neuroblastoma by testing the expression of putative 
enhancer sequences in multiple independent experiments and comparing results. I 
calculated the ratio of RNA output to DNA input within a given pool, normalised by the total 
number of unique UMIs observed (referred to as ‘normalised expression’ throughout) in 
three independent biological replicates in both HeLa cells and Neuroblastoma cells. To 
reduce the likelihood of PCR biases causing particular elements to be at much higher 
proportion in the MPRA library, all experiments were performed in four different sub-pools 
using specific primers included at the oligo synthesis step, resulting in a total 24 different 
experiments (see Methods).  
I first calculated the normalised expression of each wild-type reference sequence 
and compared the estimated expression in independent biological replicates. The 
correlation was unexpectedly low compared to that reported in Tewhey et. al (Figure 4A, r2 
= 0.06, p = 0.0002093) and there were a large number of elements that showed evidence for 
expression in one replicate and no expression in another. I reasoned that this may be the 
result of a bottleneck causing elements at low abundance in the pool to have high variance 
between pools. Ranking the elements by their abundance in the plasmid pool and restricting 
to the top 10%, I find a much higher correlation between independent replicates (Figure 4B, 
r2 = 0.58). 
This phenomenon was not reported in Tewhey et. al, so I downloaded the publicly 
available data to see if I could reproduce the same phenomenon. I saw no evidence for 
drop-out or markedly high variance at low abundance plasmids in the Tewhey et. al data, 
suggesting that differences in the experimental protocol, potentially due to the lower 
number of cells used in our experiment (5 million cells versus 100 million) or the 
transfection method used (electroporation versus lipofectamine), may have resulted in a 
bottleneck in our data that is not present in the data from Tewhey et. al. As of this writing, 
the source of this loss of complexity in our experimental workflow has not been resolved, so 
all analyses going forward have been restricted to include elements above an abundance 
threshold of 0.0014 (see Figure 4C). As a result, approximately 40% of programmed variants 
were excluded from the analysis. Even at this strict abundance cutoff, the correlation 
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between replicates in the publicly available data from Tewhey et. al is higher (r2 = 0.58 
versus r2 = 0.64). Thus resolving the potential bottleneck in our experimental pipeline is 




Figure 4 Correlation between biological replicates. (a) the number of unique plasmid molecules in 
the starting library correlates strongly with correlation between independent biological replicates. 
Increasing the starting material to tens of thousands of molecules per DNA sequence tested will 
improve reproducibility. (b) Correlation between normalised expression in HeLa cell line replicate 1 
and replicate 2 (r2 = 0.76). 
 
After establishing criteria for reliable correlation between replicates, I next sought to 
test the enhancer activity for the wild-type sequence of all 767 conserved non-coding 
elements (CNEs) and enhancer sequences included in the MPRA design. The expression of 
the reference sequences assayed showed bimodal distribution in both HeLa and 
Neuroblastoma cell lines (Figure 5A,B), indicating that a subset of elements are likely driving 
robust expression, while others are not acting as enhancers in that particular cellular 
context. 
I fit a two-component gaussian mixture model to the expression data to classify 
elements as likely active or inactive. In HeLa cells, 64% of elements showed strong evidence 
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of enhancer activity and in neuroblastoma cells, 72% showed strong evidence of activity. 
Across the two different cellular systems, 85% of all elements were active in at least cellular 
context and 50% were active in both. Elements overlapping a DNase I hypersensitive site 
(DHS) in HeLa cells showed 1.4-fold greater expression (p = 0.00003043, Wilcoxon rank sum 
test) and elements overlapping a DHS in neuroblastoma showed a 1.1-fold greater 
expression which was not significant (p = 0.24, Wilcoxon rank sum test) (Figure 5C,D). Only 
one source of DHS data was available for the neuroblastoma cell line used, and these DHS 
data were generated as part of an early ENCODE study, thus the sensitivity may not be 
equivalent to the data used in HeLa cells. Elements that are active in the MPRA experiment 
in both neuroblastoma and HeLa cells are also 1.4-fold more likely to be overlapping open 
chromatin peaks in both HeLa and Neuroblastoma (p = 0.0235, chi-square test). These 
results support the finding from Chapter 2 that a large fraction (50-70%) of the non-coding 
elements sequenced in the DDD project were likely acting as enhancers.  
 
 
Figure 5 Activity of reference sequences in different cellular contexts. Ratio of RNA to DNA in the 
wildtype sequence of 767 conserved non-coding elements and enhancers in (a) HeLa cell line and (b) 
neuroblastoma cell line shows bimodality. (c) Elements overlapping an open chromatin peak in HeLa 
cells show higher expression in the MPRA experiment. (d) Elements overlapping an open chromatin 
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peak in Neuroblastoma cells do not show any statistically significant expression differences in the 
MPRA assay.  	
Results Section 4.1.2. Impact of SNVs and indels on ultra-conserved element function 
 
 Across all of the genetic variants tested, the majority of single nucleotide variants 
and indels resulted in decreased expression relative to the reference sequence (Figure 6), 
suggesting that the evolutionary conservation of these elements may be maintained in large 
part by selection against reduction in gene expression on the genes they regulate. 
Population genetic analyses in Chapter 3 and previous reports based on patterns of 
evolutionary conservation in the non-coding genome across species suggest that selective 




Figure 6 Impact of all SNVs on reporter gene expression. In both HeLa and neuroblastoma, 




In both HeLa and neuroblastoma cells, the 5bp deletions showed substantially 
greater impact on expression of the wildtype sequence compared to SNVs (median 1.39-fold 
change from 5bp deletions compared to median 1.22-fold change for SNVs in HeLa cells p < 
2.2e-16, Figure 7A, and median 1.42-fold change from 5bp deletion compared to median 
1.34-fold change for SNVs in neuroblastoma cells p < 2.2e-16, Figure 7B). 
 While the majority of elements tested in this assay are highly evolutionarily 
conserved, not all nucleotides within these elements are conserved across species. I sought 
to test the relationship between nucleotide level evolutionary conservation across 100 
vertebrate species (measured by PhyloP) and changes in reporter gene expression. Variation 
in sites with the highest decile of evolutionary conservation reduced expression by ~7% 
more than variation in sites with the lowest decile of evolutionary conservation (median 
1.32-fold change versus 1.39-fold change, p = 0.000032, Figure 7C) in neuroblastoma, but 
the difference was not significant in HeLa. I did not find any significant difference in reporter 
gene expression and CADD score25, one of the most commonly used metrics for assessing 
variant deleteriousness in the coding and non-coding genome (Figure 7D). The data in 
neuroblastoma are suggestive of a relationship between evolutionary conservation and 
magnitude of MPRA expression changes, but given the lack of concordance between 
different cell types, further study is warranted before drawing any broad conclusions. 
 Forces of selection acting to reduce the frequency of deleterious alleles in the 
population imply that rare variation is more likely to be deleterious than common variation. 
For example, singleton variants (observed only once in the population being studied) have 
been shown to be enriched for damaging variation compared to more common variation. To 
this end, I hypothesized that the allele frequency of variants may correlate with effect size in 
the reporter assay. I used the genome aggregation database (gnomAD) and the DDD 
unaffected parents to identify variants observed as singletons and compared their effect 
size to sites with two or more alleles observed. I did not find any significant difference 
between effect size the in the reporter assay for singleton compared to non-singleton 
variation in either HeLa or neuroblastoma. However, as only approximately 3% of the 
variants assessed in the MPRA assay have been observed in these populations, power to 
detect any difference is far more limited than with PhyloP, or CADD which can be applied to 






Figure 7 Impact of SNVs and deletions on reporter gene expression. Deletions result in significantly greater 
changes than SNVs in (a) HeLa cell line and (b) neuroblastoma cell line. (c) Increase in PhyloP score is 
associated with a greater impact on reporter gene expression. (d) CADD score of the variant did not show a 
clear relationship with impact on the reporter gene. 	
Results Section 4.1.3. Assessing the impact of patient mutations using MPRAs 
 
 A lack of understanding of the nucleotide-level ‘grammar’ of enhancers, promoters, 
and other regulatory sequence presents a challenge to variant interpretation in the non-
coding genome. MPRAs present an opportunity to test the impact of thousands of 
potentially pathogenic non-coding variants in a single experiment. If these experimental 
assays prove robust and informative with respect to pathogenicity and faithfully 
recapitulate in vivo activity, they could serve as a ‘look-up’ table for variant pathogenicity, as 
well as a source of data to improve machine learning models for variant pathogenicity 
prediction. 
In Chapter 2, I identified a set of 31 non-coding elements that were recurrently 
mutated in developmental disorder cases without a pathogenic variant in the coding 
regions. These 31 recurrently mutated elements harboured 64 distinct mutations which 
were selected for saturation mutagenesis in these MPRA experiment (see Methods). I 
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sought to compare the impact of these patient-mutations to variation observed in the 
apparently healthy population. I reasoned that variation in these elements that is observed 
in a healthy population is likely benign or under weak selective constraint, whereas the 
impact of variation that had not been observed in patients, or in healthy individuals is 
unknown. For this analysis, I use any variation in the gnomAD database (15,796 individuals) 
as well as unaffected parents from the DDD project (13,192 individuals). 
While median change in expression was higher for patient mutations than for sites 
with variation observed in unaffected individuals in neuroblastoma (1.39-fold versus 1.33-
fold in neuroblastoma, Figure 8B), the difference was not statistically significant. Due to the 
high sample to sample variability described in Section 4.1.1, approximately half of the 
patient mutations and polymorphic variants had to be excluded from this analysis, and as a 
result this analysis is likely underpowered.  
I also used QuASAR-MPRA, a statistical package for detecting allele specific 
expression (ASE) in MPRA data to test the patient mutations and polymorphic variation for 
evidence of significant ASE. Approximately 10% of the variants tested were nominally 
significant, but none of the variants survived multiple hypothesis test correction. QuASAR-
MPRA uses a beta-binomial distribution and fits an overdispersion parameter to the data. 
QuASAR-MPRA has been applied successfully to MPRA data from eQTL fine-mapping studies 
where a large fraction of tests were expected to be negative16. However, in the case of the 
highly conserved non-coding elements tested here, where a large fraction of sites might be 
expected to alter gene expression, fitting the overdispersion parameter to the data may be 
overly conservative. Thus, modelling approaches that fit overdispersion on likely benign 
variation, potentially using nucleotide level conservation as a proxy as shown in Chapter 3, 
or modelling approaches that account for prior information about the fraction of sites 
expected to result in ASE may be more appropriate. This set of MPRA experiments has not 
shown any compelling evidence for dramatic expression changes resulting from patient 
mutations, but as improvements in the experimental workflow are made to ensure robust 
expression across experimental replicates, and larger numbers of robustly disease-





Figure 8 Assessing the impact of patient mutations in the MPRA assay. No significant difference in 
impact on expression of the reference sequence was observed between patient mutations and variation 
observed in gnomAD or the DDD unaffected parents in (a) HeLa cells and (b) neuroblastoma cells. 
 	
Results Section 4.2: Assessing disease-associated enhancer activity using mouse 
transgenesis assays 
Results Section 4.2.1. Mouse transgenesis assays to identify putative developmental 
enhancers 
 
 While MPRAs have the capacity to test tens of thousands of variants in a given 
experiment, they are feasible only in cellular models with high transfection efficiency, and 
therefore may provide information only within a potentially limited cellular context. In 
contrast, mouse transgenesis assays are lower throughput, but provide an opportunity to 
test the function of an enhancer element across many tissues of a developing mouse 
embryo, albeit still upstream of a reporter gene.  
In Chapter 1, I analysed sequence data from 7,390 trios where the child was affected 
with a severe developmental disorder and identified an enrichment of de novo mutations 
(DNMs) in highly evolutionary conserved non-coding elements (CNEs) with evidence for 
activity in the fetal brain. Thirty-one of the CNEs were recurrently mutated (DNM observed 
in two or more independent families). Under the null mutation rate model, we expected to 
see approximately fifteen recurrently mutated elements by chance. Thus, these thirty-one 
elements represent a source of candidate disease-associated elements with a false 
discovery rate of ~50%. I sought to test a subset of these candidate disease-associated 
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elements in a mouse transgenesis assay in collaboration with Evgeny Kvon, Diane Dickel, 
and Len Pennachio at Lawrence Berkeley Labs. 
 To prioritise elements for testing, all thirty-one recurrently mutated elements 
identified in Chapter 1 were annotated with histone modifications and measures of open 
chromatin in the fetal brain and the developing mouse brain by Evgeny Kvon. In line with 
the analysis in Chapter 1 suggesting that the majority of the conserved non-coding elements 
we tested were acting as enhancers, 26/31 recurrently mutated elements overlapped an 
H3K27ac peak, a mark associated with enhancer activity, in either human fetal brain or 
mouse brain.  
Based on evidence of activity in human/mouse brain and any testing in a mouse 
transgenesis assays, eleven of the thirty-one recurrently mutated elements were selected 
for testing. The wild-type sequence showed brain-specific expression at mouse 
developmental stage E11.5 in eight out of the eleven elements. As all eleven estimates had 
very strong evidence for H3K27ac and open chromatin in multiple developmental timepoint 
in mouse, there are a few potential explanations for the three negative elements. First, 
these elements may be functioning as enhancers in vivo, but may not be sufficient to drive 
expression on their own. Second, the mouse transgenesis assay was only completed at a 
single timepoint (E11.5) and these elements may be expressed at a different developmental 
timepoint. For example, one of the elements testing negative (chr10:131699490-
131700091) has H3K27ac marks in the midbrain and hindbrain in E12.5, E13.5, and E14.5, 
but not E11.5. Ten of the eleven elements tested in the mouse transgenesis assay were 
tested in the MPRA and drove expression in either HeLa or Neuroblastoma (see Figure 9), 
including the three elements testing negative, supporting the hypothesis that these 
elements may be acting as enhancers in a different context other than that surveyed in the 
mouse transgenesis assay. The only element that tested negative was chr6:14501358-
14501959, which had low representation in the pool likely due to its repetitive sequence 





Figure 9 MPRA expression estimates for the elements tested in the mouse transgenesis assay. All of 
the elements that were tested in the mouse transgenesis assay showed evidence for enhancer 
activity in the MPRA assay in both HeLa and neuroblastoma. 
 
 The eight elements with reproducible enhancer activity in the mouse transgenesis 
assay were modified to include patient mutations. Three of the eight mutants substantially 
altered or completely ablated expression of the reporter gene. The wild-type sequence of 
chr14: 57553276-57553757 drove reporter gene expression in the hindbrain, but hindbrain 
expression was completely absent in the element containing the two patient mutations (see 
Table 1). This regulatory element is in a gene desert near OTX2, an important gene for brain 
and eye development expressed throughout the brain in early development. Multiple lines 
of evidence support a role for the non-coding element at chr14:57553276-57553757 acting 
as an enhancer to OTX2. Both of the mutations present in patients in chr14:57553276-
57553757 resulted in loss of expression in the MPRA in both HeLa and neuroblastoma cells, 
although this difference was not significant after correcting for multiple tests. Taken 
together these results point toward loss of expression, perhaps exclusively in the hindbrain, 
of the dosage sensitive gene OTX2 as a potential regulatory cause of severe developmental 
delay. Additional functional validation such as a mouse knock-in of the patient mutation is 
warranted to establish whether the regulatory variants observed here are indeed sufficient 
to cause a severe patient phenotype.  
The wild-type sequence of chr6:14501358-14501959 drove expression in the 













mutations, expression in both the forebrain and midbrain were greatly reduced. The wild-
type sequence of chr7:13506147-13507336 drove expression in the forebrain, branchial 
arch, and trigeminal. The element containing patient mutations was active in the forebrain 
and branchial arch, but inactive in trigeminal. I was unable to assess concordance in the 
MPRA as the first element (chr6:14501358-14501959) had very low representation in the 
original pool due to its highly repetitive sequence (see Figure 3) and the second element 
(chr7:13506147-13507336) did not have sufficient observations to pass the threshold for 
correlation between biological replicates set in Section 4.1. As the MPRA experimental 





In this chapter, I presented preliminary data from two complementary experimental 
approaches to test the impact of non-coding variation on reporter gene expression. MPRAs 
have the potential to test tens of thousands of non-coding variants in a single experiment, 
but as evidenced from the data presented here, there are still experimental challenges to 
overcome to improve the utility of these assays. Using a strictly filtered set of elements, I 
find evidence for enhancer activity in a large fraction (>75%) of the developmental disorder-
associated non-coding elements tested. I also find compelling evidence for 5bp deletions 
causing a greater change in reporter gene activity compared to SNVs. This is concordant 
with evidence from evolutionary studies26, and from selective constraint in humans 
presented in Chapter 3, that indels are under stronger selective constraint in the non-coding 
genome. While MPRA assays represent a promising experimental technique for variant 
effect prediction in the non-coding genome, I was unable to draw any firm conclusions 
about the impact of patient mutations tested in this assay in large part due to low 
reproducibility between experimental replicates and a relatively small number of 
observations. As the correlation between independent replicates in published data is much 
higher, this is likely the result of experimental differences, possibly related to the the 
number of cells or the transfection method used.  
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Going forward, there are a number of important steps to optimise and adapt the 
MPRA pilot experiment conducted here. The number of cells used in this pilot experiment 
per replicate was much lower than that used in Tewhey et. al, and this likely resulted in a 
bottleneck due to the number of cells or the transfection method used. Adapting the 
method to add UMIs before each sequencing step also allowed us to determine that the 
amount of RNA sequenced was too low, as each input molecule was sequenced an average 
of three times. Increasing the number of cells used and the amount of genomic material 
sequenced will likely substantially improve the correlation between independent replicates 
and enable a larger fraction of the programmed variation to be reliably assessed. 
While we have tested two different cellular models, HeLa and neuroblastoma, we 
have not tested whether genome integration methods provide more reliable estimates of 
gene expression than the episomal method employed here, as has been suggested 
previously18. Furthermore, we tested 150bp sequences created using oligo synthesis 
technology, but other approaches exist that allow for larger sequences to be tested 
including using PCR on patient samples, and the construction of larger elements out of 
synthesized oligos, albeit at lower throughput than the method employed here. 
The current informatics pipeline does not incorporate any analysis of TFBS 
disruption. As published MPRAs have identified relationships between reporter assay 
expression and motif perturbation11, this is an important next step toward understanding 
the mechanism underlying gene mis-regulation. As more developmental disorder associated 
elements are discovered, extending saturation mutagenesis to cover a greater number of 
elements beyond the 64 tested here will provide more power to discover nucleotide-level 
patterns associated with pathogenic mis-regulation. 
In contrast to MPRAs, mouse transgenesis assays have been repeatedly validated as 
predictive of enhancer function, applied to thousands of different putative regulatory 
elements, and provide an organismal-level view of regulatory element function. However, 
these assays are much lower throughput in the number of putative regulatory elements 
they can assess and can only be cost-effectively applied to a small number of elements. For 
this reason, we selected eleven elements with strong prior evidence of enhancer activity in 
mouse and human brain, and with a high prior of association to severe DD. The majority 
(8/11) of the developmental disorder associated non-coding elements tested in the mouse 
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transgenesis assay drove robust expression in at least one tissue and introducing patient 
mutations disrupted reporter gene expression in three out of eight of the enhancers.  
One drawback of the two methods used here is that both MPRAs and mouse 
transgenesis assays rely on testing putative regulatory elements in a reporter construct, 
rather than in its endogenous locus. Ablation of expression in a reporter construct does not 
necessarily imply that expression will be ablated in vivo, as there may be compensatory 
effects from nearby elements8,27. Furthermore, mouse transgenesis assays do not provide a 
link from gene mis-regulation to the patient’s phenotype. Thus, results from the mouse 
transgenesis assay should be corroborated by CRISPR knock-ins of patient mutations into 
the endogenous locus to establish the link between genotype and phenotype. 
An additional challenge of assaying putative pathogenic variants in regulatory 
elements in MPRAs is that it is difficult to know based on sequence alone how a genetic 
variant will impact gene regulation. While variation resulting in loss-of-expression may be 
readily detectable in MPRAs, it is not clear how variation resulting in ectopic expression in 
vivo (e.g. in a different tissue/cell type) will manifest in a MPRA. Combining whole genome 
sequencing with RNA-sequencing in the relevant tissues for the patient’s disorder may 
provide an opportunity to identify patients with abnormal expression levels attributable to a 
regulatory variant that can be tested in these systems. The advent of large whole genome-
sequencing projects will likely uncover increasing numbers of disease-associated regulatory 
variants. For highly penetrant regulatory variants in particular, MPRAs, mouse transgenesis 
assays, and other functional assays will be critical to better understand the link between 
sequence and phenotypic effect. 
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Chapter 5: Discussion 
 
Gene regulation plays a central role in evolution, organismal development, 
and disease. Despite the critical importance of gene regulation throughout 
development, there have been few genetic variants in regulatory elements with 
large effects that have been robustly associated to disease (several notable 
examples are reviewed in Chapter 1). Even in common and complex disease where 
regulatory variation has estimated to account for more than 80% of disease risk 
attributable to genetics1, there is still little mechanistic understanding of how this 
risk manifests. In this work, my overarching aim was to gain a better understanding 
of the contribution of genetic variation in regulatory elements to Mendelian 
disorders and attempted to approach this problem from three different 
perspectives. I first sought to assess the contribution of regulatory variation to 
severe developmental disorders using sequence data from 8,000 affected individuals 
and their parents and to identify individual elements with a high probability of 
harbouring pathogenic regulatory elements (Chapter 2). Next, I used data from more 
than 28,000 whole genome sequenced individuals to examine the forces of selection 
operating on non-coding elements more generally (Chapter 3). Finally, I conducted a 
pilot experiment to assay >50,000 different non-coding variants across more than 
700 different non-coding elements, including variants observed in patients with 
developmental disorders in a massively parallel reporter assay (MPRA) and 
collaborated on an assessment of the impact of patient mutations in eleven different 
enhancers using mouse transgenesis assays (Chapter 4). 
 Analysing mutations in more than 8,000 trios with severe developmental 
disorders from the Deciphering Developmental Disorders (DDD) project2,3, I showed 
that de novo single nucleotide variants (SNVs) in highly conserved non-coding 
elements contribute to these disorders. The DDD project sequenced approximately 
5Mb of non-coding sequence in all 8,000 trios, but this sequence was biased to 
contain primarily highly evolutionarily conserved non-coding elements. As a result, 
the observations and estimates here are based primarily on highly conserved non-
coding sequence, although this analysis did include more than 500 experimentally 
validated enhancers with varying levels of evolutionary conservation. 
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I estimated that 1-3% of patients in this cohort carry a pathogenic de novo 
SNV in a regulatory element active in the fetal brain. Approximately ~20-50% of 
these pathogenic mutations were sequenced directly in the capture, and serve as a 
conservative lower bound for estimates of burden in the non-coding genome. While 
regulatory variants have been previously associated with Mendelian disorders 
(reviewed in the Introduction), this is the first time, to my knowledge, that a role for 
damaging regulatory variation has been reported in such a large and phenotypically 
heterogeneous set of disorders. 
 It is important to note that this estimate does not include the contribution of 
small insertions and deletions (indels), which has not yet been assessed in the DDD 
cohort. The lack of robust models of the indel mutation rate presents a challenge for 
analyses of mutational burden. These variants play a large role in disrupting protein-
coding sequence due primarily to frameshift mutations, and are also likely to be 
more damaging than SNVs in non-coding regions. Thus, there is a strong motivation 
for improved modelling of the germline mutation rate and variant calling pipelines to 
accurately detect this class of variation. The contribution of larger copy number 
variants (CNVs) in non-coding elements has also not yet been assessed on a large 
scale. As a number of Mendelian disorders are caused by enhancer duplications, 
deletions, and disrupting TAD boundaries,4 this class of variation should be 
prioritised for future work within the DDD cohort and in large whole genome 
sequencing studies which have greater sensitivity for calling CNVs and identifying 
breakpoints5.  
Using data from large-scale annotations of function in the non-coding 
genome including the Roadmap Epigenome Project6, the ENCODE project7, the 
FANTOM5 consortium8, and the VISTA enhancer database9, I showed that the 
majority of conserved non-coding elements sequenced in the DDD patients are likely 
functioning as enhancers. A subset of conserved non-coding elements show little 
evidence of enhancer activity across a wide range of tissues, but are instead 
predicted to be involved in post-transcriptional regulation. Conserved non-coding 
elements (CNEs) have long captured the interest of the scientific community due to 
their near perfect sequence identity across hundreds of millions of years of 
evolution10. These elements have been shown to be under ongoing purifying 
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selection and unlikely to be mutational coldspots11. I showed that conserved non-
coding elements sequenced in the DDD project were under selective constraint, 
albeit to a lesser degree of known developmental disorder genes, consistent with 
these previous reports11,12.  
The distribution of de novo mutations (DNMs) in CNEs in Chapter 2 also 
suggests that within a disease-associated CNE, a small fraction of sites (maximum 
likelihood estimate of 3%) are pathogenic with a dominant mechanism for DD. In 
contrast, in DD-associated haploinsufficient disease genes, 8-10% of mutations result 
in protein truncation and many missense variants may also result in loss of function 
via other mechanisms13. Thus, even for the most highly evolutionarily conserved 
regulatory elements in the genome, the role these mutations play in disease and 
therefore the forces of selection acting upon them, differs substantially from 
protein-coding genes. The pattern of evolutionary conservation in these elements 
could be the result of pleiotropy, where a single ultraconserved regulatory element 
is responsible for multiple different important regulatory functions. While this model 
could explain the relatively low contribution to severe developmental disorders from 
mutations in these elements, this model would likely result in levels of selection on 
par or greater than protein-coding genes, which I did not observe. Furthermore, 
non-coding elements are typically active in fewer tissues than coding genes, making 
the pleiotropy argument less likely14. Alternatively, evolutionary conservation in 
these elements may be maintained by weak selection against heterozygosity, or 
potentially strong selection against homozygosity that prevents deleterious variation 
from becoming fixed in the population. I found suggestive evidence in Chapter 2 that 
patient mutations more frequently resulted in gain of transcription factor binding 
than expected under a null mutational model. Thus, I hypothesise that a large 
fraction of the deleterious non-coding variants in CNEs may result in gain of function, 
as has been observed previously15,16. The answer to these questions has important 
implications for the role these elements play in disease, the study designs required 
to detect them, and potential therapeutic strategies. Furthermore, these questions 
apply not only to CNEs, but to non-coding elements genome-wide, motivating a 
more comprehensive study of selective constraint in the non-coding genome. 
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In Chapter 3, I analysed data from more than 28,000 whole genome 
sequenced individuals from the gnomAD and BRIDGE projects to examine patterns of 
selective constraint in the non-coding genome in greater detail. I detected evidence 
for pervasive constraint against SNVs in the non-coding genome, most notably in 
DNase hypersensitive sites, long non-coding RNAs, and 3’ UTRs. In each of these 
element sets, there was a strong correlation between evolutionary conservation of 
the elements and observed selective constraint. However, I found that even 
elements that are poorly evolutionarily conserved contain a subset of nucleotides 
that are evolutionary conserved which are under selective constraint. This result has 
important implications for the role of regulatory variation in disease. Namely, it 
suggests that a large fraction of active regulatory elements genome-wide may 
harbour variation conferring disease risk, albeit in a small fraction of the total 
sequence underlying the open chromatin peak or activity-associated histone mark.  
If this model holds true, then it implies that efforts to understand the 
functional bases within a putative enhancer sequence are likely to greatly improve 
power to detect pathogenic variation. This also suggests that whole genome-
sequencing, rather than targeted sequencing of a subset of selected regulatory 
elements, may be necessary to detect disease-associated variants in research or 
clinical applications where identifying pathogenic non-coding variation is a primary 
aim. Furthermore, it suggests that the conventional model of regulatory ‘elements’ 
that are hundreds or thousands of bases in length may actually be more accurately 
modelled as a loose collection of smaller functional sequences. As the de novo 
enrichment analyses presented in Chapter 2 focus on highly evolutionarily conserved 
elements, increasing genome coverage to include a greater number of less well 
conserved regulatory elements may provide further opportunity to answer this 
question. Large-scale whole genome sequencing efforts such as the Genomics 
England 100,000 Genomes project have recruited thousands of affected patients and 
their parents and these data will provide a great opportunity to assess this question 
and others. 
Evolutionary estimates suggest that a small fraction of the genome, between 
3% and 15%, is under selective constraint17,18, while large-scale annotations of 
regulatory function such as the ENCODE project have suggested as much as 80% of 
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the genome is biochemically active in at least one tissue7. The results presented in 
Chapter 3 are consistent with a model in which a large fraction of the genome may 
be biochemically active, but only a small fraction of functional nucleotides give rise 
to this activity. I have also shown that conserved transcription factor binding sites, 
regardless of the evolutionary conservation of the surrounding sequence, are under 
purifying selection. Taken together, these results lend support to the ‘billboard 
model’ of regulatory element function whereby transcription factor binding sites or 
sets of sites in close spatial proximity confer regulatory potential to previously inert 
sequences19. However, this analysis did not consider the potential impact of the 
variant (e.g. loss, gain, or neutral effect on binding), nor the impact of spacing 
between transcription factor binding sites. As this analysis incorporated data from 
approximately 28,000 healthy individuals, there is significant scope to increase this 
analysis using data from the UK Biobank and the 100,000 Genomes Project that is 
soon to be made publicly available. However, I estimated that even hundreds of 
thousands of deep whole genomes would not provide the resolution necessary to 
detect selection at 10-20bp resolution (e.g. the size of a typical transcription factor 
binding sites). Thus, understanding and predicting the precise patterns underlying 
nucleotide-level constraint in the non-coding genome represents an important area 
for future work that may not be resolved by population genetic approaches alone. 
Evolutionary studies have suggested that regulatory elements are more 
intolerant of insertions and deletions (indels) than SNVs18. Modelling selective 
constraint against indels presents several challenges, most notably the lack of well-
calibrated null models for the indel mutation rate. To overcome this challenge, I 
used de novo indels to directly account for variation in the underlying indel mutation 
rate. Results from this analysis suggest that indel constraint is substantially greater 
than SNV constraint in non-coding elements. However, the confidence intervals of 
these estimates are still large, primarily due to the relatively small number of de 
novo indels from healthy individuals used to calibrate the mutation rate model. In 
addition to simply collecting larger numbers of whole genome sequenced trios to 
more accurately quantify the indel mutation rate, a number of models are in 
development to predict the indel mutation rate from sequence context. 
Improvement of these models is critical to enable indel constraint to be quantified 
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for individual elements, rather than aggregated groups of elements as was 
performed in Chapter 3. 
As suggested by the analysis of selective constraint on the CNEs sequenced in 
the DDD project, regulatory elements show systematically lower selection on 
heterozygotes than protein-coding genes even at the same level of evolutionary 
conservation. This result, alongside the estimate that a low proportion of bases in 
regulatory elements are predicted to contribute to severe DD with a dominant 
mechanism (maximum likelihood estimate of 3%), suggests that the effect sizes of 
genetic variants in regulatory elements may, on average, be far smaller than protein-
coding genes. Apparently weaker selection on heterozygotes in regulatory elements 
could also point to a greater role for selection on homozygotes maintaining 
evolutionary conservation. While there have been attempts to model selection on 
heterozygotes with an assumed dominance coefficient of one20, there are, to my 
knowledge, no established methods for jointly modelling strength of selection and 
the dominance coefficient using human whole genome sequencing data. Recent 
population genetics work has suggested that it may be fundamentally difficult to 
separate weak selection against heterozygotes from selection against homozygotes 
using human polymorphism data21. More development in this area will improve 
modelling the genetic architecture of disease not only in the non-coding genome, 
but in protein-coding genes where incomplete penetrance or oligogenic models may 
play an important role22. 
Chapters 2 and 3 together provide insight into the patterns of selection 
shaping the non-coding genome and their role in disease. However, more in-depth 
functional assays incorporating mutations linked to severe disorders may provide a 
complementary view into the nature of gene mis-regulation and the ‘enhancer 
code’. Furthermore, these assays present an opportunity to test the impact of 
patient mutations on regulatory element function, and to validate observations from 
the population genetic analyses presented in Chapter 3.  
For this MPRA pilot experiment, I designed a set of experiments testing more 
than 50,000 different putative enhancer sequences including all possible SNV 
changes in 64 elements, and 5bp deletions tiled across more than 700 elements. The 
64 elements selected for saturation were identified as developmental disorder 
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associated in Chapter 2. More than 75% of wild-type sequence tested showed 
evidence for enhancer activity in either HeLa or Neuroblastoma cells. I also found 
evidence for a relationship between nucleotide level conservation and magnitude of 
change in expression in the MPRA in neuroblastoma, but did not find any effect in 
HeLa cells. Deletions resulted in a larger effect in the MPRA in both HeLa and 
Neuroblastoma compared to SNVs, supporting the prior evolutionary work18, and 
population genetic studies in Chapter 3 suggesting that indels may be more 
disruptive of regulatory element function, and therefore under stronger selective 
constraint. 
While population genetic studies rely on data from only a small fraction of 
nucleotides where variation is observed, MPRAs provide the opportunity to test 
every nucleotide in a given regulatory sequence of interest. Thus, these tools may 
provide deeper insight into the nucleotide-level patterns responsible for regulatory 
element function. However, these experimental assays are still limited to cell types 
amenable to transfection in the laboratory and in the data from our pilot 
experiment, show relatively low correlation across biological replicates. As published 
data shows higher correlation across experimental replicates than we observed 
here23, additional optimisation of laboratory protocols should yield higher quality 
data and allow us to make reliable inference on the impact of patient mutations. 
These experiments serve as a valuable pilot experiment to understand the power as 
well as limitations of this new experimental technique and provide a starting point 
for further experiments. 
 In addition to testing patient mutations in a series of MPRA experiments, I 
worked with collaborators at Lawrence Berkeley National Laboratory to test a subset 
of disease-associated elements in a mouse transgenesis assay. We selected eleven 
elements with two or more DNMs in patients for testing based on strong evidence of 
enhancer activity in mouse and human brain, and observed robust expression at 
specific brain regions at mouse developmental stage E11.5 for the wildtype 
sequence in 8/11 elements in the mouse transgenesis assay. Notably, I was able to 
test the wildtype sequence for 10/11 elements in the MPRA and found evidence for 
regulatory activity for all 10 in both HeLa and neuroblastoma, suggesting that the 
elements failing to drive expression in the mouse transgenesis assay are likely active 
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enhancers in a different context than that tested in the mouse transgenesis assay. 
Three of the eight enhancers testing positive in the mouse transgenesis assay 
showed marked reductions in activity after introduction of patient mutations. While 
these assays present compelling evidence for reduction or ablation in expression in 
the context of a reporter gene, further work to knock-in the patient mutations to 
their endogenous context are needed to determine whether these gene expression 
changes are sufficient to cause a severe disorder. Work is now under-way in the 
Hurles lab to further characterise the phenotype of patients carrying these 
regulatory mutations and prioritise elements for mouse knock-in modelling based on 
the mouse transgenesis results. 
Beyond evaluating the impact of patient mutations, high throughput 
functional assays have the potential to contribute to other longstanding problems in 
gene regulation. For example, predicting the target gene of a putative enhancer 
remains a substantial challenge that was evident in my analysis of de novo mutations 
in non-coding elements in severe developmental disorders in Chapter 2. I assessed 
the overlap in gene target predictions using four different approaches (Hi-C, 
DNase/RNA-seq correlation, evolutionary synteny, nearest gene) and found a low 
degree of overlap between the predictions from different methods. One challenge of 
using both Hi-C and predicting targets based on correlation between DNase I 
hypersensitivity and transcriptional output is the necessity to survey the precise 
tissue and timepoint of interaction. The sheer quantity of different cell types and 
developmental timepoints poses a fundamental challenge to observational 
approaches to gene target prediction. One possible solution is to use machine 
learning to predict gene targets in unseen tissues or timepoints by learning patterns 
from available data. For example, TargetFinder integrates 15 chromatin features 
across multiple cell types to predict gene targets24. For single-cell sequencing data, 
Cicero integrates sparse chromatin features within a single cell type to predict 
changes in gene expression25. Going forward, tools such as Hi-C or Capture-C may 
also be applied to directly to patient derived cell lines or tissue samples, allowing 
gene mis-regulation to be observed directly, rather than inferred based on gene 
target predictions produced from wild-type sequence. 
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 Another approach to improve gene target prediction is to use CRISPR 
activation (CRISPRa) to force enhancer activity in a cell line representative of the 
tissue of interest and measure the impact on nearby genes26. In principle, this 
method can be used to direct the factors required for enhancer activation to the site 
of interest, and nearby genes can be profiled with qPCR or RNA-sequencing to test 
for changes in transcriptional output. However, it is still unclear how well CRISPRa 
recapitulates enhancer-gene interactions in vivo, with the exception of a small 
number of tested cell types26,27.  CRISPR inactivation (CRISPRi) has also been used to 
selectively silence putative regulatory elements and measure the impact on the 
expression of nearby genes. This approach has been used to silence elements in 
specific loci28 as well as genome-wide as a novel method for eQTL discovery29. 
 Improvements in gene target prediction will improve power to detect 
disease-associated regulatory variation in several ways. Linking enhancers to the 
relevant gene will allow for more reliable assessment of the impact of regulatory 
mutations acting as a ‘second hit’ to a damaging protein-coding mutation. For 
patients with very distinctive disorders associated with well-characterised disease 
genes, but no pathogenic variant in the exome, regulatory variation is often cited as 
a potential source of missed diagnoses22,30,31. There have been a few examples of 
this phenomenon reported, but the prevalence cannot be reliably assessed without 
robust gene target maps in the relevant cell type or tissue. Analysis of transcriptomic 
data from patients with autism spectrum disorder and patients with cancer has 
suggested that cis-regulatory variation can modify risk of a coding variant by 
changing expression of the ‘risk haplotype’22. This analysis was performed using 
eQTLs to link regulatory variant to target genes, but in cases where gene expression 
is tightly controlled and depleted for eQTLs (e.g. near dosage sensitive genes32), 
establishing gene target prediction via alternative routes such as Capture-C, CRISPRa, 
or CRISPRi may improve power. 
CNEs and enhancers are known to cluster in the genome, and these clusters 
often, but not always, regulate the same gene or genes33. Reliable gene target 
prediction will allow enhancers active in the same tissues and time points to be 
jointly analysed, improving power to discover disease associations. Genome editing 
in mice has already revealed examples of compensatory interactions between 
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ultraconserved enhancers driving expression in the same brain region of a critical 
developmental gene16,34. As studies focused on individuals with Mendelian disorders 
begin to incorporate RNA sequencing, gene target predictions will be essential to link 
variation in enhancers to changes in transcriptional level. Regulatory variation that 
phenocopies a loss of function mutation in a gene, or decreases expression enough 
to cross a critical threshold, will be challenging to identify without reliable gene 
target predictions. 
 A sizeable fraction (>8%) of the possible mutations in protein-coding genes 
results in loss of function13. These variants can be aggregated together in gene 
burden tests, increasing power and helping to establishing clear hypotheses for 
disease mechanisms (e.g. haploinsufficiency leading to destabilisation of a protein-
complex). Variation in the non-coding genome may prove to be more similar to 
missense variation in that many changes are neutral or weakly deleterious, and a 
small fraction or highly deleterious either acting as loss-of-functions or gain of 
function13.  The MPRA experiment conducted in Chapter 4 supports this 
hypothesis—~62% of SNVs caused decrease in reporter gene expression in both 
HeLa and Neuroblastoma. Thus, assessing the impact of regulatory variation, 
particularly in a clinical context, where effect sizes are likely to be small and 
heterogeneous will require a greater understanding of the underlying ‘enhancer 
code’ or high-throughput assays to assess variant pathogenicity at scale35. 
Furthermore, there may be such a variety of risk variants or haplotypes across the 
population that observing any one variant or haplotype multiple times is rare. This 
has been the case for missense mutations in the BRCA1 and BRCA2 genes, for which 
a large proportion (>70%) of missense mutations are variants of unknown 
significance (VUS)35,36. Substantial progress has been made in separating benign from 
damaging missense variation using multiplexed assays of variant effect35,36 (MAVEs). 
It has been suggested that these experiments could produce ‘lookup tables’ for 
clinical use, and the data can also be used to train machine learning models to better 
discriminate pathogenic and benign variants computationally36. In the non-coding 
genome, machine learning models have been trained using data from synthetic 
enhancers to predict enhancer function, but these models have not yet been applied 
to clinically ascertained non-coding variants37. MAVEs have been shown to 
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outperform computational predictors of missense deleteriousness metrics, which 
are based primarily on evolutionary and physicochemical data38-40, in some 
contexts36. Thus, it stands to reason that non-coding variant deleteriousness metrics 
may be improved by incorporating information from functional assays35. 
 Extending the experimental strategies already successfully employed to study 
missense mutations in BRCA136 to the non-coding genome comes with several 
challenges. Assays of missense effect have been performed in haploid cell lines for 
which the gene of interest has been determined to be essential for survival. It may 
be more challenging to identify cell lines in which individual enhancers are essential 
for survival due to the high degree of enhancer redundancy. Even in the case that 
cell lines can be identified that are intolerant of deletion of an enhancer, individual 
genetic variants may result in change of gene expression, but not complete loss of 
function. Simultaneous advances in large scale genome sequencing projects in rare 
and common disease and high throughput experimental techniques will create 
tremendous opportunities for better understanding of the non-coding genome and 
the role of non-coding variation in disease. Going forward, approaches integrating 
regulatory mutations from patients, which have a higher prior probability of large 
effect, with high-throughput functional assays will improve our understanding of the 
principles of gene regulation and the mechanisms by which gene mis-regulation 
contributes to disease. 
 
 
1 Maurano, M. T. et al. Systematic Localization of Common Disease-
Associated Variation in Regulatory DNA. Science 337, 1190-1195, 
doi:10.1126/science.1222794 (2012). 
2 Wright, C. F. et al. Genetic diagnosis of developmental disorders in the DDD 
study: a scalable analysis of genome-wide research data. The Lancet 385, 
1305-1314, doi:10.1016/S0140-6736(14)61705-0 (2015). 
3 Study, D. D. D. Large-scale discovery of novel genetic causes of 
developmental disorders. Nature 519, 223-228, doi:10.1038/nature14135 
(2015). 
4 Spielmann, M. & Mundlos, S. Looking beyond the genes: the role of non-
coding variants in human disease. Human Molecular Genetics 25, 157-165, 
doi:10.1093/hmg/ddw205 (2016). 
5 Gilissen, C. et al. Genome sequencing identifies major causes of severe 
intellectual disability. Nature 511, 344, doi:10.1038/nature13394 (2014). 
6 Consortium, R. E. et al. Integrative analysis of 111 reference human 
epigenomes. Nature 518, 317-330, doi:10.1038/nature14248 (2015). 
 148 
7 Consortium, E. P. An integrated encyclopedia of DNA elements in the human 
genome. Nature 489, 57-74, doi:10.1038/nature11247 (2012). 
8 Andersson, R. et al. An atlas of active enhancers across human cell types and 
tissues. Nature 507, doi:10.1038/nature12787 (2014). 
9 Visel, A., Minovitsky, S., Dubchak, I. & Pennacchio, L. A. VISTA Enhancer 
Browser - A database of tissue-specific human enhancers. Nucleic Acids 
Research 35, 88-92, doi:10.1093/nar/gkl822 (2007). 
10 Bejerano, G. et al. Ultraconserved elements in the human genome. Science 
304, 1321-1325, doi:10.1126/science.1098119 (2004). 
11 Drake, J. a. et al. Conserved noncoding sequences are selectively constrained 
and not mutation cold spots. Nature Genetics 38, 223-227, 
doi:10.1038/ng1710 (2006). 
12 Derti, A., Roth, F. P., Church, G. M. & Wu, C.-t. Mammalian ultraconserved 
elements are strongly depleted among segmental duplications and copy 
number variants. Nature Genetics 38, 1216-1220, doi:10.1038/ng1888 (2006). 
13 Kryukov, G. V., Pennacchio, L. a. & Sunyaev, S. R. Most rare missense 
alleles are deleterious in humans: implications for complex disease and 
association studies. The American Journal of Human Genetics 80, 727-739, 
doi:10.1086/513473 (2007). 
14 Berthelot, C., Villar, D., Horvath, J. E., Odom, D. T. & Flicek, P. Complexity 
and conservation of regulatory landscapes underlie evolutionary resilience of 
mammalian gene expression. Nat Ecol Evol 2, 152-163, doi:10.1038/s41559-
017-0377-2 (2018). 
15 Lettice, L. A. et al. A long-range Shh enhancer regulates expression in the 
developing limb and fin and is associated with preaxial polydactyly. Human 
Molecular Genetics 12, 1725-1735, doi:10.1093/hmg/ddg180 (2003). 
16 Osterwalder, M. et al. Enhancer redundancy provides phenotypic robustness 
in mammalian development. Nature 554, 239-243, doi:10.1038/nature25461 
(2018). 
17 Lindblad-Toh, K. et al. A high-resolution map of human evolutionary 
constraint using 29 mammals. Nature 478, 476-482, doi:10.1038/nature10530 
(2011). 
18 Lunter, G., Ponting, C. P. & Hein, J. Genome-wide identification of human 
functional DNA using a neutral indel model. PLoS Comput Biol 2, e5, 
doi:10.1371/journal.pcbi.0020005 (2006). 
19 Smith, R. P. et al. Massively parallel decoding of mammalian regulatory 
sequences supports a flexible organizational model. Nature Genetics 45, 1021-
1028, doi:10.1038/ng.2713 (2013). 
20 Cassa, C. A. et al. Estimating the Selective Effect of Heterozygous Protein 
Truncating Variants from Human Exome Data. Nature Genetics 49, 806-810, 
doi:10.1038/ng.3831 (2016). 
21 Fuller, Z., Berg, J. J., Mostafavi, H., Sella, G. & Przeworski, M., Measuring 
intolerance to mutation in human genettics. biorXiv, doi:10.1101/382481 
(2018). 
22 Castel, S. E. et al. Modified penetrance of coding variants by cis-regulatory 
variation contributes to disease risk. Nature Genetics, doi:10.1038/s41588-
018-0192-y (2018). 
23 Tewhey, R. et al. Direct Identification of Hundreds of Expression- Modulating 
Variants using a Multiplexed Reporter Resource Direct Identification of 
 149 
Hundreds of Expression-Modulating Variants using a Multiplexed Reporter 
Assay. Cell 165, 1519-1529, doi:10.1016/j.cell.2016.04.027 (2016). 
24 Whalen, S., Truty, R. M. & Pollard, K. S. Enhancer-promoter interactions are 
encoded by complex genomic signatures on looping chromatin. Nature 
Genetics 48, 488-496, doi:10.1038/ng.3539 (2016). 
25 Pliner, H. A. et al. Cicero Predicts cis-Regulatory DNA Interactions from 
Single-Cell Chromatin Accessibility Data. Mol Cell, 
doi:10.1016/j.molcel.2018.06.044 (2018). 
26 Hilton, I. B. et al. Epigenome editing by a CRISPR-Cas9-based 
acetyltransferase activates genes from promoters and enhancers. Nature 
Biotechnology 33, doi:10.1038/nbt.3199 (2015). 
27 Simeonov, D. R. et al. Discovery of stimulation-responsive immune enhancers 
with CRISPR activation. Nature 549, 111-115, doi:10.1038/nature23875 
(2017). 
28 Fulco, C. P. et al. Systematic mapping of functional enhancer-promoter 
connections with CRISPR interference. Science 354, 769-773, 
doi:10.1126/science.aag2445 (2016). 
29 Gasperini, M. et al. CRISPR/Cas9-Mediated Scanning for Regulatory 
Elements Required for HPRT1 Expression via Thousands of Large, 
Programmed Genomic Deletions. Am J Hum Genet 101, 192-205, 
doi:10.1016/j.ajhg.2017.06.010 (2017). 
30 Graf, S. et al. Identification of rare sequence variation underlying heritable 
pulmonary arterial hypertension. Nature Communications 9, 
doi:10.1038/s41467-018-03672-4 (2018). 
31 Alberobello, A. T. et al. An intronic SNP in the thyroid hormone receptor β 
gene is associated with pituitary cell-specific over-expression of a mutant 
thyroid hormone receptor β2 (R338W) in the index case of pituitary-selective 
resistance to thyroid hormone. Journal of Translational Medicine 9, 144, 
doi:10.1186/1479-5876-9-144 (2011). 
32 Glassberg, E. C., Gao, Z., Harpak, A., Lan, X. & Pritchard, J. K., 
Measurement of selective constraint on human gene expression. biorXiv 
doi:10.1101/345801 (2018). 
33 Sandelin, A. et al. Arrays of ultraconserved non-coding regions span the loci 
of key developmental genes in vertebrate genomes. BMC Genomics 5, 99, 
doi:10.1186/1471-2164-5-99 (2004). 
34 Dickel, D. E. et al. Ultraconserved Enhancers Are Required for Normal 
Development. Cell 172, 491, doi:10.1016/j.cell.2017.12.017 (2018). 
35 Starita, L. M. et al. Variant Interpretation: Functional Assays to the Rescue. 
Am J Hum Genet 101, 315-325, doi:10.1016/j.ajhg.2017.07.014 (2017). 
36 Findlay, G. M. et al. Accurate functional classification of thousands of 
BRCA1 variants with saturation genome editing. bioRxiv, doi:10.1101/294520 
(2018). 
37 Kheradpour, P. et al. Systematic dissection of regulatory motifs in 2000 
predicted human enhancers using a massively parallel reporter assay. Genome 
Research, 800-811, doi:10.1101/gr.144899.112 (2013). 
38 Kircher, M. et al. A general framework for estimating the relative 
pathogenicity of human genetic variants. Nature Genetics 46, 310-315, 
doi:10.1038/ng.2892 (2014). 
 150 
39 Vaser, R., Adusumalli, S., Leng, S. N., Sikic, M. & Ng, P. C. SIFT missense 
predictions for genomes. Nature Protocols 11, 1, doi:10.1038/nprot.2015.123 
(2015). 
40 Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of 
human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 




Appendix 1 – supplementary tables and figures for: 
 





















Figure S11 A) Recurrently mutated elements likely to be an enhancer. B) Recurrently mutated 
elements likely to be transcribed or involved in alternative splicing. The element is in black, red 
markers denote observed DNMs, grey markers denote observed variation at MAF > 0.1% in 7,080 
unaffected parents, phastcons100 conservation score is shown in blue, and DNase hypersensitivity 
sites in fetal brain from the Roadmap Epigenome project are shown in blue (female) and pink (male) 











































Genomic coordinates of the 31 recurrently mutated fetal brain active CNEs and conserved enhancers. Annotated with the nearest gene and any gene interaction 
reported by Hi-C data in the fetal brain. P-value is the probability of observing at least as many as the reported number of DNMs in the 6,239 exome-negative 
probands under the null mutation model.
Region Class DNMs p-value Nearest Gene Hi-C Gene Interactions 
chr6:136594963-136595444 Conserved 3 5.30E-05 BCLAF1 AHI1,MAP7 
chr1:47040703-47041712 Conserved 3 0.000640696 MKNK1 NONE 
chr8:25867716-25868077 Conserved 2 0.001859799 EBF2 EBF2,DOCK5 
chr17:2095049-2095410 Conserved 2 0.002057076 SMG6 NONE 
chr14:57553276-57553757 Conserved 2 0.002134137 EXOC5 NONE 
chr3:71277252-71279016 Enhancer 3 0.002356077 FOXP1 NONE 
chr1:87795132-87796797 Enhancer 3 0.002754705 LMO4 NONE 
chr7:114999315-114999916 Conserved 2 0.002818309 MDFIC FOXP2 
chr14:37558933-37559534 Conserved 2 0.0032701 SLC25A21 TTC6 
chr3:136760251-136760852 Conserved 2 0.003280877 IL20RB MSL2,PPP2R3A,STAG1,CLDN18 
chr5:163987267-163987868 Conserved 2 0.003430287 MAT2B NONE 
chr4:147215258-147215935 Conserved 2 0.00352168 SLC10A7 NONE 
chr6:14501358-14501959 Conserved 2 0.003823222 CD83 NONE 
chr10:131699490-131700091 Conserved 2 0.004207684 EBF3 NONE 
chr6:91341961-91342682 Conserved 2 0.004761199 MAP3K7 NONE 
chr3:19028185-19028906 Conserved 2 0.00484094 KCNH8 NONE 
chr11:8310678-8311279 Conserved 2 0.004900527 LMO1 NONE 
chr1:90847520-90848241 Conserved 2 0.006338024 BARHL2 NONE 
chr12:17033589-17034430 Conserved 2 0.007524004 LMO3 NONE 
chr10:103245609-103246330 Conserved 2 0.008489455 BTRC LBX1 
chr7:100480136-100480803 Conserved 2 0.009844978 SRRT MUC17 
chr11:20297786-20298693 Conserved 2 0.009961525 HTATIP2 NONE 
chr11:47487425-47488506 Conserved 2 0.010602029 CELF1 MTCH2 
chr2:60077201-60078311 Conserved 2 0.012703131 BCL11A NONE 
chr7:13506147-13507336 Enhancer 2 0.013290101 ETV1 NONE 
chr3:180461765-180462934 Enhancer 2 0.014462824 CCDC39 NONE 
chr5:87839871-87841137 Conserved 2 0.014749778 MEF2C NONE 
chr14:29858890-29860091 Conserved 2 0.016188696 PRKD1 FOXG1,C14orf23 
chr8:77710296-77711833 Conserved 2 0.020547115 ZFHX4 NONE 
chr1:44989764-44991209 Enhancer 2 0.026516706 RNF220 NONE 
chr19:30840239-30843596 Enhancer 2 0.090055315 ZNF536 ZNF536 
